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ABSTRACT 
Transporter trafficking regulators can play an important role in maintaining the transporter density 
necessary for effective function.  I determine interactions that confine GAT1 at the membrane by 
investigating GAT1 lateral mobility through fluorescence recovery after photobleaching (FRAP).  I find 
that the mobility of GAT1 can be increased by depolymerizing actin or by blocking the GAT1 PDZ 
interacting domain.  I also identify ezrin as the GAT1 adaptor to actin.  Through fluorescence resonance 
energy transfer (FRET), the distance between GAT1-YFP and Ezrin-CFP is calculated as 64--68 Å, and it 
can be significantly increased by disrupting the actin cytoskeleton.  Altogether, my data reveals that actin 
confines GAT1 to the plasma membrane via ezrin, an interaction mediated through the GAT1-PDZ 
interaction domain. 
Discoveries in the field of vesicle fusion provide direct ties to translational research.  While the 
study of vesicle fusion classically has been applied to neurotransmitter and neuropeptide containing 
vesicles; there is evidence that secretory vesicles physiologically differ from vesicles trafficking membrane 
protein.  For instance, GAT1 resides on a vesicle lacking neurotransmitter but containing some v-SNARE 
proteins. These differences in the vesicle composition suggest inherent differences in trafficking 
mechanisms, which can only be confirmed through further study of membrane protein trafficking.  To this 
end, I apply total internal reflection fluorescence microscopy (TIRFM) to quantify the number of GAT1 
molecules on vesicles and to observe the movement of vesicles containing fluorescently tagged GAT1 into 
the plasma membrane.  I determine that these vesicles contain 3--7 molecules of GAT1 and uncover a 
population of GAT1 vesicles with ATP-dependent lateral displacement. 
The protein-protein interactions, trafficking, and oligomerization of mouse GAT1 were studied 
using fourteen different fusions of mGAT1 with fluorescent protein.  We determine that a natural PDZ-
interacting motif is minimally required for wild-type GAT1 behavior.  Fusions with wild-type function 
yielded up to 21% FRET efficiency, indicating efficient GAT1 oligomerization.  Additionally, 45% FRET 
was observed between a GAT1 construct and YFP-syntaxin-1A.  Inserting XFP between R565 and L566, 
resulted in 33% FRET but impaired function, which indicated the “RL” motif in the proximal C-terminus 
governs export from the endoplasmic reticulum but not transporter oligomerization.   
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Chapter 1: Introduction 
 
This chapter contains three sections.  The first section gives an overview of what is 
known about GAT1 function, subtypes in the brain, structure, trafficking, and ties to 
epilepsy.  The second section describes the optical approaches used to study the GABA 
transporter.  The chapter concludes with a summary of the subsequent chapters of the 
thesis. 
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Background 
GAT1 Function 
 Synapses help translate information in order for us to learn, recall, think, and 
exhibit emotion.  Every action is governed by synaptic networks.  Many neurological and 
psychiatric disorders stem from problems with chemical and/or electrical signal 
transmission at the synapse.  Hence several drugs used to treat these conditions target 
synaptic transporters and receptors.  For example, the antiseizure drug, carbamazapine, 
binds to the postsynaptic GABAA receptor, resulting in modulations in chloride 
conduction.  Even drugs prescribed for treatment of depression, anxiety, and attention 
deficit hyperactivity disorder (also known as “ADHD”) block synaptic transporters---the 
serotonin and norepinephrine transporters to be exact.  Therefore any insight gained into 
the structure of synapses can result in significant improvements in clinical medicine and 
human health. 
 A study of the synapse typically focuses on the proteins that facilitate and regulate 
synaptic transmission.  Figure 1 displays a representative synapse.  Synaptic transmission 
occurs when vesicles containing neurotransmitter fuse with the presynaptic membrane, 
thereby releasing neurotransmitter into the synaptic cleft.  The neurotransmitter diffuses 
throughout the synapse and binds to a postsynaptic ion channel, resulting in channel 
opening.  The opening of an ion channel allows ions to move through the channel pore.  
Hence, synaptic transmission involves the conversion of a chemical signal into an 
electrical signal.  Synaptic transmission is terminated by the action of neurotransmitter 
transporters which pump neurotransmitter from the synaptic cleft back into the 
presynaptic neuron.  Figure 2 displays the process of synaptic transmission, where the 
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neurotransmitter is GABA; the postsynaptic ion channel is the GABAA receptor; the ion 
permeating the channel pore is chloride; and the neurotransmitter transporter is the 
GABA transporter, GAT1.   
 
Figure 1. The image shows fusion of GABA-containing vesicles with the plasma 
membrane.  The binding of GABA to a GABAA receptor results in the opening of receptor 
and the movement of chloride ions through the pore of the receptor.  This process of 
inhibitory synaptic transmission is terminated by the transport of GABA from the 
synaptic cleft into the presynaptic terminal via the action of GAT1.  This process is 
considered inhibitory, because chloride ions are negatively charged, and upon entering 
the postsynaptic terminalmthey decrease in the membrane voltage (hyperpolarization), 
thereby inhibiting neuronal excitation. 
The GABA transporter, GAT1 is the focus of the studies in this thesis.  It is a 
member of the solute carrier 6 (SLC6) family of transporters.  Included in this family are 
the norepinephrine transporter (NE), serotonin transporter (SERT), dopamine transporter 
(DAT), and GABA transporters (GAT) (1).  In addition to terminating synaptic 
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transmission, these transporters are also involved in maintaining
 
a low neurotransmitter 
concentration throughout the brain and preventing excessive activation of synaptic 
receptors (2, 3).  The removal of neurotransmitter from the synapse requires energy, 
which is harnessed from the difference in intracellular and extracellular ion 
concentrations.  Table 1 specifies the intracellular and extracellular concentrations of 
Na
+
, Cl
-
, and K
+
. 
 
Table 1. Intracellular and extracellular ion concentrations adapted from Alberts (4) 
Ion Intracellular 
Concentration 
Extracellular 
Concentration 
Na
+ 
5--15 mM 145 mM 
Cl
- 
5--15 mM 110 mM 
K
+
 140 mM 5 mM 
 
Since ions move from regions of high concentration to low concentration, the difference 
in ion concentration (concentration gradient) can be used to drive the movement of 
molecules that cannot diffuse across the plasma membrane into the neuron.  GAT1 
applies this principle by transporting GABA into the neuron through co-transport of 2 
Na
+
 and 1 Cl
-
 down their concentration gradients.    
It must be noted that GAT1 can also reverse, transporting GABA out of the 
neuron either under depolarizing conditions (increased plasma membrane voltage) or due 
to a significant increase in intracellular Na
+
 or Cl
-
 concentrations.  Figure 3 displays 
GAT1 transport reversal.  Drugs that raise the intracellular concentration of Na
+
 (for 
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example, glutamate) can also cause transport reversal.  Studies of GAT reversal have 
been performed in a range of model systems including: toad and catfish retina, human 
hippocampus, rat brain synaptosomes, mouse cerebral cortex, human embryonic kidney 
cells, and Xenopus oocytes (frog eggs) (5, 6).  Wu and Richerson have found that 
physiologically relevant increases in extracellular K
+
 concentration (11--17 mM) can 
induce transport reversal in rat hippocampus (7).  Transport reversal is believed to have 
great importance during high-frequency neuronal excitation.  It is thought that transporter 
reversal and vesicular release of GABA work in tandem to inhibit neuronal firing.   
 
Figure 2. GAT1 can reverse transport under certain conditions, including: depolarizing 
conditions or upon significant increase in the sodium or chloride concentrations in the 
presynaptic terminal.   Therefore, rather than transporting GABA into the presynaptic 
terminal, GAT1 can transport GABA into the synapse. 
GABA Transporter Subtypes and Distribution 
 There are four known subtypes of the GABA transporter: GAT1, GAT2, GAT3, 
and BGT1.  GAT1 is the predominant GAT in the central nervous system (CNS).  
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Through in situ hybridization, immunocytochemistry, and fluorescence microscopy it has 
been found that GAT1 is found in high concentration in the cerebellum, hippocampus, 
and thalamic reticular nucleus (8).  GAT1 is expressed in astrocytes but primarily on 
axons and presynaptic terminals (boutons) of GABAergic inhibitory neurons.  Figure 3 
displays the localization of GAT1 in such a neuron.  This image was acquired from the 
cerebellum of a pre-natal mouse (E18) expressing a fusion of GAT1 to the green 
fluorescent protein (GFP).   
 
Figure 3.GAT1 localization in a neuron.  This image shows the localization of the GABA 
transporter, GAT1, in a neuron and its processes.  The localization of GAT1 is visualized 
through emission of a green fluorescent protein (GFP) molecule fused to GAT1.  The 
image represents primary cultures from the cerebellum of pre-natal (E18) mice 
expressing GAT1-GFP after 14 days of culture.  
  GAT3 is also specific to the central nervous system, being preferentially located 
on astrocytes and found in the olfactory bulb, cerebral cortex, thalamus, hippocampus, 
superior and inferior colliculus, substantia nigra, cerebellum, and brain stem (9-11).  
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GAT3 is believed to be developmentally regulated, being found in higher concentrations 
in the brains of post-natal mice versus adult animals (12).  Both GAT2 and BGT1 are 
preferentially found on astrocytes (non-neuronal support cells) in the CNS, and they are 
also found in the liver and the kidney (10, 11).   BGT1 is distinct from the other 
transporters, because it can transport sodium, chloride, and GABA in ratios of 3:2:1 or 
3:1:1 (13), in contrast to the previously described GAT ratio of 2 Na
+
 to 1 Cl
-
 to 1 
GABA.  BGT1 is also distinct because its role in the kidney and liver is to maintain the 
intracellular osmotic balance under hypertonic conditions (under increased extracellular 
solute concentrations), by transporting the osmolyte, betaine (13, 14).  Despite the fact 
that it can also transport betaine, BGT1 actually has a higher affinity for GABA than for 
betaine.  Given the role that BGT1 plays in maintaining osmolarity in peripheral tissues, 
it is believed that both BGT1 and GAT2 play a similar role of maintaining the osmotic 
balance within the CNS (1, 9).   
GAT1 Structure 
GAT1 contains twelve transmembrane (TM) domains with both the amino and 
carboxy termini located intracellularly (15).  Figure 4 displays a schematic of the 
transporter.  The membrane topology of GAT1 had been predicted through hydropathy 
plots and N-linked glycosylation scanning mutagenesis (16).   Another distinguishing 
characteristic of GAT1 is a large extracellular loop between TM 3--4 that contains three 
N-glycosylation sites.  Structurally, the SLC6 transporters form oligomers.  This 
hypothesis has been supported by fluorescence resonance energy transfer (FRET) studies 
with GAT, SERT, and DAT (17-19). 
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Figure 4. Schematic diagram of GAT1 membrane topology.  GAT1 contains 12 
transmembrane domains numbered from left to right with both the N-terminus and the C-
terminus found in the cytosol.  Although the figure is not drawn to scale, the transporter 
does contain a large second extracellular loop. 
In 2005, the crystal structure of the leucine transporter was solved to a 1.65 Å 
resolution (20).  The leucine transporter is bacterial in origin and shares 20--25% 
sequence identity to the transporters of the SLC6 family; hence, it is considered a 
homologue of SLC6 transporters.   The X-ray crystal structure showed 12 TM domains; 
thereby confirming the predicted membrane topology.  The structure also confirmed that 
the transporter formed homodimers and determined that the dimerization interface was 
just following TM12.   Prior to the crystal structure it was believed that transporter 
oligomerization was driven by a series of four repeated leucines (leucine heptad repeat) 
found within the TM2 (17-19).  Although the dimerization interface has now been 
confirmed to follow TM12, the previous work points to TM2 as a region significant to 
transporter structure and trafficking. 
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Figure 5. Schematic of GAT1 vesicle trafficking. GAT1 trafficking involves the movement 
of vesicles containing GAT1 from the Golgi along the axon and into the presynaptic 
terminal.  Although there is no change in GAT1 vesicle size at the presynaptic terminal, 
the size difference seen in the schematic is used to differentiate the two different GAT1 
vesicle populations.  The first pool of vesicles, represented by the larger vesicles, is 
termed the readily releasable pool.  These vesicles actively insert GAT1 into the plasma 
membrane through the process of exocytosis and remove GAT1 from the plasma 
membrane through the process of endocytosis, as indicated by the arrows.  The second 
pool is termed the reserve pool; they are represented by the smaller vesicles in the 
schematic.  As the name suggests, these vesicles are not actively involved in vesicle 
fusion, and they comprise a majority of the GAT1vesicle population, accounting for 70% 
of GAT1 vesicles.  
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GAT1 Trafficking 
 GAT1 trafficking refers to the steps from GAT1 translation and processing in the 
endoplasmic reticulum (ER) and Golgi apparatus to GAT1 arrival on the plasma 
membrane.  It also includes the retrieval of GAT1 from the membrane through the 
process of endocytosis and the recycling of GAT1 back to the membrane.  Figure 5 
displays the movement of vesicles containing the transporter from the Golgi, along the 
axon, and finally arriving at the presynaptic terminal where the GAT1 vesicles fuse to 
place GAT1 on the plasma membrane.  Many of the steps depicted in the schematic are 
regulated; therefore, what follows describes the protein interactions and GAT1 structural 
elements that control GAT1 trafficking. 
 The first steps in GAT1 trafficking involves export from the ER.  This step 
requires oligomerization of GAT1.  GAT1 mutants that are unable to oligomerize are 
therefore retained in the ER.  Additionally, GAT1 ER export and subsequent movement 
through the Golgi occurs through the action of COPII-coated vesicles, requiring the 
interaction between the RL motif on the GAT1 C-terminus (amino acids 566 & 567) and 
the COPII vesicle component, Sec24D (21, 22).  In contrast, a transporter with a mutated 
RL sequence is retained in the ER. 
 Once the transporter has met the necessary conditions for ER and Golgi export, 
the vesicle containing GAT1 is translocated to the plasma membrane by traversing 
microtubules along the axon to finally arrive at the presynaptic plasma membrane (Figure 
5).  Here, it is stationed either in a readily releasable pool (RRP) of vesicles, which 
actively inserts the transporter into the plasma membrane at a rate of 1.1 min
-1
, or it is 
part of the reserve pool of vesicles, which represents 70% of the total GAT1 pool (23).  
As the name implies, this pool does not actively traffic GAT1 onto the membrane; 
11 
 
 
 
however, if its role mirrors that the role of the synaptic vesicle reserve pool, then it can be 
recruited for vesicle fusion upon depletion of the RRP.    
 Vesicle fusion involves the interaction of vesicle SNARES (V-SNARES) with 
tethering SNARES (T-SNARES) on the plasma membrane.  The vesicle that traffics the 
transporter to the plasma membrane contains the V-SNARE, VAMP.  Additionally, it 
contains rab3A, a G-protein that aids exocytosis; rab11, a GTPase involved in vesicle 
recycling; and Syntaxin 1A, a T-SNARE that mediates vesicle fusion when on the plasma 
membrane (24).  This vesicle does not contain vGAT; therefore it is distinct from the 
synaptic vesicle that contains GABA.  It also does not contain synaptotagmin, which is 
the calcium sensor on neurotransmitter-containing vesicles (synaptic vesicles) that 
prompts vesicle fusion, nor does it contain synaptophysin, which is another marker of 
synaptic vesicles (24, 25).   
 The fusion of the GAT1 vesicle to the plasma membrane requires the interaction 
of the last 3 amino acids of GAT1 (alanine, tyrosine, and isoleucine) termed the 
postsynaptic density 95/Discs large/Zona occludens1 (PDZ) interacting motif, with a 
PDZ protein.  The mutation, truncation, or disruption of this motif results in impaired 
GAT1 trafficking, with 70% of the GAT1 that should be on the plasma membrane 
remaining in GAT1 vesicles (8).  Other proteins that increase GAT1 membrane 
localization include protein kinase C (PKC) (26-28), syntaxin 1A (29, 30), and tyrosine 
kinases (31, 32). 
 Once GAT1 has been delivered to the plasma membrane, it can also be retrieved 
from the plasma membrane through the process of endocytosis.  The average GAT1 
internalization rate is  0.7 min
-1
 (23).  As previously mentioned, tyrosine kinases increase 
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the exocytosis of GAT1; likewise, reduced phosphorylation of GAT1 by tyrosine 
phosphatases or by the inhibition of tyrosine kinase activity increases the GAT1 
internalization rate (31, 32).  This increase in GAT1 internalization by extension reduces 
the number of GAT1s that can transport GABA (33), thereby reducing GAT1 transport 
activity (31).    
GAT1 and Epilepsy: Current Therapeutic Approaches 
 GABA is the main inhibitory neurotransmitter in the CNS and when released into 
the synaptic cleft, it binds to GABAA, GABAB, and GABAC receptors (GABA binding to 
GABAA receptors is shown in Figure 1).  The binding of GABA to GABAA receptors in 
mature neurons results in the opening of the receptor and the movement of chloride ions 
through the receptor pore.  This movement of negative charge is defined as an inhibitory 
postsynaptic current, and it hyperpolarizes the cell; thereby reducing the ability of the 
neuron to fire excitatory currents (34).  Therefore, when GAT1 removes GABA from the 
synaptic cleft it terminates inhibitory signaling.  Since epilepsy is defined by abnormal 
neuronal excitation, drugs that target and inhibit GAT1 function should prolong neuron 
inhibition, thus serving as potent antiepileptics. 
 Tiagabine is currently the only FDA-approved drug that blocks GAT1.  Its side 
effects include: tremor, ataxia, dizziness, nervousness, sedation, and asthemia (3).  In 
order to determine whether these side effects are related to the block of GAT1 and not 
due to non-specific tiagabine interactions, complete knockout of the GAT1 gene was 
studied in a mouse.  The GAT1 knockout mouse neither changes the expression pattern 
of the major proteins involved in GABA transmission in the cerebellum nor in the 
hippocampus.  However, rotorad behavioral tests show that the mice exhibit loss of 
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muscular coordination (ataxia).  Additionally, open-field and exploratory cage tests 
reveal mouse anxiety and nervousness.  Tremor measurements show that the knockout 
mice exhibit constant 25--32 Hz tremor in their limbs and tails.  Electrophysiology 
performed on brain slices from the knockout mice, show an increased GABAA receptor-
mediated tonic conductance in both cerebellar granule and Purkinje cells, a slower decay 
of spontaneous inhibitory postsynaptic currents in cerebellar granule cells.  These results 
all indicate that knockout of GAT1 increases the extracellular GABA concentration.  
GAT1 knockout also produces behavioral and physiological effects that are similar to the 
side effects of tiagabine treatment.   This indicates that the tiagabine side effects are 
actually due to the blocking of the transporter, rather than from interactions with 
unintended targets.  In turn, this shows that a drug that exclusively blocks GAT1 may not 
be the most advantageous therapeutic agent, if tremor, ataxia, nervousness, and anxiety 
are to be avoided.   
Since the GAT1 knockout resulted in pronounced behavioral and physiological 
effects, an alternative treatment approach is necessary, which can confer fewer adverse 
drug effects.  One such approach would target one or more of the less predominant 
neuronal GABA transporters such as BGT1 (11, 35).  This has been tested with the 
anticonvulsant EF1502, which non-competitively blocks both GAT1 and BGT1.  EF1502 
blocks GAT1 at lower levels than tiagabine with IC50s for EF1502 and tiagabine of  4 
µM and 0.8 µM, respectively, and it blocks BGT1 at higher levels than tiagabine with 
IC50s for EF1502 and tiagabine of 22 µM and 300 µM, respectively (36).  Additionally, 
EF1502 has a significant effect on partial seizures as probed with animal seizure models 
(35).  These promising findings represent a new approach to the treatment of epilepsy. 
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In addition to the insight gained from the knockout mouse and EF,1502, research 
into transport reversal has gained a spotlight into the treatment of epilepsy.  The 
importance of transport reversal in the treatment of epilepsy is supported by recent work 
which finds that two anticonvulsants, gabapentin and vigabatrin enhance GAT transport 
reversal (6).  Additionally, in temporal lobe epilepsy (TLE) there is a decrease in 
transporter number (probed by 
3
H-nipecotic acid binding in rat hippocampus); such a 
decrease would reduce the contribution of transporter reversal on seizure inhibition.  TLE 
is also characterized by a decrease in glutamate-induced transport reversal (probed by 
human microdialysis probes of GABA concentration); since seizures are marked by 
elevated glutamate concentrations, a reduction in GAT ability to reverse in this state 
would again reduce the contribution of transporter reversal on seizure inhibition (6).   
Altogether, the drugs that target and treat epilepsy can function on a number of 
GAT1 processes.  Consequently, continued research into GAT1 protein interactions and 
structure may lead to the discovery of additional therapeutics targeting GAT1 function. 
Applying Fluorescence Microscopy to the Study of GAT1 
Studying GAT1 Vesicle Trafficking with Total Internal Reflection 
Fluorescence Microscopy 
 Discoveries in the field of vesicle fusion provide direct ties to translational 
research.  Studies of exocytosis have led to an understanding of the role of insulin 
secretion in type 2 diabetes (37) and to determining the mechanism of action of the 
antiepileptic drug levetiracetam (Keppra), which binds to the synaptic vesicle protein 
SV2A (38).  The foci of exocytosis studies have been to sensitively measure the time-
scale, protein recruitment, and regulation of each step in vesicle trafficking.  Vesicle 
fusion events have been visualized using the vesicular stomatitis virus
 
glycoprotein (39).  
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The kinetics of docking and fusion has been established through the use of 
proteoliposomes containing vesicle fusion proteins (SNARES) (40).  Although the 
SNARE proteins are well studied, only recently has fluorescence imaging been applied to 
understand the formation of the SNARE complex in fusion events (41).   
 To this end, I use total internal reflection fluorescence microscopy (TIRF) to 
study the dynamics of the GAT1 vesicle.  TIRF is a powerful technique, because it offers 
a better optical slice than confocal microscopy (~100 nm vs. ~500 nm).  The fiber optic 
cables used by the telecommunications industry also apply the principle of TIRF. The 
laws of reflection and refraction establish that when light travels from one medium into 
another, a portion may be reflected back into the starting medium and a portion may be 
transmitted into the second medium.  The index of refraction, (n), gives the ratio of the 
speed of light in a vacuum to the speed of light in a medium.  Snell’s law gives the 
relationship between indices of refraction of the mediums through which light travels (n1, 
n2), the angle of incidence of the light (1), and the angle of refraction of the light (2) 
(42): 
2211 sinsin  nn  . 
Furthermore, when a ray of light passes from a medium of high refractive index 
(for instance a glass coverslip) to one of lower refractive index (such as a neuron) a 
critical angle of incidence exists where no light is transmitted through the sample and 
100% of the light is reflected with no loss in intensity or frequency of the reflected light.  
This phenomenon is termed total internal reflection, and the critical angle (c) is given 
by: 
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Figure 6 displays the phenomenon of total internal reflection. 
 
Figure 6. Total internal reflection.  Point P is the light source with the light traveling 
from the high refractive index medium (glass) to the lower refractive index medium, 
(water).  With increasing angle of incidence, less refraction is seen until a critical angle, 
θcritical, where there is total internal reflection of the light.    
 In TIRF, energy is transmitted across the reflection plane via an evanescent wave.  
As the name suggests, this wave decays exponentially and allows for imaging within 
approximately 100 nm of the incident plane (43).  The advantage of this technique is the 
ability to excite fluorescent molecules near the coverslip.  In the case of cell cultures, 
TIRF would excite molecules on or near cell membranes adhering to the coverslip.  
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Figure 7 displays a cell illuminated such that the laser illuminates the entire sample 
(widefield fluorescence), and the same cell illuminated by a laser that is introduced at the 
TIR critical angle (TIRF).  The montage clearly shows that changing the laser angle 
reveals details on the cell membrane that were not visible under widefield fluorescence. 
  
Figure 7. Comparison of widefield fluorescence to TIRF.  The left panel shows a cell that 
has been illuminated with a laser that is introduced normal to the coverslip, resulting in 
illumination of the entire cell.  In contrast, the right panel shows the same cell, 
illuminated by a laser that is introduced at the TIRF critical angle.  Because the plasma 
membrane of the cell is adhered to the coverslip, the TIRF view reveals the cellular 
details at the plasma membrane more clearly. 
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 Achieving TIRF through a microscope objective lens requires that the maximal 
half-angle that the objective can collect photons is greater than the TIRF critical angle.  
This property of the lens is termed the numerical aperture (NA), and is defined by the 
relation: sinnNA .  A 1.45 NA objective is the minimum acceptable NA used in TIRF 
illumination, because it can obtain a maximal illumination and collection half angle of 
68.4º, a value that allows achievement of the TIRF critical angle of 65.2º.  In contrast, a 
standard 100X 1.4 NA objective can only obtain a maximum illumination half angle of 
63.8º; this value falls below the TIRF critical angle condition.  
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Studying GAT1 Structure through Fluorescence Resonance Energy 
Transfer 
 As previously mentioned, the GAT1 exists as an oligomer on the plasma 
membrane.  Fluorescence resonance energy transfer (FRET) is typically employed to 
probe the oligomerization state of a protein.  This technique allows for the determination 
of distances between neighboring molecules, essentially serving as a molecular ruler.  
There are certain conditions required for FRET to occur, which include the following: 
 the absorption spectrum of an acceptor fluorophore must overlap the emission 
spectrum of a donor fluorophore,  
 the donor and the acceptor molecules must be located within a distance of 10--
100 Å of one another, and 
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 the dipole moments of both fluorophores must be parallel. 
There are four primary methods of studying FRET.  These include: the three-cube 
method, donor photobleaching, fluorescence lifetime imaging, and donor recovery after 
acceptor photobleaching (DRAP).  In the DRAP method, the donor is excited, a 
wavelength stack of x-y images is collected and the acceptor is photobleached (44).  This 
iteration of image acquisition and photobleaching continues until complete photobleach 
of the acceptor is reached.  Figure 8 displays a representative DRAP FRET experiment.  
In this figure, cyan fluorescent protein (CFP) is the donor fluorophore and yellow 
fluorescent protein (YFP) is the acceptor fluorophore; therefore, CFP is dequenched with 
YFP photobleach.   
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Figure 8. Donor recovery after acceptor photobleach (DRAP) protocol for measuring 
FRET.  In this FRET approach, YFP is fully photobleached after 64 scans by the laser.  
The image also shows that as YFP is photobleached, there is an increase in CFP 
fluorescence, indicating FRET occurs between the two molecules.  (Explanation: When 
CFP is within 10--100 Å of a YFP molecule, it donates its energy to YFP, rather than 
emitting photons; however, when YFP is photobleached, CFP can emit photons, as 
indicated by the increase in CFP fluorescence.) Please note: The increase in CFP 
fluorescence is hard to discern by eye when looking at the “unmixed mGAT1-CFPCT 
image panels.” A clearer view of this increase is seen in the “lambda scan” images, 
where the cells clearly move from a green color (blue + yellow) to a deep blue color. 
FRET data is analyzed by normalizing fluorescence intensities to the initial 
fluorescence, and determining FRET efficiency using the following relation:
D
DA
I
I
E 1 , 
where E corresponds to the FRET efficiency.  IDA represents the intensity of the donor in 
the presence of the acceptor, this corresponds to donor fluorescence intensity prior to 
photodestruction of the acceptor.  ID represents the donor fluorescence intensity without 
the acceptor, corresponding to the dequenched donor fluorescence following 
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photodestruction of the acceptor (45).  From the FRET efficiency, the distance between 
the donor and acceptor fluorophores can be obtained from the following relation:
66
6
RR
R
E
o
o

 , where Ro is the Förster distance and is specific to the donor and acceptor 
used in the FRET experiment; it corresponds to the distance where the FRET efficiency is 
half maximal. 
Studying GAT1 Membrane Confinement with Fluorescence Recovery 
after Photobleaching 
 The lateral mobility of a protein on the plasma membrane is now accepted as a 
form of protein trafficking (23).  Lateral diffusion of the AMPA receptor is not only 
faster than trafficking by exocytosis, but it also accounts for a significant amount of 
AMPA receptor exchange in dendrites (46).  Fluorescence recovery after photobleaching 
(FRAP) allows for the measurement of molecular lateral mobility and diffusion (47).  In 
this technique, a region of interest is exposed with a high-intensity laser to irreversibly 
bleach fluorophores in the region.  After bleaching, diffusion of fluorescent molecules 
into the bleached region is monitored by acquisition of images with an attenuated laser.  
Raw data are corrected for the photobleaching that occurs during image acquisition and 
normalized by taking a ratio of the fluorescence in the observed region to the initial 
fluorescence value as follows: 
   )()()()(
)()(
ooNB tbtftbtf
tbtf


.  Here, the background 
fluorescence is represented by b(t), the fluorescence in a region not bleached is given by  
fNB (t), and the pre-bleach fluorescence intensity is represented by f(to).  A recovery curve 
is obtained from the data, and from this we can determine the fraction of molecules, Mf, 
that are free to diffuse, vs. those that are immobilized.  In the following equation, Fbo is 
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the is the initial fluorescence following photobleach and  F∞ is the asymptote of the 
recovery curve (48): .
1 bo
bo
f
F
FF
M


 
  
The diffusion coefficient is obtained by first 
determining the half time for fluorescence recovery using the following equations:
2
bo
h
FF
F

   , 
boh ttt 
2
1
 , where Fh is the value for fluorescence when half the 
recovery has occurred; th is the corresponding time for Fh; tbo is the time, following 
photobleaching, when the first recovery image is obtained; and 
2
1t  is the half time of 
equilibration (49).  Finally, the diffusion coefficient is related to the recovery half-time 
by the following relation: 
effD
t
2
2
1

 , where  is a constant that describes a circular 
Gaussian beam, ω is the radius of the bleach spot, and Deff is the effective diffusion 
coefficient 
 
(50). 
Summary of Thesis 
 In the following chapters, I visualize GAT1 membrane confinement, vesicle 
trafficking, and structure using the microscopy techniques outlined above.  In Chapter 2 I 
apply FRAP, FRET, and TIRF to determine the interactions that confine GAT1 at the 
membrane.  In Chapter 3 I apply TIRF to fluorescently resolve the vesicle that traffics 
GAT1 onto the plasma membrane, and to explore the kinematics of the GAT1 vesicle.  I 
also quantify the number of GAT1 molecules on a vesicle.  Chapter 4 applies FRET to 
determine the oligomerization state of the GAT1 mutants, and confocal microscopy to 
determine the localization of GAT1 on the plasma membrane.  Appendix I is a review of 
the structure, oligomerization, trafficking, and pharmacology of GABA transporter.  
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Finally, in Appendix II I apply TIRF to characterize the distribution of subunits of the 
neuronal nicotinic acetylcholine receptor on the plasma membrane. 
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Chapter 2: Ezrin mediates tethering of the γ-
aminobutyric acid transporter, GAT1, to actin filaments 
via a C-terminal PDZ domain 
 
This chapter has been submitted for publication.  We determine interactions that confine 
GAT1 at the membrane by investigating the lateral mobility of GAT1-YFP8 expressed in 
neuroblastoma 2a (N2a) cells.  I performed the FRAP, TIRF, and FRET experiments 
along with the analysis.  Fraser Moss performed the molecular biology, creating GAT1-
YFP8. 
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A high density of neurotransmitter 
transporters on axons and presynaptic 
boutons is required for efficient clearance of 
neurotransmitter from the synapse.  
Therefore, regulators of transporter 
trafficking (insertion, retrieval, and 
confinement) can play an important role in 
maintaining the transporter density necessary 
for effective function.  We determine 
interactions that confine GAT1 at the 
membrane by investigating the lateral 
mobility of GAT1-YFP8 expressed in 
neuroblastoma 2a (N2a) cells.  Through 
fluorescence recovery after photobleaching 
(FRAP) we find that a significant fraction (~ 
50%) of membrane-localized GAT1 is 
immobile.  The mobility of the transporter can 
be increased by depolymerizing actin or by 
interrupting the GAT1 PDZ-interacting 
domain.  Microtubule depolymerization, in 
contrast, does not affect GAT1 membrane 
mobility.  We also identify ezrin as a major 
GAT1 adaptor to actin.  Förster resonance 
energy transfer (FRET) determines that the 
distance between GAT1-YFP8 and ezrin-CFP 
is 64--68 Å.  This distance can be increased 
by disrupting the actin cytoskeleton.  
Altogether, our data reveal that actin confines 
GAT1 to the plasma membrane via ezrin, and 
this interaction is mediated through the 
GAT1-PDZ interaction domain. 
 
Key Words: GABA, transporter, GAT1, lateral 
mobility, trafficking, FRAP, actin, 
cytoskeleton, PDZ-interacting motif, 
fluorescent protein 
 
The -aminobutyric acid (GABA) transporter 
GAT1 (51), a member of the SLC6 family of 
neurotransmitter transporters, is a 12-
transmembrane domain protein that aids in 
terminating GABAergic synaptic signaling by 
transporting GABA into cells.  GAT1 is the 
predominant GABA transporter in the brain and is 
localized primarily on axons and presynaptic 
terminals of GABAergic inhibitory neurons; it is 
also expressed on astrocytes (52, 53). 
 
The uptake of each GABA molecule is coupled to 
co-transport of two Na
+
 ions and one Cl
-
 ion (54-
56).  The complete time for one transport cycle is 
~ 100 ms, which is longer than the ~ 10 ms 
decay time constant of GABAergic postsynaptic 
currents (57).  This implies that each transporter 
functions at most only once per synaptic event.  
To accommodate such functional constraints, a 
GAT1 density on the order of 1000 
transporters/µm
2 
is required (33).  The actual 
measured density of GAT1 molecules on several 
membranes, including presynaptic boutons and 
axons, is 800--1300 transporters/µm
2 
(33).  
Therefore, a high membrane density of GAT1 
underlies the efficient clearance of GABA from 
the synaptic cleft and from nearby extrasynaptic 
compartments.  Knowing that a high density of 
GAT1 on the membrane aids in clearance, one 
may ask how GAT1 trafficking is regulated and 
how GAT1 is restricted among membrane 
compartments.   
 
Some aspects of GAT1 trafficking have been 
studied, and GAT1 insertion and retrieval time 
constants of 1.1 and 0.7 min
-1
, respectively, have 
been obtained through biotinylation studies (23).  
Previous studies have also revealed that that 
30% of the GAT1 cellular pool exists within the 
plasma membrane.  The remaining 70% of GAT1 
is found in vesicles adjacent to the membrane 
surface.  The trafficking rates and the high 
number of reserve GAT1 vesicles have the 
potential to affect GAT1 membrane density and 
effectively increase GABA turnover.   
 
We seek an understanding of the restriction of 
GAT1 mobility at the membrane and by analogy 
the restriction of other SLC6 family transporters.  
To this end we apply FRAP to measure GAT1 
movement at the plasma membrane.  FRAP 
reveals both the time course and the mobile 
fraction for protein movement, which are 
governed by passive diffusion, by active 
processes, and by tethering within and near the 
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plane of the membrane.   Furthermore, lateral 
mobility is now accepted as a form of protein 
trafficking as revealed through recent work on 
postsynaptic receptors (α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor 
[AMPAR], N-methyl-D-aspartic acid receptor 
[NMDAR], GABAA subunits, and glycine receptor) 
(23).  Lateral diffusion of the AMPAR is not only 
faster than trafficking by exocytosis, but it also 
accounts for a significant amount of AMPAR 
exchange in dendritic spines (46).   
 
Since membrane protein mobility can be reduced 
or restricted by linkage to the cytoskeleton (58, 
59), we apply cytoskeleton disruptors to 
determine how interactions with actin and/or 
microtubules impact GAT1 mobility.   
 
Membrane confinement often occurs through a 
cytoskeleton adapter protein such as gephyrin, 
which serves as a scaffold between the glycine 
receptor and microtubules (60) or ezrin, which 
tethers the cystic fibrosis transmembrane 
conductance regulator (CFTR) to actin (61).  
Therefore, we utilize FRET to determine the 
proximity of an adaptor that may be involved in 
GAT1 restriction.   
 
Altogether, the data reveal novel interactions 
between GAT1, ezrin, and the actin cytoskeleton, 
and these interactions require the GAT1 C-
terminal PDZ-interacting domain. 
Results 
In this study, we used an optimized fusion protein 
between mouse GAT1 and, at the C-terminus, 
YFP, followed by an additional eight residues that 
incorporate a PDZ domain binding site.  This 
construct, GAT1-YFP8, produces the same 
maximal GABA uptake and has the same GABA 
concentration dependence as the wild type 
transporter.  We report elsewhere that the GAT1-
YFP8 transporter dimerizes correctly and is 
correctly trafficked to the plasma membrane.  We 
also report elsewhere that the N2a assay system 
is linear and nonsaturated.  Furthermore the 
surface/cytoplasmic expression ratio is sensitive, 
as in neurons, to disruption of the PDZ interaction 
motif at the C-terminus of GAT1.  We therefore 
believe that this assay system closely resembles 
the native GAT1 transporter, expressed in the 
GABAergic neurons that constitute the native 
environment of GAT1. 
Whole footprint photobleach reveals lateral 
mobility 
The question often arises whether FRAP actually 
detects lateral mobility or whether it detects 
fusion of vesicles, which are actively trafficking 
protein onto the membrane.  To address this 
question, we perform “whole footprint” FRAP.  
Figure 1A displays pre-bleach, post-bleach, and 
recovery images of a whole footprint FRAP 
experiment.  The post-bleach panel shows that > 
90% of the footprint surface area is 
photobleached, and it includes a line profile 
across the bleached region.  It is important to 
note that the ends of the line overlap non-
photobleached regions.  Figure 1B displays a 
kymograph, which represents the line profile, 
shown in Figure 1A, over time.  The kymograph 
shows that recovery occurs from regions not 
photobleached, with fluorophore entering from 
the edges.  This qualitative analysis indicates that 
FRAP largely reveals the lateral mobility of 
GAT1; however, it is possible that the speckles 
that appear in the image after ~ 60 s do represent 
some contribution from vesicle exocytosis (23).  
In separate experiments, we have visualized and 
tracked individual vesicles containing GAT1; 
these will be reported in a future study.  
 
Fitting Data to FRAP Diffusion Model 
Figure 1C displays GAT1 recovery in a FRAP 
experiment and two models for fitting to this 
recovery trace.  The diffusion model in Figure 1C 
is for a circular bleach spot; it is derived by 
Axelrod et al. and modified by Sprague et al. (62-
64).  The model is as follows: 
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Based on the Axelrod-Sprague equation,  is a 
constant that describes a circular Gaussian 
beam, D is the recovery time constant, ω is the 
radius of the bleach spot, Deff is the effective 
diffusion coefficient, A represents the recovery 
asymptote for GAT1-YFP8; therefore, is a 
correction factor that allows the diffusion model to 
converge to the GAT1-YFP8 recovery asymptote.  
Figure 1C shows that pure diffusion does not 
accurately describe the behavior of GAT1-YFP8 
recovery.  In particular, the model exhibits sharp 
recovery at early time points.  Figure 1C also 
displays fitting of GAT1-YFP8 recovery to a 
double exponential decay, which models the 
experimental data precisely.  The model is of the 
form: dtbtbo ceaeFtF
 )( , where Fbo is the 
initial value of fluorescence following 
photobleaching; a, b, c, and d are constants 
obtained through fitting.  Because the double 
exponential fitting more accurately describes 
GAT1-YFP8 mobility, t1/2 values are used in this 
study, rather than diffusion coefficients.  
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Comparing and Quantifying GAT1 mobility 
To give context to GAT1 mobility, we compare its 
mobility to minimally mobile and maximally 
mobile proteins, represented respectively by 
soluble YFP and by YFP-syntaxin1A, a 
membrane protein and t-SNARE.  Figures 2A 
and 2B display a montage of footprint 
photobleach performed on YFP, GAT1-YFP8 and 
YFP-syntaxin.  (Footprint photobleach is chosen, 
because YFP is not a membrane protein and 
cannot be accurately analyzed with a perimeter 
photobleach; however, its mobility near the 
membrane can be obtained by focusing near the 
coverslip).  Figure 2C displays the first 80 s of 
YFP, GAT1-YFP8, and YFP-Syntaxin recovery.  
Within the first seconds of detection, there is 
steep, unresolved recovery of YFP in which YFP 
recovers to 60% of its pre-bleach intensity; this 
limits the quantitative analysis of YFP mobile 
fraction.  However, a qualitative observation of 
Figure 2C shows that the YFP recovery 
asymptote is greater than that of GAT1-YFP8, 
and by extrapolating the initial YFP photobleach 
to 20% (GAT1-YFP8 Fbo), we can infer that YFP 
has a higher mobile fraction than GAT1-YFP8.  
As shown in Figure 2B, and as previously 
reported, YFP-syntaxin clusters to form 
exocytosis docking sites at the membrane, so it 
should not be expected to have high membrane 
mobility (65).  Figure 2C also displays the 
recovery of YFP-syntaxin from which a mobile 
fraction of 65% is calculated, resembling the 
GAT1-YFP8 mobile fraction of 60%.   
 
Photobleach Regions  
Variation in imaging settings such as laser 
intensity, bleach size/shape, and pixel dwell time 
can affect the results of quantitative photobleach 
experiments (66).  To provide additional 
confirmation of FRAP results, GAT1 experiments 
are performed by photobleaching the cell 
footprint and perimeter and comparing the trends 
seen between these regions of interest.  Figure 
3A displays a footprint photobleach montage.  
The 5 s post-bleach panel shows that the region 
photobleached was a circle of area 8 m
2
.  
Figure 3B displays a montage representing 
perimeter photobleach, where the laser was 
focused on a plane midway through the cell, and 
a rectangular section including the cell 
membrane, 13 m
2
 was photobleached.  It is 
important to note that perimeter photobleach 
recovery occurs in two dimensions, and the 
membrane fluorescence in the confocal slice is a 
line representation of this recovery.  Figure 3C 
displays the quantitative results of footprint and 
perimeter photobleach experiments, giving 
mobile fractions of approximately 60% and 50%, 
respectively.  These results suggest 40--50% of 
GAT1-YFP8 is immobilized.  Since a significant 
fraction of surface GAT1 is immobile, we explore 
the possibility of GAT1 tethering to the 
cytoskeleton. 
 
GAT1 interacts with cytoskeleton via actin but 
not via microtubules 
We apply nocodazole for ~ 12 h to maximally 
disrupt microtubules (67).  The first panel of 
Figure 4A displays microtubule distribution in an 
N2a cell labeled with TubulinTracker 488; the 
second panel includes nuclear labeling with 
Hoechst 33342.  Figure 4B displays microtubule 
distribution following nocodazole treatment, 
indicating complete microtubule 
depolymerization.  Figures 4C and 4D display the 
recovery traces following nocodazole treatment 
for footprint and perimeter photobleach, and for 
comparison, the recovery trace for an untreated 
sample.  All traces show that nocodazole 
treatment has no significant affect on either the 
recovery time constant or the size of the mobile 
population. 
 
Latrunculin B is used to disrupt actin filaments to 
determine whether GAT1 associates with actin.  
Figures 5A and 5B display cells with intact and 
disrupted actin filaments, respectively, as probed 
with rhodamine phalloidin labeling.  Figure 5C 
displays the footprint photobleach trace for cells 
with and without intact actin filaments.  Slight 
differences are observed between the untreated 
and the latrunculin B traces, which translates to a 
20% increase in mobile fraction, as summarized 
in Figure 6A.  Figure 5D displays the results of 
perimeter photobleach on cells with and without 
intact actin filaments.  More pronounced 
differences in the untreated and latrunculin B 
traces translate to a 60% increase in the time 
constant for recovery and a 20% increase in the 
mobile fraction as reported in Figures 6A and 6B.   
Cytochalasin D, another actin disruptor, was 
used to confirm the actin depolymerization 
results.  Figures 6A and 6B show that 
cytochalasin D treatment results in both an 
increased time constant and an increased mobile 
fraction compared to the untreated samples, 
resembling the latrunculin B results.      
 
Disrupting PDZ binding increases GAT1 
lateral mobility 
Typically, actin binding occurs through an 
adaptor protein or by an interaction with a 
scaffolding protein such as a PDZ protein (60, 
68-70).  To determine whether PDZ binding links 
GAT1 to the actin cytoskeleton, we perform 
quantitative photobleaching on GAT10-GFP, a 
fluorescent GAT1 that cannot interact with PDZ 
proteins.  In GAT10-GFP, added C-terminal 
residues (a linker followed by GFP) interrupt the 
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endogenous PDZ-interaction domain of GAT1 (C-
terminal sequence, -AYI-CO2
-
).  As a result, 
homozygous GAT10-GFP knock-in mice show a 
70% reduction in surface localization and 
synaptosomal GABA uptake (33).  Figure 6C 
illustrates the difference between the fluorescent 
GABA transporters in this study:  GAT10-GFP 
lacking all components to the PDZ-interacting 
domain versus GAT1-YFP8 having an added 
PDZ-interaction domain, downstream of the YFP 
moiety.   
 
FRAP is performed on N2a cells transfected with 
GAT10-GFP.  Figure 6D shows that GAT10-GFP 
is 30-40% more mobile on the membrane than 
GAT1-YFP8, indicating that the PDZ interaction 
domain contributes to GAT1 immobilization.  
Latrunculin B is added to probe the actin 
dependence of GAT10-GFP.   Figure 6D also 
shows that depolymerizing actin does not 
significantly affect the mobile fraction.  Since the 
PDZ-binding domain of GAT10-GFP is disrupted 
and shows no interaction with actin, we conclude 
that a GAT1 capable of interacting with PDZ 
proteins interacts with actin via its PDZ domain, 
either directly or indirectly. 
 
Ezrin and Pals1 are expressed in N2a cells 
FRAP results indicate that GAT1 interacts with 
the cytoskeleton through the PDZ-binding motif.  
Another membrane protein with this type of 
interaction is the Na
+
/H
+
 exchanger isoform 3 
(NHE3), which is restrained to actin through 
interactions with the PDZ protein, sodium-
hydrogen exchanger regulatory factor (NHERF) 
and the adaptor protein ezrin (71).  To determine 
whether ezrin could link GAT1 to the 
cytoskeleton, we first performed real time 
quantitative reverse transcription polymerase 
chain reaction (RT-PCR), testing for expression 
of two genes: the PDZ protein known to interact 
with GAT1, Pals1 (72), and the linker molecule 
ezrin.  Figure 7A shows that N2a cells express 
both ezrin and Pals1 at similar levels.  mRNA 
expression is normalized to the β-actin control.  
γ-actin was also used as a control, with 
expression levels similar to β-actin. 
 
FRET suggests a GAT1-ezrin interaction 
Figures 7B-F display the results of FRET 
experiments that combine donor recovery after 
acceptor photobleach with channel unmixing.  
Figure 7B shows pre-bleach and post-bleach 
images of a representative cell expressing GAT1-
YFP8 and ezrin-CFP.  Following photodestruction 
of GAT1-YFP8 with a 514 nm argon laser, there 
is a 23% increase in ezrin-CFP fluorescence 
(Figure 7B).  This increase is most prominently 
seen along the cell membrane.  Figure 7E also 
displays this increase in CFP fluorescence, which 
indicates FRET between the two fluorophores.  
The FRET efficiency between GAT1-YFP8 and 
ezrin-CFP of 19% ± 2% is shown in Figure 7F.  
Table 1 displays a proximity between GAT1-
YFP8 and ezrin-CFP of 64--68 Å.  This is 
calculated, by applying the FRET efficiency (ε) 
and Förster distance (Ro) for an ECFP-EYFP 
FRET pair of 50 Å to the following equation:
6
1


 oRr  (73).   
 
Inactive ezrin forms C-terminal to N-terminal 
dimers in the cytosol (74, 75).  Therefore, the 
previously studied FRET partners, ezrin-
CFP/YFP-ezrin (74) were used as a positive 
control.  As expected, Figure 7D shows that 
ezrin-CFP and YFP-ezrin are localized in the 
cytosol and exhibit the strongest interaction, with 
a distance of 63--67 Å between fluorophores 
(Table 1).  The localization of ezrin oligomers to 
the cytosol versus GAT1 to the plasma 
membrane may explain the difference in time 
course between the GAT1-YFP8 and YFP-ezrin 
photobleach curves (Figure 7E).  The cytosolic 
oligomer is expected to show less apparent 
photobleaching because of its mobility, as 
exemplified by cytosolic YFP in Figures 2A and 
2C.    
 
Actin disruption diminishes GAT1-ezrin 
interaction 
Figures 7C and 7E show that GAT1-YFP8 
photodestruction results in little or no increase in 
ezrin-CFP fluorescence when actin is disrupted.  
Latrunculin B exposure produces a FRET 
efficiency of 7% ± 5%, significantly less than the 
FRET value for both the untreated and ezrin-
CFP/YFP-ezrin control samples (Figure 7F).  This 
indicates that actin depolymerization greatly 
reduces the interaction between GAT1 and ezrin. 
Because 22% (5 of 23) GAT1-YFP8/ezrin-CFP + 
latrunculin B cells did not display detectable 
FRET, it is most appropriate to present an “at 
least” distance between GAT1 and ezrin following 
actin depolymerization (Table 1).   
Discussion 
This work establishes the role of lateral mobility 
in regulating GAT1 function by quantifying the 
mobility of GAT1 at the plasma membrane in an 
assay system resembling the native mouse 
neurons that express mGAT1.  Previous studies 
on membrane proteins have also employed 
FRAP, the most appropriate quantitative method 
for measuring membrane protein mobility in 
conjunction with manipulations of PDZ interaction 
domains (76-78), although to our knowledge this 
is the first application of FRAP to a 
neurotransmitter transporter of the SLC6 family.    
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Our FRAP experiments show that ~ 50% of the 
membrane-localized GAT1 molecules are mobile.  
Of the ~ 50% that are immobile, a fraction 
associates with the actin cytoskeleton.  This 
conclusion is based on a significant increase in 
the mobile fraction of GAT1 in two experiments: 
(1) in cells treated with pharmacological agents 
known to disrupt actin filaments, and (2) in cells 
expressing a form of fluorescently tagged GAT1 
with a disrupted PDZ-interaction domain.  
Importantly, the magnitude of the increase in the 
mobile fraction of GAT1 is similar in both of these 
experiments.  Moreover, the mobility of GAT10-
GFP, which has a disrupted PDZ-interaction 
domain, could not be further increased by 
treating cells with an actin disruptor, further 
implicating this domain in the GAT1-actin 
interaction.   
 
The fact that the PDZ domain of GAT1 plays an 
important role in tethering indicates a link 
between GAT1 and actin; most likely, this link is 
indirect and mediated by a PDZ protein and a 
linker protein.  Ion channel binding to PDZ 
proteins provides a model for this interaction.  
PSD-95/SAP-90, a member of the membrane-
associated guanylate kinase (MAGUK) family of 
PDZ proteins, serves as a scaffold for the NMDA 
receptor thereby clustering it on the postsynaptic 
membrane (79).  This type of PDZ scaffolding 
also occurs through the action of two known 
PDZ-domain-containing proteins (Na
+
/H
+
 
exchanger regulatory factor-1-2, NHERF1 and 
NHERF2) on the cystic fibrosis transmembrane 
conductance regulator (CFTR) (80).  CFTR is 
linked to the actin cytoskeleton through 
interactions between the PDZ domains of the 
proteins NHERF-1 and NHERF-2, and the actin 
binding protein, ezrin (61, 76).   
 
Recent biochemical investigations have 
established interactions between GAT1 and the 
PDZ protein, Pals1 (72) and between Pals1 and 
the actin adaptor, ezrin (81).  We show via RT-
PCR that Pals1 and ezrin are expressed in our 
cell system.  Furthermore, GAT1 and ezrin 
participate in a latrunculin B-sensitive interaction.  
A direct link between GAT1 and ezrin is unlikely, 
because such direct linkage is typically stabilized 
via a series of positively charged residues in the 
juxta-membrane region (82, 83), a region neither 
found on the GAT1 N-terminal nor the GAT1 C-
terminal domain.  Altogether, this indicates that 
the mobility of GAT1 is restricted by the actin 
cytoskeleton joined by a PDZ protein (for which 
Pals1 is a strong candidate molecule in many 
neurons) and ezrin.  
 
The cartoons in Figure 8 summarize these 
results. Figure 8A shows that an ezrin/PDZ 
complex can tether a membrane protein via the 
C-terminal PDZ interacting domain (AYI).   
Disrupting actin abolishes the tetramolecular 
GAT1-PDZ protein-ezrin-actin complex, either 
(Figure 8B1) by separating GAT1 from its PDZ 
protein or (Figure 8B2) by separating the ezrin-
PDZ protein interaction, this frees GAT1 and 
results in higher membrane mobility.  Finally, 
interrupting the endogenous C-terminal PDZ 
interacting domain of GAT1 with a linker and a 
GFP moiety, increases the membrane mobility of 
GAT1 (Figure 8C).  It is possible that other 
members of the ezrin-radixin-moesin family of 
filamentous actin binding proteins may play a role 
in restricting GAT1 movements (70, 84). 
 
The t1/2 values for recovery of untreated GAT1-
YFP8, are 3-10 times less than the t1/2 measured 
previously for GAT1 trafficking to and from the 
plasma membrane (23), supporting the idea that 
our measurements are not appreciably distorted 
by cytoplasmic / surface trafficking.  However, it 
is possible that the longest t1/2 measured after 
actin disruption, ~ 1 min, does represent a 
component from cytoplasmic-surface interaction, 
which is further supported by kymographic 
analysis of whole-cell photobleach (Supplemental 
Figure 1).  Furthermore, the increased t1/2 
following both latrunculin B and cytochalasin D 
treatment suggests that a GAT1 not bound to 
actin retains non-immobilizing interactions with 
certain molecule(s), which effectively increase its 
molecular weight.  This conclusion is based on 
the t1/2 relation to diffusion and subsequently to 
molecular mass (62-64). 
 
Microtubules play a well-established role in 
protein trafficking to the plasma membrane. 
Studies on the glycine receptor and GABAA 
subunits suggest that microtubules may also 
affect receptor restriction to the plasma 
membrane via gephyrin scaffolding (60, 68, 84-
86).  Our results show that neither GAT1 
immobilization nor its membrane diffusion 
depend on microtubules.    
  
Physiological significance of GAT1 
movements in the membrane  
The GAT1 link to actin via ezrin may point to the 
role of this interaction in the pathophysiology 
and/or treatment of epilepsy.  Although most 
studies on ezrin are focused on its role in 
epithelial structure, organization, and signaling, 
ezrin is also expressed in CNS neurons and is 
increased, at both the mRNA and protein levels, 
in certain epilepsies.  Ezrin is upregulated in the 
hippocampus of patients with mesial temporal 
lobe epilepsy (87, 88).  Likewise, in the lithium-
pilocarpine treated rat model of , a temporal lobe 
epilepsy (TLE)(89), ezrin upregulation occurs 
within 48 hours of seizure induction (90).  
Epilepsies associated with malformations of 
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cortical development such as focal cortical 
dysplasia (FCDIIb  and FCDIIa) and 
gangliogliomas are also marked by neuronal 
ezrin accumulation (91).  Although the role of 
ezrin upregulation in seizure progression has not 
been formally identified, recent evidence points to 
the role of ezrin as a downstream target in the 
phosphoinositide 3-kinase (PI3K) pathway (91, 
92).  
 
TLE also has strong ties to GABA transport; 
although TLE is marked by a loss of hippocampal 
neurons, GABAergic interneurons are preserved.  
In TLE there is a decrease in the number of 
GABA transporters (5, 6).   
 
The identification of the interaction between 
GAT1, ezrin, and actin and the quantitative study 
by FRAP contributes to further understanding of 
how transporters are clustered, regulated and 
confined on the cell surface.   Because GAT1 is 
an important drug target in the treatment of 
epilepsy, continued research into these protein 
interactions may lead to the discovery of 
additional therapeutics targeting GAT1 function 
(7, 93-95).  
Materials and Methods 
Molecular Biology  
The GAT10-GFP construct has been described, 
and was previously termed mGAT1-GFP (33).  In 
GAT10-GFP, added C-terminal residues (a linker 
followed by GFP) disrupt the endogenous PDZ-
interaction domain of GAT1 (C-terminal 
sequence, -AYI-CO2
-
). 
 
To generate the new fluorescent mutant, GAT1-
YFP8, we added an intact PDZ-interaction motif 
at the C-terminus, following the YFP moiety.  The 
wild-type mGAT1 open reading frame (ORF) was 
subcloned without its endogenous stop codon in 
to the Hind III and EcoR I sites of the 
pcDNA3.1(+) expression vector (Invitrogen, 
Carlsbad, CA) multiple cloning site (MCS).  The 
yellow fluorescent protein (YFP) (Clontech, 
Mountain View, CA) ORF into which we 
introduced the “monomeric”  A206K mutation (96) 
was then subcloned downstream from, but in 
frame with the mGAT1 ORF at the Not I and Xba 
I sites of the pcDNA3.1(+) MCS.  This resulted in 
a 12 amino acid spacer between the end of the 
mGAT1 sequence and the beginning of the 
fluorophore.  We modified Geiser et al.’s method 
for the integration of PCR fragments without the 
use of restriction enzymes (97) to then add 8 
codons worth of hGAT1 C-terminal sequence.  
These were amplified from a source plasmid 
using PfuTurbo Cx Hotstart polymerase with 5’ 
and 3’ extensions that corresponded to the 20--
22 nucleotide regions that flanked the intended 
site of insertion such that the PCR product 
integrated in frame immediately after the 
fluorophore sequence when used as the primers 
in a subsequent QuikChange II XL mutagenesis 
PCR reaction (Stratagene, La Jolla, CA).   
 
Ezrin-CFP and YFP-ezrin, gifts from Dr. Forte 
and Lixin Zhu, are previously described in Zhu et 
al. (74).  YFP-syntaxin, a gift from Dr. W. Almers, 
is previously described in An et al. (41). 
N2a Culture  
Mouse neuro-2a (N2a) cells (ATCC, Manassas, 
VA) are grown at 37 C in 95% air, 5% CO2 in 
N2a culture medium containing the following:  
44.5% DMEM, 44.5% OptiMEM, 10% fetal bovine 
serum, and 1% penicillin/streptomycin (10,000 
I.U penicillin, 10,000 mg/ml streptomycin) 
(Invitrogen, Carlsbad, CA).  Once cells are grown 
to confluence, cells are plated on glass bottom 
dishes at a density of 3×10
5
 cells/dish.  Prior to 
plating, 14 mm glass bottom dishes (#0, Mattek, 
Ashland, MA) are coated with 0.05% 
polyethylimine (PEI) (Sigma, St. Louis, MO) pH 
8.4 in borate buffer.  Transfection of a total of 1 
µg DNA per plate is performed 16--24 hr later 
with Lipofectamine and Plus reagent (Invitrogen, 
Carlsbad, CA).  The composition of the N2a 
imaging solution is as follows (mM): 128 NaCl, 
2.4 KCl, 25 HEPES, 1.2 MgCl2, 3.2 CaCl2, 
1.2 KH2PO4, and 10 D-glucose (98).   
Nocodazole treatment 
Cells are pretreated with 10 µM nocodazole in 
cell culture medium at 37 C for 16--24 hr.  This 
concentration and incubation time follow 
established protocols for maximally 
depolymerizing microtubules (67, 99, 100).  
Nocodazole (Sigma, St. Louis, MO) is dissolved 
in DMSO in a concentration of 5 mg/ml and 
stored at -20 C.  Nocodazole is added to N2a 
culture medium and cells are incubated for 16--
24 hr.  Prior to imaging, N2a culture medium is 
aspirated from cells, and cells are washed with 
imaging solution containing 10 µM nocodazole.  
Cells are allowed to equilibrate at room 
temperature for 30 min in the 10 µM nocodazole 
containing imaging solution. 
 
Latrunculin B and Cytochalasin D treatment 
Latrunculin B (Sigma-Aldrich, St. Louis, MO) is 
dissolved in DMSO and stored at -20 C at a 
stock concentration of 2.5 mM.  5 µM latrunculin 
B is added to imaging medium and warmed to 
37 C.  Cells are washed with warm imaging 
medium and the latrunculin B solution is added to 
cells.  Cells are incubated for 1 hr in latrunculin B 
solution prior to imaging.  Cytochalasin D (Sigma, 
St. Louis, MO) is dissolved in DMSO and stored 
at -20 C at a stock concentration of 1 mg/ml.  
1 µg/ml cytochalasin D is added to imaging 
medium and warmed to 37 C.  Cells are washed 
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with warm imaging medium and the cytochalasin 
D solution is added to cells.  Cells are incubated 
for 1 hr in cytochalasin D solution prior to 
imaging.   
Microtubule and Nuclear labeling with 
TubulinTracker Green and Hoechst 33342 
Microtubules are labeled according to the 
suppliers instructions using TubulinTracker 
Green reagent for live-cell tubulin labeling 
(Molecular Probes, Eugene, OR).  Briefly, N2a 
nucleus is stained by addition of 10 µg Hoechst 
33342; microtubules are stained with 
TubulinTracker in HBSS by incubating for 30 min 
at 37 ºC in a 5% CO2 incubator. Cells are rinsed 
three-times with warm imaging solution. 
Actin Labeling with Rhodamine Phalloidin  
A 14 µM rhodamine-conjugated phalloidin 
(Cytoskeleton, Denver, CO) stock solution is 
prepared by dissolving in methanol and storing at 
-20 C.  A fresh 4% solution of paraformaldehyde 
(Fluka, St. Louis, MO) at pH 7.4 is prepared.  
Medium is aspirated from dishes and cells are 
rinsed twice with 1 X PBS.  The 10 min, room 
temperature fixation and staining are performed 
by combining 4% paraformaldehyde, 0.1% Triton, 
and 2 units (5 µL) rhodamine phalloidin per dish.  
Following fixation, cells are washed twice with 
1 X PBS.   
Confocal Imaging 
All FRAP experiments are performed in the 
Caltech Biological Imaging Center on an inverted 
Zeiss 510 Meta (Carl Zeiss, Thornwood, NY) 
using a 63 X Plan-Apochromat 1.4 NA oil 
immersion objective.  The fluorescence is 
collected using a HFT KP 700/514 nm beam 
splitter and a 535 --590 nm bandpass filter.  The 
detector gain is modified to allow for near-
saturating conditions for a given region of interest 
(ROI).  There is no change to gain settings for a 
given ROI.  For footprint photobleach a circular 
ROI is chosen with an area of 9.4 ± 0.9 µm
2
.  For 
perimeter photobleach, a rectangular ROI is 
chosen with an area of 12.5 ± 1.2 µm
2
.  ROIs are 
photobleached at 25% laser transmission using 
the 514 nm laser line of a 40 mW argon laser.  
Photobleaching was optimized to obtain ~ 80% 
photodestruction within the ROI.  This was 
performed by lasing each ROI 20 times at 25% 
laser transmission with a 1.60 µs pixel dwell time.  
Pre-bleach and recovery images are collected at 
0.25% laser transmission at 5 s intervals.  Lens 
zoom is set to 3 X.  12-bit images are collected at 
pixel resolution of 512 x 512.  Pinhole diameter is 
set to 144 μm. 
 
Dye labeled N2a cells are imaged on an inverted 
Zeiss 510 Meta at 12 bits and 512x512 pixel 
resolution.  Stack slices were 0.10 µm.    Hoechst 
33342 nuclear labeled cells are imaged using a 
Plan-Apochromat 100x 1.4 NA oil immersion 
objective.  Cells are excited using a two-photon 
pulsed laser tuned to 700 nm at 2.5% laser 
transmission.  The fluorescence is collected 
using a HFT KP 700/488 beam splitter and FT 
510 and BP 390--465 IR filters.  A stack slice is 
100 nm and the pinhole diameter is maximal (693 
µm).  TubulinTracker green labeled N2a cells are 
imaged using a 100x 1.4 NA oil immersion 
objective.  Cells are excited with a 488 nm argon 
laser at 2.5% laser transmission.  Fluorescence 
is collected with a HFT 488 beam splitter and 
NFT 490 and BP 500--550 IR filters.  The stack 
slice is 100 nm and the pinhole diameter is 213 
µm.  Rhodamine phalloidin labeled N2a cells are 
imaged with a Plan-Neuofluar 63x 1.25 oil 
immersion objective.  Cells were excited with a 
543 nm helium neon laser at 7.75% laser 
transmission.  The fluorescence is collected 
using a 488/543 beam splitter and NFT 545 and 
BP 565--615 filters.  Zoom is 2X, a stack slice is 
550 nm, and the pinhole is 121 µm. 
 
FRET experiments are performed on a Nikon 
(Nikon Instruments, Melville, NY) C1 laser-
scanning confocal microscope system equipped 
with spectral imaging capabilities and a Prior 
(Rockland, ME) remote-focus stage as described 
in Drenan et al. (101).  Spectral FRET analysis is 
performed as described in Nashmi et al. (102). 
Data are reported as mean ± SEM.   
FRAP Analysis 
Raw data are processed using algorithms written 
in house (Matlab: MathWorks, Natick, MA) to 
obtain the ratio fluorescence = 
   )()()()(
)()(
ooNB tbtftbtf
tbtf


.  This expression is 
obtained by subtracting the background 
fluorescence, b(t), correcting for photobleaching 
that occurs during recovery scanning by 
obtaining the fluorescence in a region not 
bleached, fNB (t), and normalizing to the pre 
bleach fluorescence intensity f(to).  Normalized 
traces are averaged; error bars are calculated as 
the standard error of the mean.  Normalized data 
are fitted to a double exponential, 5 parameter 
regression in SigmaPlot (Systat Software Inc., 
San Jose, CA) of the form: 
dtbt
bo ceaeFtF
 )( , where Fbo is the initial 
value of fluorescence following photobleaching, 
a, b, c, and d are constants obtained through 
fitting. The mobile fraction is determined by 
applying regression data to the following 
equation: 
bo
bo
f
F
FF
M


 
1
, where Mf is the mobile 
fraction and F∞ is the asymptote of the recovery 
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curve.  Values for 
2
1t  were determined by 
applying regression data to the following 
equations:
2
bo
h
FF
F

   , 
boh ttt 
2
1
 where Fh 
is the value for fluorescence when half the 
recovery has occurred, th is the corresponding 
time for Fh, tbo is the time, following 
photobleaching, when the first recovery image is 
obtained, and 
2
1t  is the half time of equilibration 
(49). 
Real time quantitative reverse transcription 
PCR 
Total RNA is prepared using the RNeasy Plus 
Mini Kit (Qiagen, Valencia, CA).  RNA 
concentrations are quantified using the ND-1000 
UV-Vis Spectrophotometer (Nanodrop 
Technologies, Wilmington, DE).  The primer and 
probe sets for Pals1, ezrin, β-actin, and γ-actin 
are designed by the Roche Universal Probe 
Library (UPL) Assay Design Center (Roche 
Applied Science, Indianapolis, IN).  Primer sets 
were obtained from Integrated DNA Technologies 
(Coralville, IA).  Table 1 displays the primer and 
probe sets used for RT-PCR analysis of each 
gene in N2a cells.  One step RT-PCR is 
performed using the hydrolysis probe mix, 96-
well plates, and the LightCycler 480 RNA Master 
system (Roche Applied Science) according to 
manufacturer instructions.  Briefly, samples along 
with serially diluted mRNA (1:50, 1:100, 1:1000, 
1:5000, 1:10000) are added to a plate, 
centrifuged 2 min at 1500 x g, and loaded into the 
instrument. The one step RT-PCR is performed 
as follows: 1 cycle reverse transcription at 61 ºC 
for 12 min; 1 cycle denaturation at 95 ºC for 30 s; 
45 cycles amplification at 95 ºC for 10 s, 57 ºC for 
30 s, and 72 ºC for 1 s; and 1 cycle cooling at 50 
ºC for 10 s.  Serial dilutions of mRNA provide the 
standard curves needed to quantify relative 
mRNA concentrations.   
Statistical Analysis  
Values are expressed as mean ± SEM.  Unless 
otherwise noted. p < 0.05 is considered 
statistically significant. 
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Figure Legends 
 
Figure 1: Whole footprint photobleach reveals lateral mobility.  A) Confocal images of GAT1-YFP8 
localized at the cell footprint are shown before, and after photobleaching an area representing > 90% of the 
footprint surface area.  Proportion bar,10 µm.  B) The kymograph is obtained by performing line profile 
analysis of the photobleached region and plotting the line profile over time.  The intensity ramp shows that 
photobleached regions are represented by the lower intensity colors, and increased fluorescence is 
represented by higher intensity colors.  C) The diffusion model was simulated using the Axelrod-Sprague 
pure-diffusion model and data from GAT1-YFP8 footprint FRAP recovery.  The GAT1-YFP8 recovery curve 
is not well fit by the Axelrod-Sprague pure-diffusion model.  The GAT1-YFP8 footprint FRAP recovery curve 
does fit to a double exponential decay equation, dtbtbo ceaeFtF
 )(
 
with a, b, c, & d = 3.3, 0.30, 0.45, & 
0.033, respectively. 
 
Figure 2: Comparing GAT1 mobility.  Footprint FRAP performed on (A) YFP, GAT1-YFP8 and (B) YFP-
syntaxin.  (C) Recovery curves show that YFP, which exhibits cytosolic localization, has a faster recovery 
than either of the membrane proteins.  The initial YFP recovery is faster than the frequency of detection.  
The membrane proteins, GAT1-YFP8 and Syntaxin-YFP, recovered at nearly equivalent rates.   
 
Figure 3: Photobleached regions.  FRAP pre-bleach and post-bleach images of N2a cells expressing 
GAT1-YFP8.  A) Photobleaching is confined to the cell footprint indicated by the red circle 8 m
2
.  Scale bar, 
3 µm.  B) Photobleaching is confined to the cell perimeter, indicated by the red rectangle 13 m
2
.  Scale bar, 
4µm.  C) GAT1-YFP8 footprint photobleach gave a recovery t1/2 = 10 s and a mobile fraction of 60%.  GAT1-
YFP8 perimeter photobleach gave a recovery t1/2=20 s and a mobile fraction of 50%.   
 
Figure 4: GAT1 does not associate with microtubules.  A/B) Microtubules are visible after treatment with 
TubulinTracker 488.  The second panel sets display nuclear labeling with Hoechst 33342.  B) Microtubules 
are disrupted by treatment with 10 µM nocodazole.  Scale bars, 10 µm.  C/D) Traces display GAT1-YFP8 
fluorescence recovery in cells with and without intact microtubules.  Cells are photobleached at the (C) 
footprint and at the cell (D) perimeter.  
 
Figure 5: GAT1 associates with cytoskeleton through an interaction with actin.  A/B) Actin is visible 
after N2a cells are treated with rhodamine-conjugated phalloidin.  B) Actin filaments are disrupted by 
treatment with latrunculin B.  Scale bars, 10 µm.  Traces display GAT1-YFP8 fluorescence recovery in cells 
with and without an intact actin network.  Fluorescence is photobleached at the cell (C) footprint and at the 
cell (D) perimeter.  
 
Figure 6: Summary of GAT1 mobile fractions and recovery time constants.  A) GAT1-YFP8 mobile 
fraction.  Disrupting actin with 5 µM latrunculin B significantly increases the amount of freely diffusing GAT1 
on the plasma membrane (p < 0.001, t-test).  The addition of 1 µg/ml cytochalasin D, another actin 
depolymerizer, also significantly increases the mobile fraction when probed with footprint photobleach (p < 
0.001, t-test).  Depolymerizing microtubules with 10 µM nocodazole does not affect the mobile fraction of 
GAT1-YFP8.  B) GAT1-YFP8 time constant.  Disrupting actin with cytochalasin D or latrunculin B increases 
the time for recovery with perimeter photobleach (p < 0.05, Mann-Whitney).  Cytochalasin D treatment also 
significantly increases the time constant for recovery with footprint photobleach (p < 0.05, Mann-Whitney).  
Microtubule disruption does not significantly affect the time constant. [GAT1-YFP8 footprint: n = 18, GAT1-
YFP8 + nocodazole footprint: n = 8, GAT1-YFP8 + latrunculin B footprint: n = 12, GAT1-YFP8 + cytochalasin 
D footprint: n = 10. GAT1-YFP8 perimeter: n = 12, GAT1-YFP8 + nocodazole perimeter: n = 9, GAT1-YFP8 
+ latrunculin B perimeter: n = 12, GAT1-YFP8 + cytochalasin D perimeter: n = 10.]  C) Schematics of GAT1-
YFP8 and GAT10-GFP.   GAT10-GFP is mostly found in vesicles near the plasma membrane (33); this faulty 
trafficking arises because the addition of linker and GFP moiety interrupts the PDZ binding motif.  GAT1-
YFP8 traffics properly due to the addition of 8 amino acids following the fluorescent protein, the final 3 amino 
acids being a consensus PDZ-binding motif, AYI-CO2
-
.  D)  GAT10-GFP has a higher mobile fraction than 
GAT1-YFP8 (p < 0.05, t-test).  Disrupting actin does not significantly affect the mobile fraction of GAT10-
GFP compared to GAT10-GFP mobility in cells with intact actin.  [GAT10-GFP footprint: n = 9, GAT10-GFP + 
latrunculin B footprint: n = 9 GAT10-GFP perimeter: n = 12, GAT10-GFP + latrunculin B perimeter: n = 10]. 
 
Figure 7: Real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) 
determines the expression of ezrin and Pals1 in N2a cells, and FRET reveals an interaction between 
ezrin and GAT1-YFP8.  A) mRNA levels of β-actin, γ-actin, ezrin, and Pals1, normalized to β-actin 
expression.  One-step RT-PCR shows that ezrin is expressed in N2a cells at levels similar to the PDZ 
protein Pals1.  B/C/D/E/F) FRET results.  When CFP and YFP fusion proteins are in close proximity (10-100 
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Å), 440 nm excitation of CFP (donor) results in nonradiative transfer of energy (FRET) to YFP (acceptor), 
resulting in an emission peak of 527 nm.  Acceptor photobleaching reveals FRET by measuring incremental 
dequenching of CFP during photodestruction of YFP with a high intensity 514 nm laser line.  Spectral 
imaging was performed on a confocal microscope at 5 nm resolution.  B/C/D) Display pre-bleaching and 
post bleaching images of the respective CFP and YFP fused proteins.  Scale bar 5 µm.  E) GAT1-YFP8 and 
ezrin-CFP interact as represented by the 25% ± 3% increase in ezrin-CFP fluorescence with 
photodestruction of GAT1-YFP8.  The disruption of actin through addition of 5 µm latrunculin B significantly 
abolished FRET between ezrin-CFP and GAT1-YFP8.  As a positive control, FRET between YFP-ezrin and  
ezrin-CFP was performed, resulting in a 26% ± 3% increase in ezrin-CFP fluorescence with 
photodestruction of YFP-ezrin.  F) The FRET efficiency for ezrin-CFP/GAT1-YFP8 was 19% ± 2%, for ezrin-
CFP/GAT1-YFP8 + latrunculin B 7% ± 5%, and for ezrin-CFP/YFP-ezrin was 20% ± 2%.  Values are 
represented as the mean of 23 replicates ± SEM.  Significance was determined by Tukey’s one way analysis 
of variance p < 0.05. 
 
Figure 8: Schematic of GAT1 interaction with Pals1, ezrin, and actin.  A) Schematic of GAT1-YFP8 
interaction with actin via ezrin and Pals1.  The additional PDZ domain following the YFP moiety restores the 
interaction between GAT1 and the PDZ protein.  B) The addition of 5 µM latrunculin B disrupts actin, 
reduces the interaction between ezrin and GAT1 either by (B1) pulling away the GAT1-PDZ interaction or by 
(B2) reducing the interaction between ezrin and the PDZ protein.  Altogether, this increases the mobility of 
GAT1 on the membrane.  C) GAT10GFP, a GAT1 with a disrupted PDZ domain, is more mobile on the 
membrane, indicating that this domain may also stabilize the GAT1-ezrin-actin interaction.   
 
Supplemental figure 1: Whole footprint photobleach of latrunculin B treated cells. A) Confocal images 
of GAT1-YFP8 localized at the cell footprint are shown before and after photobleaching an area of the cell 
representing > 90% footprint.  Proportion bar,10 µm.  B) A kymograph is obtained by performing line profile 
analysis of the photobleached region and plotting the line profile over time.  The intensity ramp shows that 
photobleached regions are represented by the lower intensity colors, and increased fluorescence is 
represented by higher intensity colors.  
  
Supplemental figure 2: Total internal reflection fluorescence images of N2a cells transfected with 
GAT1-YFP8 A) GAT1-YFP8 localizes on the cell membrane and in filopodia.  Neither overnight treatment 
with (B) 10 µM nocodazole nor (C) 1 hr treatment with 5 µM latrunculin B affect cell attachment to the 
coverslip.  C) Latrunculin B treatment does significantly reduce the number of filopodial contacts the 
coverslip.  
 
Supplemental figure 3: Comparison of GAT1 mobile fractions.   Perimeter photobleach indicates that 
disrupting actin filaments via latrunculin B treatment results in a significantly reduced recovery time constant 
for GAT10-GFP compared to GAT1-YFP8 (p < 0.05, Mann-Whitney).  This result suggests that a GAT1 that 
can interact with PDZ proteins has a higher effective molecular weight than a GAT1 that cannot interact with 
PDZ proteins (recovery time constant proportional to the molecular weight of the species).  [GAT10-GFP 
footprint: n = 9, GAT10-GFP + latrunculin B footprint: n = 9 GAT1-YFP footprint: n=18, GAT10-GFP 
perimeter: n = 12, GAT10-GFP + latrunculin B perimeter: n = 10, GAT1-YFP8 perimeter: n=12]. 
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Table 1. Distance between fluorophores obtained from FRET  
FRET Pairs r  (Å) 
GAT1-YFP8/Ezrin-CFP, n=25 66 ± 2 
YFP-Ezrin/Ezrin-CFP, n=25 65 ± 2 
GAT1-YFP8/Ezrin-CFP + Latrunculin B, n=18 > 72
 
*The “at least” estimate is presented because 5 out of 23 cells do not display FRET.  Cells not exhibiting 
FRET would indicate fluorophore distances > 100 Å.   
 
 
 
 
 
Table 2. Primers and UPL probes used in RT-PCR analysis of Pals1, ezrin, β-actin, and γ-actin 
expression in N2a cells.  All primer/probe sets were designed using the Roche Universal Probe 
Library Assay Design Center. 
 
Protein  
(Gene accession #) 
Primer Sequences  
UPL 
# Forward (5’ 3’) Reverse (5’ 3’) 
Pals1   
(NM_019579.1) 
TGATTCCTAGTCAACAGATCAAGC GTCAAAATGAGCTTTCACATGG 51 
Ezrin  
 (NM_009510.2) 
AGCCGAATAGCCGAGGAC GTCACCCGGACGTTGATT 21 
β-Actin   
(NM_007393.1) 
CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA 64 
γ-Actin   
(NM_009609.2) 
GAGCACGCTGTAGATGAGAAAG GATCACTCAGTGGTGCTCACA 64 
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Chapter 3: Total internal reflection fluorescence 
microscopy and single molecule analysis reveal GAT1 
vesicle kinematics and number of GAT1s per vesicle 
 
Discoveries in the field of vesicle fusion provide direct ties to translational research.  
While the study of vesicle fusion classically has been applied to neurotransmitter- and 
neuropeptide-containing vesicles; there is evidence that secretory vesicles physiologically 
differ from vesicles trafficking membrane protein.  For instance, GAT1 resides on a 
vesicle lacking neurotransmitter but containing some v-SNARE proteins. These 
differences in the vesicle composition suggest inherent differences in trafficking 
mechanisms, which can only be confirmed through further study of membrane protein 
trafficking.  To this end, I apply total internal reflection fluorescence microscopy 
(TIRFM) to quantify the number of GAT1 molecules on vesicles and to observe the 
movement of vesicles containing fluorescently tagged GAT1 into the plasma membrane.  
I determine that these vesicles contain 3--7 molecules of GAT1 and uncover a population 
of GAT1 vesicles with ATP-dependent lateral displacement. 
 
 
58 
 
 
 
 
Introduction 
 GABA transporter subtype 1 (GAT1) transport of GABA into the presynaptic 
nerve terminal helps to maintain
 
low extracellular GABA concentrations throughout the 
brain,
 
prevent excessive tonic activation of synaptic and extrasynaptic
 
receptors, and 
replenish
 
the supply of presynaptic transmitter (1).  Due to the important role GAT1 plays 
in modulating neuronal inhibition, many studies have focused on identifying regulators of 
GAT1 function.  Some GAT1 regulators affect the dynamics the GAT1 vesicle, by 
controlling GAT1 internalization rates.  For example, syntaxin 1A, a T-SNARE, can 
down-regulate GAT1 transport activity through interaction with the N-terminus of GAT1, 
and it can also increase the expression of GAT1 on the plasma membrane (2, 3).  Protein 
kinase C (PKC) and tyrosine kinases can also increase GAT1 surface expression (4-7), 
with tyrosine kinases specifically decreasing GAT1 internalization rates.  Additionally, 
when GAT1 contains a mutant PDZ domain, the transporter remains in the GAT1 vesicle, 
adjacent to the plasma membrane.  This trafficking deficiency reduces GABA uptake by 
up to 70% (1, 8).  Given that GAT1 trafficking plays an important role in GAT1-function, 
more study is needed into the vesicle that places GAT1 on the membrane.  
 The study of vesicle movement has been classically applied to neurotransmitter- 
and neuropeptide containing vesicles; however, there is evidence that synaptic vesicles 
differ from membrane protein trafficking vesicles, physiologically.  For example, the 
GAT1 vesicle lacks neurotransmitter; the calcium sensor, synaptotagmin; and the 
synaptic vesicle marker, synaptophysin (9).  Surface biotinylation has also shown that the 
GAT1 vesicle contains the V-SNARE, VAMP, along with rab11, rab3a, and syntaxin 1A 
(9).  These differences in the vesicle composition suggest inherent differences in 
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trafficking mechanisms, which can only be confirmed through further study of GAT1 
trafficking. 
 Much of what is known about GAT1 trafficking has been established through 
studies on the glucose transporter, GLUT4.  Between the two transporters there is 
similarity in second messenger signaling; PKC isoforms translocate both GLUT4 and 
GAT1 from vesicles onto the membrane (5, 10).  However, all membrane protein vesicles 
may not respond to the same cues.  There is at least one known difference between the 
trafficking of the non-neuronal GLUT4 and GAT1.  GLUT4 vesicle fusion is upregulated 
by insulin (10), whereas there is no known correlating substrate that positively regulates 
GAT1 membrane distribution (11).   
 Our goal has been to exploit the nanometer resolution offered by total internal 
reflection fluorescence microscopy (TIRF) to visualize the GAT1 vesicle, quantify GAT1 
vesicle kinematics, and quantify the number of GAT1 molecules on a GAT1 vesicle.  
Altogether, the data reveal an ATP dependent class of GAT1 vesicles, and 
mathematically establish the role of GAT1 vesicle fusion in modulating neuronal 
inhibition.  
Materials and Methods 
N2a Culture  
 Mouse neuroblastoma-2a (N2a) cells (ATCC, Manassas, VA) are grown at 37 C 
in 95% air 5% CO2 in N2a culture medium containing the following:  44.5% DMEM, 
44.5% OptiMEM, 10% fetal bovine serum, and 1% penicillin/streptomycin (10,000 I.U 
penicillin, 10,000 mg/ml streptomycin) (Invitrogen, Carlsbad, CA).  Once cells are grown 
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to confluence, cells are plated on 14-mm pre-coated poly-D-lysine glass bottom dishes 
(#1.5, Mattek, Ashland, MA) at a density of 3×10
5
 cells/dish.  Transfection of a total of 1 
µg DNA per plate is performed 16--24 hr later with Lipofectamine and Plus reagent 
(Invitrogen, Carlsbad, CA).  The composition of the N2a imaging solution is as follows 
(mM): 128 NaCl, 2.4 KCl, 25 HEPES, 1.2 MgCl2, 3.2 CaCl2, 1.2 KH2PO4, and 10 D-
glucose (12).   
Dissociated culture 
 Cerebellum from embryonic (E18) pups is minced (~ 1 mm pieces) and added to 
sterile papain (pH 7.4).  Digestion is performed for 20 minutes in a 35 ºC water bath.  
Cells are placed in 2 ml DNase (1 mg/ml) (Sigma, St. Louis, MO), washed in plating 
media, and titurated.  100 µL of cells are grown on polyethylimine-coated glass bottom 
dishes (400 cells per square mm).  Cells are flooded with plating media approximately 3--
4 hours after plating.  After 2 days, 50% of the media is removed and is replaced with 
maintenance media.  50% of the maintenance media is refreshed every 4--6 days. 2 µL of 
Ara-C is added, if needed, within the first week of plating.  Imaging is performed 
between 14--16 days post-plating.  Plating medum includes 45 mL of the maintenance 
media and 5 mL of equine serum.  Maintenance medium includes 500 mL neurobasal 
medium (Invitrogen, Carlsbad, CA) supplemented with 10 mL B27 (Invitrogen, Carlsbad, 
CA), and 1.25 mL glutamax (Invitrogen, Carlsbad, CA).  The composition of the 
neuronal imaging solution is as follows (mM):  150 NaCl, 4 KCl, 10 HEPES, 2 MgCl2, 2 
CaCl2, 10 D-glucose, and 2 L-ascorbic acid.   
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Total Internal Reflection Fluorescence (TIRF) Microscopy 
 Single fluorophore TIRF imaging is performed on an inverted IX71 (Olympus, 
Melville, NY) configured for TIR excitation as described in Drenan et al. (13).  Briefly, 
IX71 imaging is carried out with an Olympus PlanApo 100X 1.45NA oil objective, 
samples are excited with a multi-line (458/488/515 nm) 40 mW argon laser (Melles 
Griot, Carlsbad, CA) and filtered with an XF104-2 (YFP) filter Cube (Omega Optical, 
Brattleboro, VT).  Images are captured with a 16-bit-resolution Cascade 650 CCD (Roper 
Scientific, Tuscon, AZ) controlled by Slidebook 4.0 imaging software (Intelligent 
Imaging Innovations).   
Addition of BamHI and HindIII restriction sites to EYFP via PCR  
 PCR is used to introduce the BamHI and HindIII restriction sites into the 
EYFPN1 sequence.  The forward EYFP primer included a 7-nucleotide spacer followed 
by the BamHI restriction site, and a 5-nucleotide spacer, which placed the EYFPN1 in 
frame with the pQE32 start codon, and the first 7 codons of the EYFPN1 sequence 
(forward primer sequence: TCG ATC GGG ATC CGA TCG ATG GTG AGC AAG 
GGC GAG GAG).  The reverse primer contained the final 9 codons of the EYFPN1 
sequence, the HindIII restriction site, the SmaI restriction site, and an additional 2 
nucleotides (reverse primer sequence: GAC CCG GGA AGC TTC TTT ACT TGT ACA 
GCT CGT CCA TGC CG).  The primer melting points are greater than 78 ºC, as 
determined from the following equation:  
N
GCTm
675
%41.05.81  , where %GC 
corresponds to the percentage of nucleotides that are either G or C, and N corresponds to 
the total number of nucleotides contained in the primer.  Polyacrylamide gel 
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electrophoresis purified primers are obtained from Integrated DNA Technologies 
(Coralville, IA). 
 PCR is performed by combining 2 μL (100 μg) EYFPN1 vector, 1.25 μL (125 ng) 
forward primer, 1.25 μL (125 ng) reverse primer, 0.5 μL (10 mM) dNTPs, 40 μL 
nuclease free ddH2O, 5 μL Quikchange 10X reaction buffer, and 1 μL (2.5 U) PfuTurbo 
DNA polymerase (Stratagene, La Jolla, CA).  The PCR reaction is performed under the 
conditions outlined in Table 1.  Following PCR, the BamHI-EYFP-HindIII linear plasmid 
is separated by gel electrophoresis using a 1% agarose gel, removed with a razor, and 
purified using a Qiagen Gel Extraction Kit (Valencia, CA).   
 
 Table 2. PCR conditions 
Segment Cycles Temperature Time 
1 1 95 ºC 2 minutes 
2 30 95 ºC 30 seconds 
55 ºC 30 seconds 
68 ºC @ 2 kb/minute 1 minute, 37 seconds 
3 1 68 ºC 7 minutes 
4 1 4 ºC ∞ 
Subcloning and amplification of His6-YFP 
 The BamHI-EYFP-HindIII plasmid and pQE32 vector are sequentially digested, 
the pQE32 vector is dephosphorylated with shrimp alkaline phosphatase, and the vectors 
are ligated using T4 DNA ligase sites. Top ten cells are used for the transformation of the 
ligation product by electroporating 2 µL DNA, resuspending in 500 µL SOC media, 
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incubating 1 hr on a 37 ºC shaker, and growing overnight on LB-Amp plates.  Single 
colonies are added to 5 mL 2xyt+Amp and grown on 37 ºC shaker overnight.  DNA is 
purified using the Qiagen Miniprep kit (Valencia, CA).  XL1-blue cells are transformed 
by heat pulse with the miniprep product, incubated for 1 hr in a 37 ºC shaker, and grown 
overnight on LB-Amp plates.  Single colonies are grown in 10 mL 2xyt overnight, 5 mL 
of which is then added to10mL 2xyt+amp and grown for 1 hr and diluted with 2xyt+amp 
to an 0.6 OD.  Protein is amplified through addition of 1 mM IPTG.  His-YFP is purified 
using Qiagen Ni-NTA spin columns (Valencia, CA) using solutions described in (14).   
Quantifying His6-YFP concentration 
 His-YFP concentration is obtained by calibrating to a BSA standard via the BCA 
protein assay (Bio-rad, Hercules, CA), and multiplying this concentration value by the 
correction factor 0.764, reported from His6-GFP amino acid analysis (15).  His6-YFP is 
stored at -20C as a 50% sucrose slurry.  10
-11
, 10
-12
 M concentrations of His6-YFP are 
incubated overnight at 4 ºC with 30 µL Qiagen Ni-NTA agarose beads (Valencia, CA).   
Results 
TIRF imaging of GAT1 plasma membrane distribution 
 Figure 1A displays the distribution of GAT10-GFP distribution in primary 
cultures from the cerebellum of homozygous neonatal GAT10-GFP knock-in mice with 
both widefield fluorescence and TIRF illumination.  As previously reported, GAT10-GFP 
does not traffic properly due to the interruption of the endogenous PDZ-interaction 
domain by the fusion of the GFP molecule to the GAT1 C-terminus (1).  Due to this 
deficiency, we moved to imaging GAT1-YFP8, a fluorescent GAT1 with WT trafficking, 
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GABA uptake, and surface distribution.  Figure 1B displays the distribution of GAT1-
YFP8 on N2a cells.  As a comparison, we imaged YFP-syntaxin which interacts with the 
GAT1 N-terminal domain, thereby down-regulating GABA transport.  Figure 1C shows 
that YFP-syntaxin forms membrane clusters, this is consistent with previous reports that 
describe syntaxin membrane pools (13, 16).  In contrast, Figure 1B shows that GAT1-
YFP8 is distributed throughout the membrane and along filopodia, which are 
distinguished by arrows.   
TIRF imaging of the GAT1 vesicle  
 Figure 2A displays the maximum lateral displacement of a GAT1-YFP8 vesicle.  
The average vesicle lateral displacement is 1.4 ± 0.1 µm when vesicles with zero 
displacement are discounted.  Figure 2A also displays a zoomed view about the average 
vesicle displacement, showing that very few vesicles move distances greater than 4 µm.  
Figure 2B displays a histogram of the average vesicle velocity.  Vesicles move between 0 
and 1 µm/s, with an average vesicle velocity of 95 nm/s.  Figure 2B displays a zoomed 
view of the vesicle velocity about the average. 
 Figures 3A and 4A display N2a cells transfected with GAT1-YFP8.   Figure 3B 
represents the tracking of a vesicle that displays the type average vesicle displacement 
displayed in Figure 2A, moving a distance of 1.8 µm.  The vesicle is present for 15 
seconds and disappears after the sixth frame (acquisition 0.3 Hz).  As displayed in Figure 
2A, vesicles can exhibit long-range displacements (> 4 µm).   Figure 4B displays a 
montage of a vesicle exhibiting this type of movement.  The tracked vesicle has a 
displacement of 12 µm and traveling at a rate of 170 nm/s (acquisition 0.4 Hz).  The 
vesicle travels a linear x-y path, which may indicate ATP-directed movement. 
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GAT1 vesicle movement depends on ATP 
 Cells are depleted of ATP to determine the role of energy in GAT1 vesicle 
movement.  Figure 5A displays the results of a luciferase assay showing that cells reach 
maximal ATP depletion after 10 min.  Figure 5B displays TIRF, widefield fluorescence, 
and brightfield images of a representative cell that has been depleted of ATP after a10- 
min treatment with 5 mM 2-deoxy-D-glucose and 5 µg/ml oligomycin.  Following ATP 
depletion, vesicle visibility increases relative to an untreated N2a cell.  Figure 4C 
displays the vesicle MSD plot for ATP depleted cells, untreated cells, and untreated cells 
displaying average displacement.  Average vesicle displacement is defined as less than 2 
standard deviations from the average vesicle displacement.  Both the untreated cells and 
the ATP depleted cells display sigmoidal MSD.  At short Δt, the untreated cells display 
directed movement.  An inflection point occurs around a Δt of 20 s, at this point untreated 
cells display caged (constrained) vesicle movement.  Untreated cells that give an average 
vesicle displacement exhibit caged movement at all Δt.  Depleting ATP decreases the 
MSD for short Δt, but for Δt > 20 s, ATP depleted vesicles also exhibit caged movement.   
Quantifying GAT1 number on vesicles 
 Single molecule imaging is employed to count the number of GAT1 molecules on 
vesicles that traffic GAT1 onto the membrane.  Previous counting of GAT10-GFP on 
synapses applied His6-GFP37 (1, 14, 15).  We created His6-YFP to count GAT1-YFP8 on 
vesicles as described in the Materials and Methods.   Figure 5A displays single molecules 
of His6-YFP tethered to Ni-NTA agarose beads.  Presented in Figure 5B is the 
fluorescence intensity over time for a representative single molecule of His6-YFP.  This 
image shows that there is mild fluctuation in fluorescence intensity over time culminating 
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with photobleach of the fluorophore.  The step function photobleach seen in Figure 5B is 
representative of single molecule photobleach rather than ensemble photobleach, which 
would display exponentially decaying fluorescence intensity.  Figure 5C displays the 
fluorescence intensity for single molecules of His6-YFP represented as a histogram, with 
an average of 32 ± 1 arbitrary units.   
 Figure 6A illustrates the constraints to quantifying the number of GAT1 
molecules per vesicle with TIRF.  Figure 6A shows a poly-D-lysine substrate thickness of 
12.5 nm (17) and a plasma membrane thickness of 4--7 nm (18, 19).  The TIRF 
penetration depth represents the distance from the coverslip where the evanescent wave 
has decayed by 63%.  It is defined as follows: 
2
2
22
1 sin4 nn
d
c



(20), where λ 
represents the wavelength (514 nm), n1 represents the index of refraction for glass (1.51), 
θc represents the TIRF critical angle (~ 63º), and n2 represents the index of refraction 
within the cell (~ 1.38), giving a value of ~ 145 nm. 
 Since the single molecules of His6-YFP are located at the coverslip, and the 
closest GAT1-YFP8 vesicle is located a distance of 16.5 nm from the coverslip, we 
correct for distance dependent His6-YFP fluorescence decay using the following 
equation: d
z
oeII

 (20).  In this equation, Io is the average single molecule fluorescence 
intensity at the coverslip (32 au) and d is the TIRF penetration depth (145 nm).  Figure 
7B divides the fluorescence intensity for GAT1-YFP8 vesicles by the His6-YFP 
fluorescence intensity change over distance.  Figure 7B shows that a vesicle at the plasma 
membrane appears to have 3 GAT1-YFP8 molecules per vesicle, while a vesicle 145 nm 
away appears to have fewer than 8 GAT1-YFP8 molecules per vesicle. Since 
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dimerization is required for GAT1 endoplasmic reticulum export (21), a vesicle would 
contain 2--4 assembled dimers.   
Discussion 
 We report GAT1 distribution on the membrane and characterize the vesicle that 
traffics GAT1 onto the membrane through fluorescence analysis of vesicle kinematics.  
We have also determined for the first time the number of transporter molecules on 
vesicles that traffic neurotransmitter transporters onto the membrane.   
 Despite the GAT10-GFP trafficking deficiency, we are able to view localization of 
the transporter on the membrane of primary cultures from neonatal mouse cerebellum.  
We were also able to view the distribution of a transporter with WT GABA uptake, 
which partitions correctly to the cell surface and intracellular compartments.  GAT1-
YFP8 membrane distribution is strikingly different from the distribution of YFP-
Syntaxin, a T-SNARE that regulates GAT1 transport activity.  The difference in surface 
localization indicates that only some transporter molecules are in close enough proximity 
to syntaxin pools to be subject to syntaxin regulation of GAT1 function.  It is known that 
the phosphorylation of Munc18 by protein kinase C (PKC) causes the dissociation of the 
Munc18-syntaxin interaction, freeing syntaxin to associate with GAT1 (22).   We have 
previously reported GAT1 tethering to actin, via a PDZ protein and ezrin.  It would be 
notable to determine whether the signaling pathways that affect GAT1-syntaxin 
association also regulate GAT1 confinement.   
 A majority of our vesicles undergo displacements of 1.4 µm.  This suggests a 
similarity between the GAT1 vesicle and the Na
+
/K
+
-ATPase vesicle, which also exhibits 
average displacements of ~ 1 µm (23).  Additionally,  > 80% of observed secretory 
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vesicles in pollen tubes undergo displacements less than 1 µm (24) and 97% of 
chromaffin granules undergo average displacements of ~ 1 µm (25).  The remaining 3% 
the chromaffin granules exhibit displacements > 10 µm (25). 
 Our results show that a small fraction of GAT1 vesicles have the ability to 
laterally traverse long distances near the plasma membrane.  Long-range vesicles are 
governed by an ATP-dependent process.  This conclusion is based on three observations: 
(i) When we consider the MSD of vesicles that move within two standard deviations of 
the average displacement, the MSD of these average vesicles is concave downward (
t
1/2
), indicating caged (constrained) movement, which would not be directed by ATP (26, 
27). (ii) When we include long-range vesicles in the MSD analysis, the trend is 
sigmoidal: displaying a concave upward MSD for short Δt, indicating directed movement 
(  t
2
)(27), and displaying concave downward MSD for Δt > 20 s, indicating caged 
movement ( t
1/2
) (26).  (iii) The MSD for ATP treated cells indicates caged movement 
for Δt > 20 s ( t1/2) (26, 27).  Altogether, the long-range vesicles display ATP- 
dependent movement for Δt < 20 s, after which they display the same caged movement as 
average vesicles.    
 The fact that a majority of GAT1 vesicles display caged movement indicates a 
similarity between the GAT1 vesicle and other membrane protein containing vesicles.  
For example, both the GLUT4 vesicle and the TRPC vesicle display caged movement 
(28, 29).  Constrained vesicle movement is also representative of the secretory, bovine 
chromaffin granule (30).  However, the existence of a fraction of GAT1 vesicles that 
display ATP-directed, lateral movement reveals a sub-population of vesicles requiring 
further study.  The rationale behind the long-range movement may include: ATP- 
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dependent vesicle recruitment to exocytosis active zones (31), as exhibited by synaptic 
vesicles (32, 33) or recycling of vesicles from endosomal compartments (34).    
 It has been previously reported that a majority of GAT1 vesicles reside in a 
reserve pool (RP), which does not actively insert into the membrane (35).  Wang et al. 
report that this pool comprises 70% of GAT1 vesicles.  Although the GAT1 vesicle does 
not contain neurotransmitter (9), the approximate size of the reserve pool correlates well 
to the size of the synaptic vesicle reserve pool in the Drosophila neuromuscular junction 
(~ 70% of the available synaptic vesicles)(36). Since we do not observe vesicle fusion, it 
is possible that we are monitoring reserve pool vesicles.  If the caged GAT1 vesicles are 
in fact reserve vesicles, it should be noted that their excitation by the evanescent wave 
signifies perimembrane residence; therefore, recruitment to the readily releasable pool 
would not require significant z-translocation. 
Functional implications of GAT1 vesicle characterization.  
 Previous estimates of transporter on and off rates reported that 3--5 transporters 
are added to the membrane every second (35).  Our estimate of transporter number per 
vesicle reveals a GAT1 vesicle fusion rate of 1 event per second.  Since the complete 
time for one GAT1 transport cycle is ~ 100 ms, and the decay time constant of 
GABAergic postsynaptic currents is ~ 10 ms (37), GAT1 vesicle fusion does not have the 
ability to directly influence GABAergic synaptic transmission.  However, the estimate of 
1 vesicle per second suggests that the replenishment of GAT1 is a dynamic process that 
requires continuous recruitment of vesicle fusion machinery.   
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Figure Legends 
Figure 1.  TIRF imaging of fluorescent GAT1 distribution on neurons 
and N2a cells 
A) Homozygous primary cultures from E18 GAT10-GFP knock-in mice display 
fluorescence on cell bodies, as previously reported by Chiu et al.  Scale bar, 5 µm.  
Widefield fluorescence and TIRF images also show membrane localization.  (B) GAT1-
YFP8 transfected in N2a cells also shows complete labeling of the plasma membrane.   
(C) YFP-Synaxin, which can interact with the N-terminus of GAT1, displays clustered 
plasma membrane distribution.  Scale bars, 10 µm.  
Figure 2. GAT1-YFP8 vesicle kinematics 
A) GAT1-YFP8 vesicle displacement histogram. The histogram shows the percentage of 
GAT1-YFP8 vesicles that display a maximal lateral displacement up to 12 µm. The 
average vesicle displacement is 1.4 ± 0.1 µm (± standard error of the mean).  The 
histogram includes a magnified view about the average vesicle displacement.  The 
histogram highlights the fact that only a few vesicles display the type of long-range 
movement. (B) GAT1-YFP8 vesicle velocity histogram.  The histogram shows the 
percentage of GAT1-YFP8 vesicles that display a maximal lateral velocity greater than 0.  
The average vesicle velocity is 95 ± 3 nm/s.   
Figure 3. Tracking of a GAT1-YFP8 vesicle exhibiting average 
displacement   
A) TIRF image of an N2a cell transfected with GAT1-YFP8.  Scale bar, 10 µm. The 
boxed region includes the vesicle that is tracked in (B). The vesicle moves a distance of 
1.8 µm.  The frame rate is 0.3 Hz and the proportion bars, 1 µm. 
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Figure 4. Tracking of a GAT1-YFP8 vesicle exhibiting long-range 
displacement  
A)  TIRF image of N2a cell expressing GAT1-YFP8.  Scale bar, 10 µm. The boxed 
region includes the vesicle that is tracked in (B).  (B) Long-range vesicle tracking.  After 
frame 8, the vesicle goes out of the evanescent field and is not visible for 9 frames, 
during this time it continues its course, and is seen again in frame 18.  This vesicle moves 
a distance of 12 µm.  The frame rate is 0.4 Hz and the proportion bars, 1 µm. 
Figure 5. ATP depletion 
A) TIRF, brightfield, and widefield fluorescence images of a cell that has undergone ATP 
depletion.  Vesicles can be seen in the TIRF image.  Scale bars, 10 µm. (B) Luciferase 
assay confirming ATP depletion of cells treated with 5 mM 2-deoxy-D-glucose and 5 
µg/ml oligomycin.  N2a cells are maximally depleted of ATP after 10 minute incubation.  
(C) Mean square displacement of vesicles before and following ATP depletion display 
sigmoidal trends.  The MSD results show that when long-range vesicle displacement 
(MSD > 2 standard deviations from the average) is included in the MSD calculation, 
there is an increase in MSD, corresponding to a vesicle dependence on ATP.  When these 
long-range displacements are removed from the MSD calculation, there is no ATP 
dependence on displacement.  
Figure 6. Quantifying the number of GAT1-YFP8 molecules/vesicle 
A) Single molecules of His6-YFP tethered to Ni-NTA agarose beads.  Scale bar, 1 µm.  
(B) Representative fluorescence trace for a single molecule of His6-YFP.  The step 
function His6-YFP photobleach trace is characteristic of single molecule photobleach.  
(C) Magnitude of single molecule photobleach as a percentage of observed single 
molecules.  The average single molecule fluorescence is 32 ± 1 arbitrary units. 
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Figure 7. Distance dependence on # GAT1-YFP8 molecules per 
vesicle. 
A) Schematic of vesicle distance from coverslip.  The TIRF illumination field decays 
exponentially as the distance from the coverslip increases.  His6-YFP single molecule 
imaging occurs at the coverslip, and gives maximal fluorescence intensity values; 
however, the center of a vesicle containing the transporter can be at the closest, 41.5 nm 
from the coverslip.  At this distance, the fluorescence intensity for a single molecule of 
His6-YFP will be reduced by 25%.   (B) Number of GAT1-YFP8 molecules/vesicle as a 
function of z distance from the coverslip.  Using the exponential relation between 
distance and fluorescence intensity, the fluorescence from a vesicle is divided by the 
average magnitude of His6-YFP fluorescence from 16.5--145 nm from the coverslip.  
This gives 3--8 molecules of GAT1-YFP8/vesicle.  Because GAT1 exists as a dimer upon 
export from the endoplasmic reticulum, the number of GAT1-YFP8 dimers/vesicle is 2--
4.   
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Chapter 4: Fluorescent mGAT1 constructs reveal motifs 
important for correct trafficking and dimerization 
 
This chapter is modified from a manuscript being prepared for publication.  We 
determine the trafficking, oligomerization, plasma membrane localization, and protein 
interactions of fluorescently labeled GAT1s.  I determined the oligomerization states of 
the GABA transporters through fluorescence resonance energy transfer (FRET) studies,  
determined the plasma membrane localization through confocal microscopy, and 
contributed to the functional characterization of the transporter through GABA uptake 
experiments.  Fraser Moss, Joanna Jankowsky, and Amber Southwell created the GAT1 
fluorescent proteins, identified the appropriate cell line for the studies, established the 
transfection protocol, and performed functional characterization of GAT1 through kinetic 
studies of GABA uptake.  Jia Hu performed the surface biotinylation experiments.   
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Abstract 
 
The protein-protein interactions, trafficking, and oligomerization of mGAT1, the 
mouse -aminobutyric acid (GABA) transporter, were studied using fourteen different 
fusions of mGAT1 with cyan, yellow, or green fluorescent protein (CFP, YFP, or GFP; 
collectively XFP).  The constructs were expressed in neuroblastoma 2a cells, their 
function tested in a linear [
3
H]GABA uptake assay, and their oligomerization probed with 
CFP-YFP Förster resonance energy transfer (FRET).  XFP fused to the mGAT1 C-
terminus (mGAT1XFP) significantly inhibited transporter function and trafficking 
despite the presence of a synthetic class II PDZ-interacting motif, -YKI.  Replacing the 
terminal isoleucine with valine or adding the last 3 to 28 C-terminal residues of human 
GAT1 after the XFP restored wild-type function.  Therefore a natural PDZ-interacting 
motif was minimally required for wild-type behavior. mGAT1XFP C-terminal fusions 
with wild-type function yielded up to 21% FRET efficiency, indicating efficient mGAT1 
oligomerization.  However, 45% FRET between one of these constructs and YFP-
syntaxin 1A, which associates with the GAT1 N-terminus, indicated that the N- and C-
terminals of mGAT1 oligomers are closer together in the cytosol than adjacent C-
terminals.  Adding the 45 hGAT1 C-terminal residues after mGAT1XFP resulted in little 
function, poor trafficking, and no detectable FRET.  Similar properties were observed for 
an N-terminal XFP-mGAT1 fusion.  These two constructs implicated the last ten residues 
of TM12 and the N-terminus in the mGAT1 oligomerization process.  Inserting XFP 
between R565 and L566, resulted in 33% FRET but impaired function, which indicated 
the “RL” motif in the proximal C-terminus governs export from the endoplasmic 
reticulum but not transporter oligomerization. 
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Introduction 
 
The -aminobutyric acid (GABA) transporter GAT1 is widely expressed in the 
mammalian brain.  It is member of the solute carrier 6 (SLC6) gene family, which also 
includes transporters for dopamine (DAT), serotonin (SERT), norepinephrine (NET), and 
glycine (GlyT).  This family is characterized by the co-transport of two Na
+
 ions and one 
Cl
-
 ion to take up the neurotransmitter substrate against its thermodynamic gradient into 
the cell (125, 126). 
GAT1 shapes the synaptic signaling events at inhibitory synapses by removing 
GABA within a few milliseconds of its release (127).  Inhibition of GAT1 by 
pharmacological agents such as the antiepileptic tiagabine (128, 129), or its genetic 
knockout in mice, results in prolonged neurotransmitter lifetime in the synapse and 
concomitant increase in GABAA receptor-mediated tonic conductance, decreasing the 
excitability of the postsynaptic cell (3).  Tiagabine is an effective therapy for epilepsy, 
but side effects include dizziness, asthenia, sedation, nonspecific nervousness ,and tremor 
(130, 131).  The phenotype of GAT1 knockout mice reproduces many aspects of these 
side effects, indicating that they may arise directly from GAT1 inhibition. 
In the healthy brain, density and surface/cytoplasm distribution of GAT1 
transporters is tightly regulated.  Previously, we quantified the mean number of GAT1 
molecules in a presynaptic bouton to be 800--1300/μm2, with 61--63% of these molecules 
expressed on the plasma membrane (8).  This pool of transporters recycling to and from 
the plasma membrane plays a critical role in shaping neurotransmission and is both 
constitutively and functionally regulated (29, 132-138).  Although SLC6 transporters are 
capable of transporting their substrate when expressed as monomers (139), 
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oligomerization is a major factor in the release of newly synthesized transporter from the 
endoplasmic reticulum (140).  The crystal structure of the leucine transporter LeuTAa 
from the bacteria Aquifex aeolicus, (an orthologue of the mammalian SLC6 
neurotransmitter transporters), crystallized as a dimer, with transmembrane domains 
(TM) 9 and 12 probably providing the interface for assembly (141).  However, this 
structure likely represents only a low-order oligomerization state for these transporters, as 
evidence exists for the further oligomerization of transporter dimers (142, 143). 
Even though oligomerization is absolutely required for release from the 
endoplasmic reticulum (ER), sequence elements in the cytoplasmic N- and C-termini 
exert additional control over trafficking.  They can serve as substrates for cytosolic 
regulators such as kinases, or as motifs for interactions with other proteins, including 
PDZ (postsynaptic density 95/Discs large/zona occludens 1) domain-containing and 
soluble N-ethylmaleimide-sensitive fusion receptor (SNARE) proteins, which determine 
the insertion and withdrawal of transporter complexes from the cell surface (29, 134, 135, 
137, 144, 145). 
In this work, we describe a collection of mutated mGAT1 constructs with fusions 
to the cyan and yellow fluorescent proteins (CFP and YFP respectively, and XFP 
collectively).  Some of these fluorescent mGAT1 molecules oligomerize, traffic, and 
function essentially as the wild-type mGAT1 in all respects.  They have highlighted that a 
class II PDZ-interacting domain at the mGAT1 C-terminus is required for appropriate 
plasma membrane expression.  Other fluorescent constructs with deficits in their 
trafficking and/or oligomerization have helped us to determine residues in the final 
transmembrane domain and in the cytoplasmic termini of GAT1 critical for efficient 
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transporter trafficking and oligomerization.  We also ascertained structural information 
about the cytoplasmic arrangement of these intracellular termini in mGAT1 oligomers.  
We find that the accurate comparison of mutated mGAT1 molecules to wild-type 
transporter required use of a non-saturated in vitro assay described herein.  We propose 
this system as a model transient expression system for the characterization of all mutant 
neuronal transporters. 
Experimental Procedures 
 
Materials  
pEYFP-C1 or pECFP-C1 vectors were purchased from Clontech (Mountain View, 
CA).  The pcDNA3.1-YFP-syntaxin 1A construct was kindly provided by Wolfhard 
Almers (Vollum Institute, Oregon Health and Science University, Portland, OR).  
PfuTurbo Cx Hotstart polymerase and the Quickchange II XL site-directed mutagenesis 
kit was purchased from Stratagene (La Jolla, CA).  The mouse neuroblastoma 2a (N2a; 
CCL-131) and the human embryonic kidney T/17 cell line (HEK 293T; CRL-11268) 
were obtained from ATCC (Manassas, VA).  The pcDNA3.1(+) expression vector, 
Dulbecco's modified eagle media with 4 mM L-glutamine (DMEM), OptiMEM 1, fetal 
bovine serum (FBS), Lipofectamine and Plus reagents were purchased from Invitrogen 
(Carlsbad, CA).  Penicillin/Streptomycin 100X and Sodium Pyruvate 100X solutions 
were purchased from Mediatech (Herndon, VA).  35-mm culture dishes with 14-mm 
glass bottoms of #0 thickness were procured from Mattek (Ashland, MA).  Other tissue-
culture plastic-ware was purchased from Greiner Bio-One (Monroe, CA).  The 
bicinchoninic acid (BCA) protein assay, EZ-Link Sulfo-NHS-Biotin and immobilized 
monomeric avidin beads were obtained from Pierce (Rockford, IL).  4-Amino-n-[2,3-
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3
H]butyric acid ([
3
H]GABA; 87 Ci/mmol) and Amersham ECL Plus Western blotting 
detection reagents were obtained from GE Healthcare (Piscataway, NJ). Anti-GAT1 
antibody AB1570W and goat anti-rabbit peroxidase conjugated secondary antibody were 
obtained from Chemicon International, Inc. (Temecula, CA).  Anti-GFP rabbit antiserum 
132002 was obtained from Synaptic Systems (Goettingen, Germany).  Protease inhibitor 
cocktail tablets were obtained from Roche Diagnostics (Indianapolis, IN).  Scinti-Safe 
30% liquid scintillation cocktail was purchased from Fisher Scientific (Fair Lawn, NJ).  
Polyethyleneimine (PEI) 50% solution in H2O, -amino-n-butyric acid (GABA) and all 
other reagents were purchased from SigmaAldrich (St. Louis, MO). 
Molecular Biology 
Wild-type mGAT1 and mGAT1GFP constructs have been described previously 
(8).  To generate the fluorescent mutants mGAT1XFP* through mGAT1XFP45, the 
wild-type mGAT1 open reading frame (ORF) was subcloned without its endogenous stop 
codon in to the Hind III and EcoR I sites of the pcDNA3.1(+) expression vector multiple 
cloning site (MCS).  XFP ORFs were then subcloned downstream from, but in frame 
with the mGAT1 ORF at the Not I and Xba I sites of the pcDNA3.1(+) MCS.  This 
resulted in a 12-amino-acid spacer between the end of the mGAT1 sequence and the 
beginning of the fluorophore.  We modified Geiser et al.’s method for the integration of 
PCR fragments without the use of restriction enzymes (97) to add the final 3, 8, 20, 28, or 
45 codons of the hGAT1 ORF.  These were amplified from a source plasmid using 
PfuTurbo Cx Hotstart polymerase with 5’ and 3’ extensions corresponding to the 20--22 
nucleotide regions that flanked the intended site of insertion, such that the PCR product 
integrated in frame immediately after the fluorophore sequence when used as the primers 
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in a subsequent QuikChange II XL mutagenesis PCR reaction.  For mGAT1XFP*, we 
simply added a GTC codon for valine after the fluorophore ORF.  The same PCR 
insertion technique was applied to amplify and integrate YFP or CFP directly between 
residues R565 and L566 of mGAT1 to generate the mGAT1XFPCT constructs.  
Similarly, we used this approach to amplify the YFP or CFP ORFs with 15 additional 
codons from the downstream MCS of pEYFP-C1 or pECFP-C1 vectors, and fused the 
fragment directly onto the 5’ end of the mGAT1 ORF in pcDNA3.1(+) to generate the 
XFP15mGAT1 N-terminally tagged constructs. 
Cell culture and transfections  
N2a cells were cultured at 37 C in 95% air / 5% CO2 in media composed of 
44.5% DMEM, 44.5% OptiMEM1, 5% FBS, 100 I.U/ml penicillin, and 100 μg/ml 
streptomycin.  For all experiments, cells were plated onto either 12-well plates, 60-mm 
dishes or 35-mm culture dishes with 14-mm glass bottoms that we pre-coated with 0.05% 
PEI (pH 8.4 in borate buffer; 100 mM sodium borate, 100 mM boric acid).  Transfections 
were performed using a modification of the manufacturer’s Lipofectamine and Plus 
reagent protocol that resulted in non-saturated expression level of transporter (see Table 
1).  Cells were plated 16 h prior to transfection (Table 1, Step 1).  The mass of cDNA in 
Table 1 is for the vector pcDNA3.1(+)mGAT1.  To account for the difference in size 
between the wild-type mGAT plasmid and those of the fluorescent mGAT1 constructs or 
empty pcDNA3.1(+) vector, an equimolar equivalent of these cDNAs was used.  The day 
of the transfection, cDNA was diluted in DMEM in one tube to which Plus reagent was 
subsequently added (Table 1, Step 2).  In a second tube, Lipofectamine was diluted in 
DMEM (Table 1, Step 3).  The tubes were briefly vortexed and incubated at room 
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temperature for 15 min.  The diluted Lipofectamine was subsequently added to the 
cDNA/Plus reagent dilution and vortexed (Step 4).  The transfection mixes were 
incubated for a further 15 min at room temperature, while the pre-plated cells were 
washed once with DMEM to remove residual sera from the culture media and then placed 
in the appropriate volume of DMEM to perform the transfection (Table 1, Step 5).  The 
cDNA/Plus/Lipofectamine mixes were then added to the cells (Table 1, Step 6), which 
were placed in the incubator for 16 h; then the transfection cocktail was replaced by 
complete N2a media.  For experiments where cDNA quantity was the experimental 
variable, the amount transfected is stated in the relevant results section.  However, cell 
density, amount of Lipofectamine and Plus reagents were kept constant for each size of 
culture dish/well; conditions remained within the manufacturer’s recommended cDNA : 
transfectant ratio in any experiment.  For GABA uptake experiments performed in HEK 
293T cells, we plated 2 x 10
5
 cells per well in 12-well plates pre-coated with PEI, 16 h 
before transfection.  Otherwise, the transfection was performed as for N2a cells.  HEK 
293T cells were cultured at 37 C in 95% air/5% CO2 in culture media composed of 88% 
DMEM, 10% FBS, 100 I.U/ml penicillin, 100 μg/ml streptomycin, and 1 mM sodium 
pyruvate. 
GABA Uptake  
Uptake assays were performed in 12-well plates 48 h after transfection as follows:  
Culture medium was aspirated and cells equilibrated for 10 min at room temperature in 
1 ml Krebs-Ringer’s (KRH) buffer containing (in mM): 130 NaCl, 1.3 KCl, 2.2 CaCl2, 
1.2 MgSO4, 1.2 KH2PO4, 10 glucose, 10 HEPES, pH 7.4 (146).  GABA uptake was 
initiated on aspiration of KRH buffer and addition of 500 μl 2.5, 5, 10, 30, or 80 μM 
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GABA and 25 nM [
3
H]GABA in KRH at room temperature.  Uptake was terminated by 
four rapid washes with KRH + GABA using the same total GABA concentration as used 
during the uptake step.  Cells were lysed in 1 ml 2% SDS in phosphate-buffered saline 
(PBS).  [
3
H]GABA accumulation was assayed by liquid scintillation spectrometry.   
Specific uptake was normalized to the total protein in each well as determined using the 
BCA protein assay. 
Surface biotinylation   
48 h after transfection, N2a cells were incubated in Hank´s balanced salt solution 
(HBSS) containing 1 mg/ml biotin on ice for 30 min with gentle shaking. Excess
 
biotin 
was removed by rapid washing twice in HBSS.  Biotin was then quenched for 15 min on 
ice with 100 mM glycine dissolved in PBS/Ca
2+
/Mg
2+
 (PBS plus 0.1 mM CaCl2, and 
0.2 mM MgCl2). The cells were lysed with 500 μl radioimmunoprecipitation assay 
(RIPA) buffer (10 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 
1% sodium deoxycholate, 0.1% SDS, supplemented with one protease inhibitor
 
cocktail 
tablet per 10 ml) at 4 °C for 60 min, shaking vigorously.  The cell lysates were 
centrifuged at 20,000 × g at 4 °C for 15 min to remove cell debris; 50 μl of cell lysate 
was saved for the quantification of total mGAT1 protein.  The rest of the sample was 
mixed with 100 μl immobilized monomeric avidin beads and incubated on a rotating 
platform at 4 ºC overnight.  The lysate was separated from the beads and kept for 
quantification of the intracellular mGAT1 fraction.  The beads were then washed three 
times with ice-cold RIPA buffer and protein adsorbed by the beads (the plasma 
membrane bound fraction) was eluted with 100 μl SDS loading buffer (62.5 mM Tris-Cl, 
pH 6.8, 2% SDS, 100 mM -mercaptoethanol) at room temperature for 30 min on a 
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rotating platform. Protein samples were quantified by standard Western blotting 
procedures using a 1:1000 dilution of AB1570W anti-GAT1 or a 1:5000 dilution of anti-
GFP rabbit antiserum 132002 for the primary antibodies.  Goat anti-rabbit peroxidase 
conjugated secondary antibody was applied at a 1:2000 dilution and blots were developed 
using the ECL Plus Western blotting detection reagent and an AlphaImager HP imaging 
system (Alpha Innotech, San Leandro, CA). 
Förster Resonance Energy Transfer (FRET)  
N2a cells were visualized at room temperature in KRH buffer, 48 h after 
transfection.  A series of lambda stack X-Y images were collected from an inverted 
LSM 510 Meta laser scanning confocal microscope using an Achroplan IR 63X, 1.4 
numerical aperture oil objective (Carl Zeiss, Thronwood, NY).  Additional experiments 
were performed on an Eclipse C1si laser scanning confocal microscope using a 63X, 1.4 
numerical aperture VC Plan Apo oil objective (Nikon Instruments Inc., Melville, NY).  
FRET was recorded using the donor recovery after acceptor photobleach (DRAP) 
technique, examining the dequenching of CFP during incremental photobleaching of YFP 
by the 514 nm argon laser line.  Using reference spectra of YFP and CFP, lambda stacks 
were linearly unmixed and analyzed for FRET efficiency (147, 148).  Using ImageJ 
(149), mean fluorescence intensities of CFP and YFP were determined by tracing the 
outer perimeter of the cell and subtracting background fluorescence, obtained from an 
area containing cells not expressing the construct.  Fluorescence intensities of CFP and 
YFP at various time points after photobleaching were normalized to that at time 0 
(100%).  FRET efficiency (E) was calculated: 
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
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


D
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I
I
E 1   (Equation 1) 
 
IDA represents the normalized fluorescence intensity of CFP (100%) in the 
presence of non-bleached acceptor.  ID represents the normalized fluorescence intensity 
of CFP following 100% photobleach of the acceptor, YFP.  The ID value was 
extrapolated from a scatter plot of the percentage increase of CFP versus the percentage 
decrease of YFP for each cell (150).  The distance between fluorophores (R) was 
calculated:   
  6/110 1 ERR   (Equation 2) 
R0 is the Förster distance for the pair of fluorophores used in the experiment.   
The Förster distance depends on the overlap integral of the donor emission spectrum with 
the acceptor absorption spectrum and their mutual molecular orientation as expressed by: 
JQR 0
42236
0 108.8
    (Equation 3) 
where κ2 is the dipole orientation factor,   is the refractive index of the medium, QD is 
the fluorescence quantum yield of the donor in the absence of the acceptor, and J is the 
spectral overlap integral.  For the purpose of this investigation -4 QD J can be assumed to 
be a constant of 2.41 × 10
-14
.  Resonance energy transfer equations were obtained from 
two sources (151, 152). 
Results 
 
A non-saturated [3H]GABA uptake assay in heterologous cells 
To evaluate the function of fluorescently modified mGAT1 constructs relative to 
wild-type, it was critical to establish an uptake assay in an appropriate heterologous 
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expression system in which mGAT1 expression levels, the concentration of applied 
substrate, and the experimental time course were not saturating.  We compared the 
function of the wild-type mGAT1 with mGAT1GFP, a construct known to have a major 
trafficking deficit in vivo (8), when expressed in two different mammalian cell lines.  The 
N2a line is both neuronal and murine in origin and may possesses much of the necessary 
cellular machinery to process and traffic mGAT1 correctly; HEK 293T cells are a model 
mammalian line frequently used to assess the function of plasma membrane proteins.  0, 
50, 100, 250, or 500 ng of wild-type mGAT1 plasmid or its equimolar equivalent of 
mGAT1GFP or pcDNA3.1(+) plasmid was transfected/well in 12- well plates.  20 min 
[
3
H]GABA uptake experiments were performed in both low (2.5 μM) and high (80 μM) 
extracellular GABA concentrations ([GABA]O).  [
3
H]GABA uptake in N2a cells 
transfected with wild-type mGAT1 remained in the linear range for transfections up to 
100 ng cDNA/well in both 2.5 μM and 80 μM [GABA]O (Figures 1A and 1B).  For 
transfections of > 250 ng cDNA/well, the uptake began to saturate.  Importantly, 
[
3
H]GABA uptake by N2a cells transfected with the mGAT1GFP construct was reduced 
(28--65%) for all cDNA transfection amounts in both 2.5 μM and 80 μM [GABA]O, 
reproducing the functional deficit reported for synaptosome preparations from 
mGAT1GFP knock-in mice (8).  This was not the case for HEK 293T cells.  [
3
H]GABA 
uptake was almost completely saturated in 2.5 μM [GABA]O in cells transfected with as 
little as 100 ng cDNA/well of wild-type mGAT1 plasmid (V100ng = 
83.5  1.9 fmol/μg/min; Vmax = 86.9  2.4 fmol/μg/min; Fig. 1C).  Furthermore, 
maximum [
3
H]GABA uptake for mGAT1GFP was not significantly different (Vmax = 
93.5  17.9 fmol/μg/min) from wild-type mGAT1 for all transfections performed 
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(Figure 1C).  This indicated that plasma membrane surface expression of mGAT1, when 
expressed at the levels we tested in HEK 293T cells, was not dependent on the same 
mechanisms that exist in its native environment.  Therefore, we decided a) that N2a cells 
are the more suitable cell type in which to perform our experiments and b) that we should 
transfect 100 ng/well of wild-type mGAT1 plasmid or its equimolar equivalent of 
fluorescent mGAT1 plasmid to assess transporter function at non-saturated expression 
levels.  In addition, we established that for these transfection conditions [
3
H]GABA 
uptake remained linear for up to 60 min in both 2.5 μM or 80 μM [GABA]O as linear 
regression analysis of the 3, 10, 20, and 60 min data points revealed r
2 
= 0.997 and 0.989 
respectively (Figure 1D and 1E). 
Functional characterization of fluorescent mGAT1 constructs   
We generated fourteen fluorescent mGAT1 constructs to study trafficking and 
dimerization of the GAT1 transporter.  Our previously characterized construct 
mGAT1GFP (8) served as the template for the majority of our new designs.  For all 
constructs described in this study, we exchanged the GFP fluorophore for CFP or YFP to 
facilitate the study of protein-protein interactions by FRET. 
One series of modified constructs was designed to relieve the trafficking deficit 
that occurs because the GFP fusion blocks access to the free carboxylate group of the 
isoleucine in the mGAT1 
596
AYI
598
 PDZ class II interacting C-terminal residues in 
mGAT1GFP (137).  In a serendipitous quirk of the cloning of the mGAT1GFP into the 
expression vector, the construct’s C-terminal residues are -YKI (Supplemental figure 1).  
In a broad definition, this sequence represents a consensus PDZ class II interacting motif 
(X--X-, where  designates a hydrophobic residue and X any amino acid (153, 154)).  
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However, mining the Ensembl databases using Biomart (http://www.ebi.ac.uk/biomart) 
and applying the GO:0005886 “plasma membrane” cellular component filter did not 
yield any membrane proteins that possess this exact sequence at their C-termini.  
Therefore we defined the terminal residue P(0) more narrowly.  We chose to perform a 
single conservative amino acid substitution, changing the terminal isoleucine residue 
present in mGAT1GFP to a valine in mGAT1XFP* (Supplemental figure 1).  The 
resulting C-terminal sequence, -YKV, reconstituted a functional PDZ class II interacting 
motif present in Ephrin B receptors, a species known to rely on interactions with PDZ 
domain containing proteins for clustering and shown experimentally to interact with the 
PDZ proteins, syntenin, the Fas-associated phosphatase, FAP-1, protein interacting with 
C kinase 1, PICK1, and the glutamate receptor interacting protein, GRIP (155-157).  
Also, PICK1’s PDZ domain shows a preference for class II binding motifs with valine at 
P(0) over those terminating with isoleucine or leucine (158).   
In another series of constructs, mGAT1XFP3, mGAT1XFP8, mGAT1XFP20, 
mGAT1XFP28, and mGAT1XFP45, had the most C-terminal 3, 8, 20, 28, or 45 residues 
of hGAT1 appended after the mGAT1XFP fusion (Supplemental figure 1).  The 
differences in nucleotide sequence between the hGAT1 and mGAT1 C-termini were a 
useful source of positive identification when we analyzed the clones during construction.  
We expected that these constructs would allow us to determine a) how much extra native 
C-terminal sequence was required to generate wild-type-like mGAT1XFP behavior and 
b) whether additional regulatory signals resided in the C-terminal.  Furthermore, 
comparison of mGAT1XFP3-45 and mGAT1XFP* function might also highlight any 
sequence specificity for the PDZ interactions that occur at the mGAT1 C-terminal.   
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In the third construct strategy, we interrupted the mGAT1 C-terminus with the 
XFP moiety shortly after the end of TM12 between residues R565 and L566 
(Supplemental figure 1).  Our fourth and final pair of constructs were N-terminal 
XFP15mGAT1 fusions, the number between the fluorophore and the transporter 
indicating the length of the linker fusing the two protein species together (Supplemental 
figure 1). 
We applied the non-saturating parameters described above to transfect all 14 
fluorescently tagged mGAT1 constructs into N2a cells.  We studied both their 
distribution by laser scanning confocal fluorescence microscopy (Figure 2A), and we 
compared their function to non-fluorescent wild-type mGAT1 in 20-minute [
3
H]GABA 
uptake assays (Figure 2B).  mGAT1GFP is visible throughout the cytoplasm of N2a cells, 
but also appears to be expressed in the plasma membrane region.  However, as expected 
from our earlier work in the assay optimization and previously published studies (8), 
[
3
H]GABA uptake by the mGAT1GFP construct was significantly reduced (24  0.03%) 
compared to wild-type.  These data support our previous findings in synaptic boutons 
from mGAT1GFP knock-in mice, that mGAT1GFP is primarily an intercellular species; 
concentrating within few hundred nm of the plasma membrane, only a small fraction of 
the transporter pool actually appearing on the cell surface (8). 
The constructs mGAT1XFP*, mGAT1XFP3, mGAT1XFP8, mGAT1XFP20, and 
mGAT1XFP28 localized primarily in the plasma membrane when expressed at non-
saturating levels in N2a cells (Figure 2A).  We confirmed that this was genuine surface-
membrane expression in three separate assays.  1) For all five constructs, [
3
H]GABA 
uptake from transfected N2a cells was not significantly different from wild-type mGAT1 
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(Figure 2B).  2) Surface biotinylation experiments determined that the percentage of the 
total expressed mGAT1XFP*, mGAT1XFP3, mGAT1XFP8, mGAT1XFP20, or 
mGAT1XFP28 protein that inserted into the plasma membrane was not significantly 
different from wild-type mGAT1 (Figure 2C).  3) Concentration dependence of 
[
3
H]GABA uptake for mGAT1XFP*, mGAT1XFP8, mGAT1YFP3 and mGAT1YFP20 
was identical to wild-type mGAT1 (Figure 2D).  Each panel of Figure 2D presents the 
concentration dependence data for two fluorescent constructs vs. wild-type mGAT1 
transfections performed on the same day. Within each set of experiments the Km and Vmax 
for the fluorescently tagged transporters were not significantly different from those of 
wild-type mGAT1.  Collectively, these data indicated that reconstituting a naturally 
occurring PDZ class II interacting motif at the C-terminal of an mGAT1XFP fusion 
protein was both necessary and sufficient to confer wild-type like plasma membrane 
expression when expressed in N2a cells, whether the motif’s sequence was the native 
mGAT1 -AYI sequence or the alternative Ephrin B receptor-like -YKV residues.  
Furthermore, in the N2a cell assay that we employed, residues P(-3) to P(-27) of the 
GAT1 C-terminus contain little additional information that influences transporter 
trafficking to the plasma membrane or its normal function. 
In contrast to the wild-type behavior of mGAT1XFP* and 3-28, it was clear that 
mGAT1XFP45 was located primarily inside the cell (Figure 2A) and this was reflected in 
its markedly impaired [
3
H]GABA uptake compared to wild-type mGAT1 (22  0.03%; 
Figure 2B) and very small fraction of the total mGAT1XFP45 protein that partitioned 
into the plasma membrane (2.8  0.6% compared to 44  4.5% for wild-type; Figure 2C).  
It should be noted that mGAT1XFP45 was particularly challenging to process during 
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surface biotinylation experiments because the majority of the protein sample aggregated 
in the well of the acrylamide gels and did not separate under electrophoresis.  We are 
certain that this experimental difficulty amplified the actual shift in ratio from membrane 
to intracellular partitioned mGAT1XFP expression.  Nonetheless, these three lines of 
evidence combined indicated that there was a marked biochemical difference between 
mGAT1XFP45 protein and the other fluorescent constructs, so that mGAT1XFP45 
remained intracellular and also aggregated in detergent concentrations that readily 
solubilized other mGAT1XFP fusions.  Furthermore, this difference apparently arose 
because mGAT1XFP45 possesses two copies of the GAT1 P(-28) to P(-44) C-terminal 
amino acids, which presumably dominated any trafficking rescue conferred by the 
presence of the C-terminal -AYI PDZ class II interacting motif. 
Although constructed with an entirely different approach, mGAT1CFPCT and 
mGAT1YFPCT, like mGAT1XFP45, were primarily expressed intracellularly (Figure 
2A) and exhibited reduced [
3
H]GABA uptake compared to wild-type mGAT1 (35  2% 
and 23  2% respectively; Figure 2B).  C-terminal residues P(0) through P(-32) remained 
intact in mGAT1XFPCT and therefore so too did any potential PDZ interaction.  
Consequently, it appeared that inserting the XFP moiety between R565 and L566 
impeded appropriate trafficking of mGAT1XFPCT upstream from interaction with PDZ 
domain containing proteins. 
The N-terminally-labeled XFP15mGAT1 fusions were also primarily retained 
within the cell (Figure 2A), and displayed significantly reduced [
3
H]GABA uptake 
compared to wild type mGAT1 (CFP15mGAT1 35  2% and YFP15mGAT1 28  6%; 
Figure 2B).  This extended our previous experience with an N-terminally-labeled 
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GFPmGAT1 fusion that had only eight amino acids in its linker between the fluorophore 
and the mGAT1 (8).  Apparently lengthening the linker by an additional seven amino 
acids did not rescue the N-terminal interaction necessary for insertion of GAT1 into the 
plasma membrane. 
mGAT1XFP constructs reveal important interactions for dimerization 
and trafficking  
We applied the DRAP technique to measure FRET between the CFP and YFP 
moieties of paired mGAT1XFP constructs when expressed in N2a cells under the same 
non-saturating transfection conditions described for all previous experiments.  We first 
investigated oligomerization between mGAT1XFP* and mGAT1XFP8 pairs, constructs 
that function like wild-type mGAT1 in uptake and surface biotinylation experiments 
(Figures 3A and 3B).  To quantify FRET between the mGAT1 oligomers, we constructed 
a scatterplot of the photobleach-induced changes in CFP and YFP fluorescence of each 
cell during the entire bleaching time and fitted a regression line to the data (Figure 3C).   
The y-intercepts for the regression lines for the mGAT1CFP*/mGAT1YFP* and the 
mGAT1CFP8/mGAT1YFP8 transfection pairs were 1.10  0.01 and 1.26  0.01, 
respectively (Figure 3C).  When inserted into equation 1, these translated to FRET 
efficiencies of 21% for mGAT1CFP*/mGAT1YFP* and 9% for 
mGAT1CFP8/mGAT1YFP8.  We inserted these FRET efficiencies into Equation 2 
(assuming R0 = 49.2 Å for the CFP-YFP pair and κ
2
 = 0.67 (159)) to determine that the 
fluorophores in mGAT1CFP8/mGAT1YFP8 and mGAT1CFP*/mGAT1YFP* pairs are 
separated by 72 Å and 61 Å, respectively.  Given that mGAT1XFP* and mGAT1XFP8 
are essentially identical with the exception of 8 amino acids after the fluorophore, we 
were initially surprised that these two construct sets yielded such a difference in 
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measured FRET efficiency.  One possibility for mGAT1XFP* having increased FRET 
compared to mGAT1XFP8 is that oligomer assembly is more efficient in this construct.  
Previous investigations from our laboratory performed with the 4-YFP and 2-CFP 
labeled nicotinic acetylcholine receptor subunits have demonstrated that marked 
differences in FRET efficiencies can result from improved receptor assembly (150).  
However, [
3
H]GABA uptake and biotinylation assays had already demonstrated that 
mGAT1XFP* and mGAT1XFP8 insert into the plasma membrane with equal efficiency; 
and we know from the work of other laboratories that this process is dependent on the 
efficient assembly of the mGAT1 subunits (139, 144).  Therefore the difference in FRET 
efficiency most likely occurs because the fluorophores are closer together or the dipoles 
are orientated slightly differently to one another to yield an increased FRET efficiency 
for mGAT1XFP* compared to mGAT1XFP8. 
In addition to studying the fluorescent constructs that behaved like wild-type in 
functional assays, we were also interested to learn what FRET could reveal about the 
assembly and trafficking (or lack thereof) of the constructs which showed impaired 
function.  We found no measurable FRET between mGAT1CFP45/mGAT1YFP45 co-
expressed in N2a cells (Figure 4A), indicating that the intracellular retention of this 
protein highlighted by our previous functional and biochemical experiments occurred in 
large part because the assembly of mGAT1XFP45 oligomers was severely impaired.  
Furthermore, oligomerization of mGAT1YFP45 could not be rescued by co-expression 
with the wild-type-like mGAT1CFP8 (Figure 4B), which displayed the same strong 
plasma membrane localization as if it were expressed alone (Figure 4C).  These results 
were confirmed by [
3
H]GABA uptake assay.  Assays were performed on N2a cells co-
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transfected with 50 ng mGAT1CFP8 plasmid plus an additional 0, 12.5, 25, or 50 ng of 
mGAT1CFP8, mGAT1YFP8, or mGAT1YFP45.  Figure 4D shows that under these non-
saturating transfection conditions, increasing the quantity of mGAT1CFP8 or 
mGAT1YFP8 co-expressed with 50 ng of mGAT1CFP8 augmented [
3
H]GABA uptake, 
such that upon the eventual transfection of 100 ng total of mGAT1XFP8 uptake was 
greater than twice that for 50 ng mGAT1XFP8.  However, co-expression of up to 50 ng 
of mGAT1XFP45 was unable to significantly improve the [
3
H]GABA uptake from 50 ng 
mGAT1CFP8 alone (Figure 4D).  Surprisingly, the presence of increasing levels of 
mGAT1XFP45 did not decrease the function of mGAT1CFP8; i.e., mGAT1XFP45 did 
not exert a dominant-negative effect on the trafficking of mGAT1CFP8.  That 
mGAT1XFP45 did not sequester normally functioning mGAT1 molecules indicated that 
possessing two copies per transporter protein of the P(-28) through P(-44) C-terminal 
residues resulted in an autoinhibition of mGAT1XFP45 oligomerization. 
The mGAT1XFPCT constructs had also shown impaired function in [
3
H]GABA 
uptake assays (Figure 2A).  However, these constructs produced a robust FRET signal 
upon co-expression of mGAT1CFPCT with mGAT1YFPCT (Figure 4E).  When 
mGAT1YFPCT photobleach was plotted against mGAT1CFPCT photorecovery, the 
regression line intercepted the y-axis at 1.50  0.01, implying a FRET efficiency of 33% 
(Figure 4F).  This suggested that mGAT1XFPCT constructs could oligomerize but had 
their trafficking to the membrane inhibited by locating the fluorophore between residues 
R565 and L566.   
 [
3
H]GABA uptake experiments had determined that the N-terminally-labeled 
XFP15mGAT1 constructs were poorly expressed on the plasma membrane (Figure 2A).  
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We asked whether placing the XFP only 15 residues from the N-terminus of mGAT1 had 
disturbed a protein-protein interaction crucial for normal plasma membrane expression.  
A well-studied interaction of the GAT1 N-terminus occurs with syntaxin1A (160-162), 
which acts as a positive regulator of GAT1 surface expression.  Treatment of neurons in 
hippocampal culture with botulinum neurotoxin 1C, which cleaves syntaxin 1A, causes a 
reduction in surface-expressed mGAT1 and a corresponding increase in the cytosolic 
transporter (161).  We co-expressed a YFP-syntaxin 1A fusion protein with both 
mGAT1CFP8 and CFP15mGAT1 in N2a cells and measured good FRET efficiencies 
between the co-expressed proteins in both transfections (Figures 5A and 5B, 
respectively).  The y-axis intercept of the regression lines for mGAT1CFP8/YFP-
syntaxin 1A and CFP15mGAT1/YFP-syntaxin 1A were 1.78  0.002 and 1.41  0.006 
respectively (Figure 5C), implying FRET efficiencies of 44% and 29% (Equation 1).  
Assuming the canonical R0 = 49.2 Å and κ
2
 = 0.67 for CFP (159), these efficiencies 
imply that the distance between the fluorophores is 51.2 Å and 58.0 Å for 
mGAT1CFP8/YFP-syntaxin 1A and CFP15mGAT1/YFP-syntaxin 1A, respectively 
(Equation 2).  This indicates that the mGAT1 N- and C-termini could reside as close as 
7 Å from one another.  Whether this represents an intra- or inter-molecular convergence 
of termini in an mGAT1 oligomer cannot be determined from these data.  That 
YFP-syntaxin 1A yielded a lower FRET efficiency with the N-terminal CFP15mGAT1 
fusion than the C-terminal mGAT1CFP8 indicated that, although the syntaxin 1A binding 
site is located closer to the fluorophore in CFP15mGAT1, there must be a deficiency in 
the association of the two molecules.  However, a FRET efficiency of 29% indicated that 
the N-terminal CFP fusion nonetheless allowed a substantial physical interaction between 
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mGAT1 and syntaxin 1A.  We suspected that rather than directly interfering with 
syntaxin 1A-mGAT1 binding, the XFP15mGAT1 fusions were oligomerization deficient 
which reduced the availability of mGAT1 transporter complexes to couple with 
syntaxin 1A.  CFP15mGAT1 and YFP15mGAT1 showed no detectable FRET when co-
expressed (Figure 5D), indicating that these constructs indeed likely fail to oligomerize 
and consequently reduce the amount of transporter oligomers available to interact with 
syntaxin 1A in the exocyst.  
Discussion 
A linear assay system for mGAT1 in N2a cells  
Various cell lines and transient transfection techniques have been applied to 
investigate the oligomerization and trafficking of SLC6 transporters (8, 132, 135, 143-
145, 163-168).  However, over-expression of neurotransmitter transporters in vitro may 
often fail to recapitulate the behavior of the protein in its native in vivo environment.  The 
data presented in this study, as well as our laboratory’s previously reported findings, have 
shown that when mGAT1GFP is transiently expressed in the widely used HEK 293T cell 
line, its [
3
H]GABA uptake appears normal despite its significant trafficking deficits in 
vivo (8).  Several possible mechanisms could prevent mGAT1GFP from recapitulating its 
neuronal cell behavior when expressed in HEK 293T cells.  The first is overexpression 
caused by the presence of the simian virus 40 (SV40) large T-antigen in HEK 293T cells, 
which allows for episomal replication of transfected plasmids such as pcDNA3.1(+) used 
here that contain the SV40 origin of replication. Consistent with this hypothesis, we find 
that [
3
H]GABA uptake becomes saturated in HEK 293T cells transfected with as little as 
50--100 ng of mGAT1 plasmid, whereas transfection of 500 ng of mGAT1 plasmid into 
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N2a cells (which lack the SV40 T antigen) remained unsaturated.  We suspect 
overexpression of mGAT1 in HEK 293T cells could saturate the cellular trafficking 
machinery so that it is no longer able to dynamically regulate transporter number at the 
cell surface.  Under these conditions, mutants like mGAT1GFP are mistargeted to the 
membrane when they should be retained within the cell.   
A second explanation for the difference in trafficking between HEK 293T cells 
and mouse neurons is that HEK 293T cells do not express the necessary collection of 
associating proteins to regulate GAT1 trafficking appropriately.  For example, PICK1 is 
expressed in N2a cells, but is hardly detectable in HEK 293 cells (168).   However, 
because HEK 293T cells appear to process and traffic mGAT1GFP like wild-type 
mGAT1, it suggests that this cell type does not utilize PDZ interactions to deliver GAT1 
to the plasma membrane.  Rather HEK 293T cells may use a  distinct pathway for this 
process.  In fact, hNET mutants with truncated C-termini function like wild-type 
transporter in HEK 293 cells (from which HEK 293T is derived), although in many other 
cell lines  truncation mutants exhibited reduced substrate uptake (169). 
HEK 293T cells were invaluable for pioneering heterologous expression studies 
of excitability proteins (170) and still serve well when one desires sheer quantity rather 
than faithful processing, assembly, sorting, regulation, and targeting.  However, our 
studies required a system that more closely resembled the native environment in which 
mGAT1 normally expressed.  We developed a heterologous transfection protocol and 
uptake assay in the N2a cell line that was non-saturating with respect to protein 
expression level, substrate concentration, and time course.  We chose to work with the 
N2a cell line because its background closely matched that of the mGAT1 protein that we 
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were studying; mouse and neuronal.  We therefore expected that it would express the 
appropriate complement of accessory proteins for assessing mGAT1 assembly and 
trafficking.  While we cannot claim perfect fidelity, the lack of saturation provides 
confidence that changes in expression, oligomerization, and trafficking are readily 
detected under these assay conditions.  
Trafficking domains in the mGAT1 C-terminus  
We used the above N2a expression system to express fluorescently tagged 
mGAT1 transporter mutants and identify regions critical for mGAT1 assembly and 
trafficking.  We show that constructs mGAT1XFP*, mGAT1XFP3, mGAT1XFP8, 
mGAT1XFP20, and mGAT1XFP28 all function without significant difference from wild-
type mGAT1; the additional C-terminal residues after the fluorophore in this series 
rescued deficits observed in the original mGAT1GFP construct.  These data demonstrate 
that the terminal residues of mGAT1 must form a PDZ class II interacting domain for 
appropriate plasma membrane expression, whether the primary sequence of that motif is 
the native -AYI from GAT1 or another type II motif from a different receptor (-YKV).  
Nevertheless, the rules for recognition of the class II PDZ-interacting motif extend 
further than the consensus X--X-  pattern.  The identity and combination of the 
hydrophobic residues at P(0) and P(-2) is critical (154, 171). The terminal -YKI sequence 
of mGAT1GFP is not present at the C-terminus of any known membrane protein and 
clearly is not utilized by PDZ-domain-containing proteins in N2a cells or in vivo (8).  
Besides the terminal -AYI sequence, there are apparently no other motifs that influence 
trafficking between the P(-3) and P(-28) positions in the GAT1 C-terminus.  These 
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findings corroborate previous studies of truncation mutations in neuronal SLC6 
transporter trafficking (144, 145). 
One potential caveat to the apparent equivalence of -YKV and -AYI terminal 
residues in our constructs is the significant difference in FRET efficiency between 
mGATCFP*/mGAT1YFP* and mGAT1CFP8/mGAT1YFP8.   However, we show that 
the [
3
H]GABA uptake and surface biotinylation were similar between the two constructs 
and comparable to wild-type mGAT1, suggesting that the differing FRET efficiencies 
were not attributable to variations in either construct design’s ability to form functional 
oligomers.   Rather, we believe the variation in FRET efficiencies resulted from different 
distances between the CFP and YFP molecules or altered relative orientations of the 
chromophore dipoles in the mGAT1XFP* vs. the mGAT1XFP8 transporter oligomers.  
These two constructs differ only in their most C-terminal residues: mGAT1XFP* 
terminates with the residues –ELYKV, while mGAT1XFP8 terminates -KEAYI.  Though 
both motifs represent class II PDZ interacting domains, these two particular sequences 
are almost unique in nature to the Ephrin B receptors and the GAT1 transporter 
respectively (157, 172).   It is conceivable that by changing the primary sequence of 
mGAT1’s PDZ interacting motif we have changed the identity of the interacting proteins 
with which GAT1 now associates.  The -AYI motif of GAT1 can interact with the PDZ 
domain containing protein PALS1 (137), with similar data showing the interaction of 
Ephrin B receptors and Syntenin, FAP-1, GRIP, and PICK1 (155-157).  These potential 
interacting partners range in size from 627 amino acids to 2485 amino acids.  If 
substitution of the PDZ interaction motif altered mGAT1’s preferred interacting partner, 
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the size of the interacting protein will no doubt influence the arrangement of the adjacent 
fluorophores on the C-terminal of mGAT1XFP* and mGAT1XFP8 oligomers.   
Our studies also confirmed the presence of a important trafficking motif in the 
mGAT1 C-terminus recently identified by Farhan et al. (163).  Our mGAT1XFPCT 
constructs disrupted an "RL" motif by placing the fluorophore directly between residues 
R565 and L566.  This construct readily formed oligomers but exhibited poor trafficking 
to the plasma membrane. Farhan et al. showed this motif to be responsible for binding the 
COPII coat protein Sec24D, which mediates export of assembled transporters from the 
ER.  Our data thus support Farhan et al.’s findings that the “RL” motif in the proximal 
C-terminus controls ER export in a manner that is dominant over the presence of a class 
II PDZ-interacting motif at the distal C-terminus. 
Structural implications of the FRET data for mGAT1 oligomers   
Our FRET experiments with the YFP-CFP pairs of our various constructs 
provided structural insight into the relationship between the N- and C-termini of the 
mGAT1 dimer.  The greatest FRET efficiency that we measured for mGAT1 oligomers 
in this study was 33% for the mGAT1XFPCT CFP-YFP pair.  According to Equation 2, 
the calculated distance between the two fluorophores was 55 Å.  However, this 
calculation was based on the canonical Förster distance (R0) for a CFP-YFP combination 
of 49.2 Å which assumes that the relative dipole orientation factor κ2 is 0.67 for rapid 
random orientation (159).  The CFP and YFP molecules consist of β-cans 24 Å in 
diameter and 42 Å in length (173) at the center of which is the fluorescent chromophore. 
The major dipole moment of the fluorophore is oriented approximately 60 from the long 
axis the β-can (174).  In reality, κ2 can range from 0.01 to 4.  Our measured FRET 
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efficiency therefore implies that the chromophores are separated by a minimum of 27.5 Å 
and a maximum of 74.6 Å.  Comparison of the mGAT1XFPCT sequence with the 
structure of LeuTAa (141) fuses the fluorophores in mGAT1XFPCT only two amino acids 
after the terminal α-helical residue of TM12.  The ends of TM12 are only 15 Å apart in 
the LeuTAa crystal structure dimer.  The dimensions of XFP limit the smallest measurable 
distance for side-by- side chromophores in an oligomerized membrane protein to 24 Å 
(173).   Therefore, the separation range we measured for the chromophores in 
mGAT1XFPCT oligomers corroborates the close proximity of the cytoplsmic ends of 
TM12 inferred for the SLC6 transporters from the LeuTAa crystal structure (141). 
Although less informative than the C-terminal XFP fusions, our N-terminal 
XFPmGAT1 yielded insight into the structural requirements for mGAT1 dimerization.  In 
our attempts to build a fluorescent mGAT1 with the XFP on the N-terminus, we extended 
the linker by another seven amino acids, to 15 residues, compared to an 8-residue linker 
in a previously published construct (8).  Another laboratory has made N-terminal XFP-
GAT fusions with a longer, 27-amino acid linker that functions identically to wild-type 
GAT1 (139).  In contrast, our FRET experiments with the shorter 15-amino acid linker 
show that transporter oligomerization is inhibited by the N-terminal fluorophore, 
although the monomers appeared to retain the ability to associate with syntaxin 1A.  It 
would therefore appear that the trafficking deficit in our N-terminal constructs must be 
caused by steric hindrance of an interaction that is important for its oligomerization, 
rather than for its export to the plasma membrane. 
Finally, our FRET experiments predict the distance separating the N- and C-
termini of adjacent mGAT1 molecules in an oligomer.  It has been previously reported 
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that the distance between the adjacent N- and C-termini in a hSERT oligomer is less than 
the distance between pairs of  N-termini or C-termini (143).  FRET data from our 
fluorescent mGAT1 constructs agrees with this finding, although via a different 
experimental approach.  We calculated the distances from measured FRET efficiencies 
for the separation of the fluorophores in mGAT1CFP8/YFP-syntaxin 1A that the N- and 
C-termini are separated by approximately 51 Å.  FRET efficiencies for 
mGAT1CFP*/mGAT1YFP* or mGAT1CFP8/mGAT1YFP8 complexes indicate that the 
C-termini to C-termini distance is between 61--72 Å. 
A role for the final 10 residues of TM12 in oligomerization  
The crystal structure of the bacterial orthologue of mGAT1, LeuTAa, suggested 
that TM9 and TM12 could be the major interfaces for the dimerization of SLC6 
transporters.  It further showed that the last 10 residues of TM12 extend beyond the 
transmembrane region into the cytosol as -helices that are separated by only 8.3 Å at 
their closest point (141).  Prior to the crystallization of LeuTAa, at least four regions--- 
including leucine repeats in TM2 (175), a glycophorin A-like motif in TM6 (176), and 
symmetrical interfaces (142) on TM4 and the TM11-12 region (143) --- had been 
suggested to support SLC6 transporter oligomerization.  The LeuTAa structure has now 
placed some of these postulated contact sites in question, implying they may instead be 
important for quaternary structure of transporter monomers rather than for oligomer 
assembly (140). Further support for the importance of the TM12 region comes from the 
ability of a TM11-12 hSERT partial transporter to homodimerize when expressed alone 
and to strongly inhibit surface trafficking of full-length hSERT when the two are co-
expressed.   Our current data suggests that a critical region of interaction is located in the 
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last 10 amino acids of TM12.  The non-functional mGAT1XFP45 constructs were 
particularly informative.  FRET experiments show that mGAT1XFP45 does not associate 
with other mGAT1XFP45 molecules or with mGAT1XFP8.  In addition, functional 
experiments determined that normal expression of the wild-type-like mGAT1CFP8 was 
not adversely affected by co-expression of increasing quantities of mGAT1YFP45.  Most 
reported transporter mutants with trafficking and assembly deficits exert a dominant 
negative effect upon the expression of the wild-type protein (139, 143-145, 163, 177).  
That mGAT1XFP45 did not follow this rule suggested that it was inhibiting its own 
assembly via an intra-molecular interaction.  To understand why mGAT1XFP45 did not 
co-assemble with other GAT1 monomers, we compared its primary sequence with the 
construct mGAT1XFP28 that behaves essentially as wild-type mGAT1 in our functional 
assay.  The difference between the two constructs is the presence of the extra P(-28) to 
P(-44) hGAT1 C-terminal sequence after the fluorophore in mGAT1XFP45.  We 
hypothesize that auto-inhibition of oligomerization occurs in the nascent mGAT1XFP45 
protein when the second copy of the -helical P(-34) through P(-44) C-terminal region 
from hGAT1 located after the XFP moiety is able to associate with the mGAT1 TM12 
within the same polypeptide.   Considering that mGAT1XFPCT, in which the 
fluorophore bisects residues P(-32) and P(-33) (R565 and L566), dimerized but did not 
traffic, we do not expect that the residues C-terminal to P(-34) are involved in 
dimerization. 
Conclusion   
We have described a stringent technique to assay the function of neuronal SLC6 
transporters in vitro and determined that regions in both the N-terminus and TM12 are 
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critical for GAT1 oligomerization.  The interface for GAT1 oligomerization almost 
certainly requires association of the final 10 residues of TM12 from each monomer.  We 
have also highlighted two motifs that control GAT1 trafficking to the plasma membrane 
that are present in the C-termini and determined information about the arrangement N- 
and C-termini of mGAT1 oligomers in the cytosol. 
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Figure Legends 
 
Figure 1.  Establishing a non-saturated [
3
H]GABA uptake assay in an appropriate 
cell type.  50, 100, 250, or 500 ng of wild-type mGAT1 plasmid or an equimolar 
equivalent of mGAT1GFP and pcDNA3.1(+) plasmids were transfected/well. 20-min 
uptakes were performed on transfected N2a cells in 2.5 μM (A) or 80 μM (B) [GABA]O. 
(C) The same transfections were performed in HEK 293T cells, and 20- min uptakes 
were performed in 2.5 μM extracellular [GABA]O.  Each point represents the mean of 6 
transfections ± S.E.M.  Time course experiments were performed in 2.5 μM (D) or 80 
μM (E) [GABA]O on N2a cells transfected with 100 ng/well wild-type mGAT1 plasmid 
or an equimolar equivalent of the pcDNA3.1(+) plasmid.  Each data point represents the 
mean of 6 transfections ± S.E.M. 
Figure 2. Functional characterization of fluorescent mGAT1 constructs.  (A) 
Representative fluorescence microscopy images of live cells expressing each of the 
fluorescent constructs 48 h after transfection using the non-saturating parameters 
described in the experimental procedures.  Scale bar = 10 μm.  Beside the image of each 
construct’s expression in N2a cells, a cartoon schematic describes the location of the 
fluorophore in the mGAT1 protein sequence.  A key to the color code used in these 
cartoons is located at the top of the panel. (B) 20-min [
3
H]GABA uptake from N2a cells 
transfected with 100 ng/well of mGAT1 wild-type plasmid or an equimolar equivalent of 
the fluorescently tagged mGAT1 plasmids or blank pcDNA3.1(+) vector.  Results 
represent the mean  S. E. M of between 6 and 18 transfections for each construct.  * 
denotes significant difference compared to wild-type, P  0.05 (one-way analysis of 
variance (ANOVA) with Tukey’s post hoc test). (C) Surface biotinylation experiments 
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comparing the plasma membrane partitioning of mGAT1XFP constructs that had 
displayed wild-type like [
3
H]GABA uptake and one which presented an uptake deficit.  
Representative bands of the biotinylated mGAT1 surface fractions are displayed above 
the graph.  Bands were arranged in the image to correspond to the appropriate column in 
the graph.  Results represent the mean  S. E. M of between 5 and 8 transfections for 
each construct. * denotes significant difference compared to wild-type, P  0.05 (one-
way ANOVA with Tukey’s post hoc test).  (D) We examined the concentration 
dependence relationship of six selected clones whose uptake was closest to wild-type in 
panel B.  Panels from left to right present three experiments in which the constructs were 
tested in pairs vs. wild-type mGAT1 (100 ng cDNA transfected per 12-well-plate well).  
The non-specific uptake was determined from wells transfected with empty 
pcDNA3.1(+) vector, and subtracted from the test samples, but is displayed for reference 
in each plot.  No significant difference was found between any of the fluorescent clones 
and wild-type mGAT1 for all concentrations as determined by one-way ANOVA with 
Tukey’s post hoc test, P  0.05. Data represents the mean uptake for each concentration 
 S. E. M for between 6 and 9 transfections. 
Figure 3.  Förster resonance energy transfer between wild-type like fluorescent 
mGAT1 proteins.  Plots of acceptor photobleach and donor photorecovery for 
mGAT1CFP*/mGAT1YFP* (A; n=10) or mGAT1CFP8/mGAT1YFP8 (B; n=7) co-
expressed in N2a cells.  (C)  A scatter plot of CFP photorecovery versus YFP 
photobleach for the FRET pairs in panels A and B.  FRET efficiency for each transfection 
was calculated by extrapolating to the y-axis intercept, the value for which was entered 
into Equation 1. 
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Figure 4. Oligomerization state of mGAT1XFP constructs with functional deficits. 
Plots of acceptor photobleach and donor photorecovery for 
mGAT1CFP45/mGAT1YFP45 (A; n = 12) and mGAT1CFP8/mGAT1YFP45 co-
transfections in N2a cells (B; n = 12). (C) Representative image of N2a cells co-
expressing mGAT1CFP8 and mGAT1YFP45.  Scale bar = 10 μM.  (D)  [3H]GABA 
uptake assay from N2a cells in 12-well plates expressing 50 ng of mGAT1CFP8 together 
with increasing co-transfection amounts of mGAT1CFP8, mGAT1YFP8, or 
mGAT1YFP45.  Results for 12.5, 25, 50 ng mGAT1YFP8 and mGAT1YFP45 
transfected alone are included for reference.  Each data point is the mean  the S.E.M of 
at least 6 separate transfections.  Significant differences for the 
mGAT1YFP8/mGAT1CFP8 co-transfections or the mGAT1CFP8/mGAT1CFP8 co-
transfections compared to 50 ng mGAT1CFP8 alone are denoted by * and #, 
respectively, P  0.05 (One-way ANOVA with Tukey’s post hoc test). (E) Mean 
acceptor photobleach and donor photorecovery for mGAT1CFPCT/mGAT1YFPCT 
transfected N2a cells (n = 5).  (F) A scatter plot of mean mGAT1CFPCT photorecovery 
versus mGAT1YFPCT photobleach. 
Figure 5.  Association of fluorescent mGAT1 constructs with syntaxin 1A. 
Plots of mean acceptor photobleach and donor photorecovery for mGAT1CFP8/YFP-
synatxin 1A (A; n = 5) and CFP15mGAT1/ YFP-synatxin 1A co-transfections in N2a 
cells (B; n = 8).  (C) A scatter plot of CFP photorecovery versus YFP photobleach for the 
FRET pairs in panels A and B.  (D) Mean acceptor photobleach and donor photorecovery 
for the CFP15mGAT1/YFP15mGAT1 co-transfection in N2a cells (n = 5).
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Table 
 
Table 1.  Cell density, transfection reagent and cDNA quantities required for non-saturated 
transient mGAT1 expression in N2a cells 
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Protocol Steps 1 2 3 2 & 3 4 5 6 
96 well 0.50 1.75  104 12.5 1 10 0.5 0.05 0.07 
48 well 
0.95 3.50  104 25 2 17.5 0.75 0.1 0.125 
24 well 1.9 7.00  104 50 4 25 1 0.2 0.25 
12 well 3.8 1.37  105 100 5 50 2 0.4 0.50 
6 well 
/35 mm 
9.6 3.50  105 250 6 100 4 0.8 1.0 
60 mm 28.3 1.03  106 750 8 250 12 2 2.5 
100 mm 78.6 2.86  106 2000 20 750 30 5 6.5 
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Appendix I: GABA transporters: Structure, 
oligomerization, trafficking, and pharmacology 
determine neuronal excitability 
 
This appendix reviews the structure, oligomerization, trafficking and pharmacology of 
GABA transporter.  I describe the physiological and pathological roles of the GABA 
transporters, physiological consequences of GABA transporter malfunction, and 
neurotransmitter reuptake mechanisms.  Fraser Moss and Herwig Just describe the 
following: class, subtypes, structure, function, and regulation of GABA transporters.  
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Synopsis 
 
-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the vertebrate 
central nervous system.  Activation of ionotropic and metabotropic GABA receptors by 
GABA reduces the excitability of the cell, inhibiting neuronal firing.  Plasma membrane 
GABA transporters maintain the extracellular GABA concentration in the vicinity of the 
synapse and consequently control the activity of the GABA receptors.   Synaptic 
transporters play an important role in terminating neurotransmission while extrasynaptic 
transporters control GABAergic tone.  Here we review how the structure, assembly, 
trafficking, and pharmacology of the four known GABA transporter isoforms modulates 
extracellular [GABA] and determines neuronal excitability. 
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Physiological Roles of the GABA transporters 
 
The canonical role of GABA transporters (GATs) is to remove GABA from the 
synapse following phasic neurotransmitter release, terminating GABAergic 
neurotransmission.  GABAergic transmission is usually inhibitory, because GABAA and 
GABAB receptors activate Cl
-
 and K
+
 channels, respectively (although some young 
neurons have a high intracellular Cl
-
 concentration, producing a depolarized Cl
-
 
equilibrium potential and therefore leading to excitatory GABAergic postsynaptic 
events).  Additionally, GATs perpetually maintain the ambient extracellular 
concentration ([GABA]o) at a non-zero concentration which dictates the amplitude of 
tonic GABAergic currents via activation of extrasynaptic GABA receptors.  Even after 
synaptic activity, [GABA]o is much less than the intracellular GABA concentration 
([GABA]i) in the presynaptic boutons and surrounding glia.  To move the 
neurotransmitter against this concentration gradient, an electrogenic process co-transports 
GABA with Na
+
 and Cl
-
 down the combined electrochemical gradient of the 
co-transported ions. GATs are therefore attractive targets in the treatment of epilepsy 
because inhibiting GABA uptake, through either pharmacological or genetic intervention, 
prolongs neurotransmitter lifetime and increases ambient [GABA]o to decrease 
excitability.  Importantly, GATs are equally able to transport substrate in either the 
forward (into the cell) or reverse (out of the cell) direction.  Reverse GABA transport is a 
physiological process that occurs under depolarizing conditions.  Consequently, 
inhibitory interneuron activation can stimulate both quantal GABA release from synaptic 
vesicles and nonvesicular GABA release via reverse GABA transport.  During periods of 
high-frequency stimulation, synaptic vesicle stores may become depleted but the 
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transporter-mediated GABA release continues.  Furthermore, surrounding astroglia can 
become depolarized and release GABA through reverse transport. Therefore, during a 
seizure, reverse transport could have an important neuroprotective function. 
This chapter serves as a brief introduction to the several GAT isoforms expressed in 
the brain and how their differential tissue distribution, their structure, and their 
physiological and pharmacological modulation can control neuronal excitability. 
Classification and Differential CNS Expression of GABA Transporters 
 
The GATs are part of the neurotransmitter sodium symporter (NSS) transporter 
family which includes transporters for the neurotransmitters dopamine, serotonin (5HT), 
norepinephrine, and glycine.  The NSS transporters are also known as the solute carrier 6 
(SLC6) family of membrane proteins.  Our laboratory helped to clone the first SLC6 
transporter, rat GAT-1 (SLC6A1); 21 human SLC6 transporter genes were subsequently 
identified, including three other GABA transporters: GAT-2 (SLC6A13), GAT-3 
(SLC6A11), and the betaine/GABA transporter, BGT-1 (SLC6A12).  GAT-2, GAT-3, 
and BGT-1 respectively show 51%, 50%, and 48% amino acid identity with GAT-1, 
conservation occurring primarily in their predicted transmembrane spanning regions 
(Figure 1).  The “GAT” nomenclature of the GABA transporters is not the same across 
species (Table 1).  The SLC6 gene nomenclature offers a standardized taxonomy but 
because this thesis focuses on human epilepsy, we prefer to use the more descriptive 
human/rat classification of the transporter proteins. 
Differential CNS Distribution of GAT Isoforms 
 
Expression of GAT-1 and GAT-3 is restricted to the brain, whereas BGT-1 and 
GAT-2 are found in peripheral tissues and in the CNS. GAT-1 is the predominant GABA 
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transporter in the CNS and is localized primarily on axons and presynaptic boutons of 
GABAergic inhibitory neurons, but is also expressed in astrocytes. 
Our laboratory generated knock-in mice expressing GAT-1 transporters fused to green 
fluorescent protein (GFP).  These mice allow direct visualization and quantification of 
GAT-1 expression in situ, strongly complementing earlier immunohistochemical and 
radiolabeling studies.  The cerebellar pinceaux exhibit impressively high GAT-1 density, 
containing almost 8 million GAT-1 molecules per pinceau.  The Bergman glia in the 
molecular layer and the axons and boutons of Golgi cells in the glomeruli of the granule 
cell layer account for the more diffuse GAT-1-GFP expression elsewhere in the 
cerebellum.  In the hippocampus, GAT-1 is localized to the axons and synaptic boutons 
of basket and chandelier cells in strata oriens and pyramidale.  A bouton in stratum oriens 
expresses 79% of the GAT-1 volume density observed in a cerebellar pinceau.  The 
relative fluorescence intensity of GAT-1-GFP in the neuropil of hippocampal pyramidal 
and dentate gyrus cell layers is approximately 50% of that seen in cerebellar pinceaux but 
no clear axon or bouton labeling is observed due to high fluorescence in surrounding 
astrocytes.  In human hippocampus, the termini of GAT-1-expressing axon terminals 
cluster with high density around the dentate gyrus granule cell somata.  GAT-1 expresses 
at low levels in the cerebellar white matter, striatum, and most thalamic nuclei, the latter 
tissue restricting GAT-1 expression to the astrocytes.  Higher expression occurs in the 
GABAergic thalamic reticular nucleus.  In neocortex, GAT-1 immunostaining is 
associated exclusively with punctate structures resembling axon terminals around the 
perikarya, and especially in cartridges surrounding the proximal portions of the apical 
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dendrites of pyramidal cells.  Cartridges are comprised at least in part by the terminals of 
cortical chandelier and basket cells. 
Weak GAT-2 expression is detected in neurons and astrocytes in the cerebral cortex, 
cerebellum, brainstem, and hippocampus. The greatest GAT-2 expression occurs in the 
leptomeninges, ependyma and choroid plexus.  Similarly to GAT-1 and GAT-3, distal 
astrocytic processes express GAT-2.  However, GAT-2 is uniquely expressed in 
astrocytic cell bodies and proximal processes.  Neuronal GAT-2 expression occurs in 
axon terminals, mainly in deep layers of rat cerebral cortex, but in areas distant from the 
synaptic cleft.  Weak GAT-2 expression is also detected in the cytoplasm of dendrites 
from rat cortical neurons.  It is unclear if these transporters are ever present at the 
dendrite surface.  Thus, the subcellular distribution of GAT-2 suggests that its primary 
function is modulating the ambient [GABA]o rather than terminating GABAergic 
neurotransmission.   
  The physiological role of GAT-3 is probably similar to GAT-2, as it is exclusively 
expressed in distal astrocytic processes.  GAT-3 is present in the hindbrain, midbrain, 
olfactory bulb, subfornical organ, hypothalamus, thalamus, and brainstem.  Within the 
basal ganglia, GAT-3 expression is high in globus pallidus, subthalamic nucleus, and 
substantia nigra but low in the caudate nucleus and putamen. In the neocortex, punctate 
GAT-3 labeling of distal astrocytic processes forms a continuous sheet around the somata 
of both pyramidal and nonpyramidal neurons in all layers. 
BGT-1 was first identified in kidney, where it accumulates the osmolyte betaine in the 
hypertonic environment of the renal medulla.  Nonetheless, it is also expressed in the 
CNS, although its distribution does not closely correlate with GABAergic pathways, 
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despite having a higher substrate affinity for GABA than betaine.  Astrocytic cultures 
from rat brain express BGT-1; while monkey BGT-1 expression has been reported in the 
somata and dendrites of excitatory pyramidal neurons in cerebral cortex and in the CA 
fields of the hippocampus. 
Temporal lobe epilepsy (TLE) has strong ties to GABA transport; although 
GABAergic interneurons are preserved in sclerotic hippocampal tissue from TLE 
patients, there is a marked reduction in the typical punctate GAT-1 immunoreactivity 
around the cell bodies of pyramidal cells in the CA regions and granule cells of the 
dentate gyrus.  This indicates reduced GABAergic innervation of these cell types, 
predisposing them to hyperexcitability.  Furthermore, TLE is also characterized by a 
decrease in glutamate-induced GABA transport reversal; since seizures are marked by 
elevated glutamate concentrations, reduced GAT-1 reversal in these conditions would 
lessen the contribution of reverse GABA transport on seizure inhibition.  These regional 
increases in excitability may be further compounded by general increases in extrasynaptic 
GAT-3, which could lead to excess GABA removal, thus reducing GABAergic tone and 
promoting hyperexcitablity. 
Structure, Function and Regulation of GABA Transporters 
Structure --- insights from recent crystal structure 
When GAT-1 was first cloned in 1990, its primary sequence predicted that the 
transporter possessed 12 transmembrane (TM) spanning segments topologically oriented 
in the plasma membrane with the carboxy (C-) and amino (N-) termini residing in the 
cytoplasm.  Functional characterization determined that GABA transport was dependent 
on the co-transport of two Na
+
 ions and one Cl
-
.  In 2005, Eric Gouaux’s laboratory 
reported the crystal structure of a functional leucine transporter, LeuTAa, a homologue of 
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the mammalian NSS transporters (20--25% sequence identity) isolated from the bacteria 
Aquifex aeolicus.  The LeuTAa crystal structure provides a model on which all future 
structure/function research on NSS transporters can be based.  Importantly, features were 
revealed that could not have been predicted from fifteen years of previous experimental 
data.  TMs 1--5 and TMs 6--10 form a structural repeat arranged around a pseudo-two-
fold axis in the plane of the membrane (Figures 2A and 2B).  TM1 and TM6 run 
antiparallel to each other at the core of the protomer and the center of their helices 
unwind in the middle of the plasma membrane (Figure 2A).  The exposed main-chain 
carbonyl oxygen and nitrogen atoms afford hydrogen bonding partners that form most of 
the contacts with the bound substrate (Figure 2C).  The unwinding of TM1 and TM6 
further stabilizes the substrate.  The negative α-helical dipole moments of TM1a and 
TM6a are placed adjacent to the amino group of the leucine and the positive moment of 
TM1b is located next to its carboxy group.  The two Na
+
 ions co-transported with 
substrate stabilize the unwound helices at the transporter core for high-affinity substrate 
binding.  Na1 makes direct contact with the carboxyl group of the substrate (Figures 2C 
and 3A) which, at limiting substrate concentrations could determine the apparent Na
+
 
affinity of substrate transport.  Residues from TM3, TM7, and TM8 form the remainder 
of the dehydrated substrate/Na
+
 binding core.  The selectivity for Na
+
 as the co-
transporting ion arises simply because the pockets are too small to accommodate larger 
cations like K
+
 (Figures 3A and 3B).  LeuTAa does not require Cl
-
 co-transport to 
function, but a Cl
-
 ion functions as the trigger of the conformational changes that allow 
substrate to permeate to the cytoplasm in mammalian NSS transporters.  The Cl
- 
is 
proposed to bind within 5Å of Na1; the proximity allows the Cl
-
 to strongly couple with 
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Na1 and stabilize the substrate binding site.  Cl
-
 is coordinated by the residues that align 
with GAT-1 Tyr86, Ser295, Asn327, and Ser331 (Figure 3C).  One laboratory also 
reports the involvement of Gln291.  Asn327 is conserved in almost all known NSS 
members.  Ser331 is conserved in all mammalian Cl
-
-dependent NSS.  Replacing Ser331 
or Asn327 (or their aligning residues) in GAT-1, GAT-3, SERT, or DAT (the dopamine 
transporter), with a carboxylic residue makes substrate transport independent of Cl
-
.  
Reciprocal mutations in the Cl
-
-independent LeuTAa make leucine transport Cl
-
-dependent.  Thus all NSS transporters require a negative charge (from co-transported Cl
-
 
or an acidic side chain) to be supplied in this pocket during substrate transport. 
In the general “alternating access transport” scheme, a transporter has a cavity that is   
alternately available for substrate/ion permeation from the extracellular or intracellular 
side of the membrane; and substrate and co-transported ions must all be bound together 
before translocation across the membrane occurs.  Access to the cavity is controlled by 
intracellular and extracellular “gates” which open and close with conformational changes 
in the transporter.  The LeuTAa structure captures the protein in an intermediate substrate 
occluded state, in which both these gates are closed.  The closed extracellular gate is 
formed by a water-mediated salt bridge between Arg30 and Asp404 and beneath that, the 
large hydrophobic side chains on Tyr108 and Phe253.  The occluded structure and 
sulphydryl accessibility studies on mammalian NSS suggest that the extracellular gate 
opens via movements in TMs 1, 3, 6, and 10 moving Arg30 and Asp404 apart, coupled to 
a major rearrangement of extracellular loop 4 (ECL4) whose V-shaped tip forms a lid that 
dips into the extracellular cavity when the gate is closed.  The closed cytoplasmic gate is 
more complicated, comprising 20 Å of packed protein between the substrate and the 
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cytoplasmic face of the protein.  Part of this is formed by the backbones of TM1a, TM6b, 
and TM8 below the substrate binding site, an Arg5-Asp369 charge pair, an Arg5-Ser267 
H-bond, and an Arg5-Tyr268 cation- interaction at the cytoplasmic face.  Trp8 inserts 
between the backbones of TM1 and TM6b and anchors the N-terminus including Arg5.  
These residues are conserved throughout the NSS family, and mutation of the aligning 
amino acids in mammalian NSS transporters impairs transport.   
Experiments on SERT have begun to define the pathway through which the substrate 
diffuses from the transporter core to the cytoplasm.  When cysteine residues are 
substituted at positions that correspond to LeuTAa residues Gly190, Ile191, Phe194, 
Ile197, Ala198 and Thr201 in the cytoplasmic half of TM5, the cysteines become 
extremely reactive to sulphydryl reagents in the presence of 5HT.  This indicates that 
these residues, which are buried in the LeuTAa occluded structure, become available in a 
substrate-bound state.  They are protected from MTSEA reaction in the presence of 
cocaine, which traps the SERT in the extracellular-facing conformation. 
Trafficking --- modulating transporter number at the plasma membrane 
 
The number of GABA transporters at the plasma membrane shapes neurotransmission 
and controls excitability.  Quantifying the fluorescence intensity in presynaptic boutons 
and axons in the cerebellum and hippocampus of GAT-1GFP knock-in mice determined 
that the membrane density of GAT-1 molecules ranges from 800--1300 per m2.  Of this 
value, 61--63% of these molecules are inserted in the plasma membrane, and the 
reminder are just below the membrane in cytoplasmic vesicles (see below).  However, the 
interplay of constitutive and functional regulatory elements controls the density of 
transporter at the cell surface at any given point in time. 
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Constitutive transporter trafficking 
 
Several laboratories, including ourselves, have measured Förster resonance energy 
transfer (FRET) between transporters fused with the cyan and yellow fluorescent proteins 
(CFP and YFP respectively) to demonstrate the constitutive oligomerization of 
transporter protomers.  Although single transporter protomers are transport competent, 
mutations that prevent oligomerization eliminate FRET; and the fluorescently tagged 
transporter proteins are retained in intracellular compartments.  LeuTAa crystallized as a 
dimer, with TM9 and TM12 probably providing the assembly interface.  However, this 
structure likely represents only a low-order oligomerization state for these transporters, as 
evidence exists for the further oligomerization of transporter dimers.  FRET between 
YFP tagged Sec24D, a fluorescently tagged component of the COPII vesicle coat, and a 
CFP tagged GAT-1 demonstrates that after oligomerization, export from the endoplasmic 
reticulum (ER) occurs via COPII coated vesicles.  Sec24D interacts with a conserved 
motif (R/L-I/L consensus sequence) in the C-terminal of all NSS transporters.  
Transporters lacking this proximal C-terminal motif are retained in the ER and exert a 
dominant negative effect when co-expressed with wild-type protein.   Additionally, the 
ER retention of oligomerization deficient mutants in which the Sec24D interaction is 
preserved demonstrates that COPII vesicle coat interaction is necessary but not sufficient 
for ER export. 
GAT-1 transporters are delivered to the plasma membrane on a population of vesicles 
~ 50 nm in diameter that are distinct from neurotransmitter-containing vesicles.  This 
probably allows regulated transporter expression independent of neurotransmitter release.  
These vesicles insert their cargo into the plasma membrane under control of the exocyst.  
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The three most C-terminal residues of GAT-1 conform to a consensus sequence for a type 
II PDZ-interacting motif (Figure 1, PDZ = Postsynaptic density 95/Discs large/Zona 
occludens 1).  This sequence mediates transporter interaction with the exocyst by 
association with PDZ-domain-containing proteins and stabilizes the transporter in this 
location once inserted.  Importantly, NSS transporters are primarily located intracellularly 
unless they interact with a PDZ-domain containing protein at their distal C-terminus. For 
example, a truncated GAT-1 lacking the PDZ-interacting epitope exhibits impaired 
plasma membrane expression in vitro.  Similarly, GAT-1GFP knock-in mice, which 
express the same amount of total GAT-1 protein as wild type mice, exhibit a three-fold 
decrease in cell surface expressed transporter, because the GFP masks the endogenous 
PDZ-interacting epitope (-AYI).  Yet the GAT-1GFP mice do not phenocopy GAT-1 
knockout mice, which have a constant 25--32 Hz tremor in their limbs and tail and 
display ataxia and anxiety.  Thus, there appears to remain a default exocyst-independent 
pathway through which sufficient GAT1-GFP can be delivered to the cell surface to 
maintain wild-type-equivalent GABAergic tone. 
Live-cell imaging of GAT-1 molecules suggests that plasma membrane GAT-1 is 
tethered to the actin cytoskeleton via a multi-component protein assembly in which the 
PDZ-interaction forms an important link.  Through fluorescence recovery after 
photobleaching (FRAP), we recently established that GAT-1 exhibits 30% greater lateral 
mobility in the plasma membrane when the PDZ-interacting domain is disrupted.    
Therefore, interaction with PDZ proteins mediates transporter anchoring in the 
membrane.  A candidate PDZ-domain containing scaffold protein that mediates these 
properties is the membrane associated guanylate kinase (MAGUK) PALS1 (protein 
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associated with LIN-7, subtype 1).  The PALS1/GAT-1 interaction is dependent on the 
C-terminal –AYI residues and its co-expression with GAT-1 promotes increased 
transporter surface expression, presumably by stabilizing the residence of membrane -
inserted GAT-1.  Neuronal expression of PALS1 and GAT-1 does not perfectly overlap, 
and it follows that both molecules almost certainly interact with other partners in some 
cell types and in some subcellular compartments.  The interaction of GAT-1 with PDZ-
domain containing MAGUKs may play a cell-specific and compartment-specific role in 
regulating transporter availability, location, and stability. 
GAT-2, GAT-3, and BGT-1 possess PDZ-type-I-like interacting motifs at their C-
termini (Figure 1).  GAT-2 and BGT-1 interact with PDZ proteins, including Gαi-
interacting protein COOH terminus (GIPC) and LIN-7,  respectively, to stabilize their 
presence in the plasma membrane.  Deletion of these motifs results in redistribution of 
transporter to intracellular regions but does not perturb the sorting of GAT-2 or BGT-1 to 
the appropriate cellular compartments.  GAT-2 and BGT-1 sort to the basolateral surface 
when expressed in Madin-Darby canine kidney II (MDCK) cells, a well-established 
expression system to study polarized sorting of proteins into cellular compartments.  The 
seven amino acids immediately proximal to the PDZ-interacting motifs in GAT-2 and 
BGT-1 comprise a motif unique to these particular transporters that dictates their delivery 
to the basolateral surface of MDCK cells (Figure 1).  In general, basolateral sorting in 
epithelial cells corresponds to somatodendric sorting in neurons, while apical sorting, 
which is observed for GAT-1 and GAT-3, corresponds to axonal (and consequently 
presynaptic) sorting, although not all proteins fit this paradigm.  Truncation of the entire 
GAT-1 C-terminus does not perturb its apical sorting, but removing the three C-terminal 
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residues from GAT-3 is sufficient to result in mixed apical and basolateral sorting.  The 
-THF terminal amino acids of GAT-3 resemble but do not rigidly conform to a Type-I 
PDZ interacting motif (X-S/T-X-V/L) and reportedly bind the PDZ-domain protein 
CAP70.  For GAT-3 at least, the PDZ-interaction may therefore play an important role in 
both axonal sorting in neurons and stabilizing its expression in the plasma membrane. 
 Constitutive endocytosis of NSS transporters from the plasma membrane is 
controlled in large part by the non-polar residues within the non-classical endocytic 
motifs present in their proximal C-termini (consensus sequence L(X)ERLAY(X)IT, 
Figure 1).  Regulated endocytosis and exocytosis occur through pathways distinct from 
the constitutive processes. 
  Regulated transporter trafficking 
 
One third of the total cellular GAT-1 resides in a pool acutely recycling between the 
plasma membrane and cytoplasm.  In the basal state, 33% of this pool resides in the 
plasma membrane.  However, protein kinase and phosphatase activity serves to modulate 
the transporter cytoplasmic/plasma membrane distribution equilibrium through multiple 
and distinct pathways.  The motif in the proximal C-terminus responsible for constitutive 
internalization is also implicated in protein kinase C (PKC)-induced transporter 
endocytosis.  PKC-mediated endocytosis is absolutely dependent on the L(X)ERL 
portion of the L(X)ERLAY(X)IT region and is located immediately downstream from a 
conserved putative serine/threonine phosphoacceptor residue.  Stimulation of PKC 
promotes a relative decrease in surface transporter levels, attenuating transporter 
recycling and redistributing transporter to the endosomal compartments.  Stimulating 
tyrosine kinase activity has the opposite effect: When high neuronal activity elicits large 
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amounts of quantal GABA release, the cell may benefit from redistributing transporters 
from the intracellular pool to the plasma membrane in a rapid homeostatic response to 
maintain the local [GABA] close to equilibrium [GABA]o.  As substrate permeates the 
transporter, conformational changes present tyrosines at the cytoplasmic ends of TM2 or 
TM7 for modification.  The phosphorylated side-chains signal for reduced transporter 
internalization, resulting in substrate- induced transporter up-regulation.  Analogously, 
direct inhibition of tyrosine kinases results in rapid attenuation of uptake by GAT-1.  
NSS transporters therefore exist in mutually exclusive PKC or tyrosine kinase 
phosphorylated states, and the relative abundance of each of these states dictates the 
proportion of the recycling transporter pool that is present at the plasma membrane.  
Nonetheless, direct transporter phosphorylation is often insufficient to drive 
redistribution.  PKC mediated regulation is still reported even after removal of all 
consensus phosphorylation sites in the transporter.  Protein phosphatases (PP) also 
regulate transporter function; in general, PP1 and PP2A inhibition down-regulates 
transporter activity.  Elevated [Ca
2+
]i is also reported to decrease GAT-mediated uptake 
via calmodulin- and calpain-sensitive pathways. 
The SNARE complex protein syntaxin 1A is present in the distinct vesicle population 
that delivers GAT-1 to the cell surface; its co-expression with GAT-1 results in increased 
transporter numbers on the plasma membrane.  A paradoxical feature of this interaction is 
that syntaxin 1A also serves as negative regulator of the transporter’s intrinsic properties.  
Syntaxin 1A binds to three negatively charged aspartates in the GAT-1 N-terminus 
(Figure 1), but a cluster of four arginines in GAT-1 IL4 competes with syntaxin 1A at 
this binding site.  Syntaxin 1A interaction with GAT-1 N-terminus releases IL4, which 
166 
 
 
 
inhibits GABA transport.  However, chronic exposure to substrate relieves this inhibition 
by causing dissociation of syntaxin 1A from the transporter, freeing the N-terminus to 
sequester IL4. The GAT-1/syntaxin 1A interaction probably forms only part of a 
multimeric protein complex that modulates transporter function.  PKC-mediated 
phosphorylation of syntaxin 1A binding partners (e.g., Munc 18) inhibits their interaction 
with the SNARE proteins and promotes the syntaxin 1A- mediated effects on GAT-1, 
while SNAP-25, another SNARE protein, both potentiates syntaxin 1A-mediated 
inhibition of substrate transport and promotes GAT-1 surface expression.  GAT-2 and 
GAT-3 are not modulated by syntaxin 1A, and FRET indicates that no direct interaction 
occurs between syntaxin 1A and these transporters, presumably because their N-termini 
lack the necessary triplet of aspartate residues present in the N-terminus of GAT-1 and 
other NSS family members (Figure 1). 
Pharmacology --- Modulation of the GABA Transporter by Antiepileptics 
 
GATs are an attractive target in anticonvulsive therapy, because their inhibition leads 
to activity-dependent prolongation of GABA signals in otherwise hypo-GABAergic 
synapses.  Although many GABA transporter inhibitors possess antiepileptic properties 
in animal models, tiagabine is the only FDA-approved second-generation antiepileptic 
drug that selectively inhibits a GABA transporter, GAT-1.  Tiagabine-mediated GAT-1 
inhibition enhances GABAergic inhibition by prolonging phasic GABA currents.  The 
drug also blocks reverse transport, so it potentially has pro-convulsive properties.  
Cognitive side-effects of tiagabine are minimal in comparison to first-generation 
antiepileptics such as valproate, which cause general psychomotor slowing.  Nonetheless, 
the major side-effect of tiagabine is tremor, which can be accompanied by ataxia, 
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dizziness, asthenia, sedation, and nonspecific nervousness.  Genetic knock-out of GAT-1 
produces mice with increased GABAA-receptor-mediated tonic conductance in both 
cerebellar granule and Purkinje cells, and a slower decay of spontaneous inhibitory 
postsynaptic currents in cerebellar granule cells.  This points to increased extracellular 
[GABA]o due to the lack of GAT-1-mediated clearance.  Importantly, these  mice also 
partially phenocopy several of the clinical side effects of tiagabine, particularly tremor, 
indicating the side-effects are inherent to a clinical strategy that specifically targets 
GAT-1 rather than to non-selective actions on other targets.   
Gabapentin and vigabatrin, other antiepileptics in clinical use, do not act directly on 
GATs, but still influence their function.  They indirectly enhance reverse GABA 
transport during high-frequency stimulation, which could be neuroprotective during 
seizure. 
Although primarily localized on astrocytes and in extrasynaptic regions, BGT-1 is 
emerging as an attractive antiepileptic target.  EF1502 is an equipotent, non-competitive 
GAT-1/BGT-1 inhibitor.  It has a broad-spectrum anticonvulsant profile in animal models 
of generalized and partial epilepsy, exhibits a superior tolerability profile in comparison 
to tiagabine, and displays a synergistic rather than additive anticonvulsant interaction 
when co-administered with tiagabine.  The efficacy of EF1502 is likely explained by its 
inhibition of extrasynaptic BGT-1, increasing GABA-induced tonic conductance.  
Similarly, co-administration of NO711 (a selective GAT-1 inhibitor) and SNAP-5114 (a 
GAT-2/-3 inhibitor) in rat neocortex increased GABAergic tone, but application of either 
drug alone was insufficient to effect tonic currents.  Administration of non-GAT-1 
transporter inhibitors alone show enhanced efficacy in the generalized epilepsy models, 
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but reduced efficacy on partial seizures when compared to tiagabine.  To date there is no 
known compound that specifically targets BGT-1, GAT-2, or GAT-3.  The development 
of anticonvulsants that specifically target each GAT isoform is therefore of great 
importance.  Administration of these compounds alone or in combination could form the 
basis of new treatment paradigms for controlling CNS GABAergic disorders in a regional 
or cell-type specific manner.  The recent advances in our understanding of how the NSS 
transporters’ molecular structure relates to their function might allow the design of new 
compounds that specifically modulate either forward or reverse substrate transport 
modes, leading to exceptionally refined treatment of complex neurological disorders. 
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Figure Legends 
Figure 1:  Alignment, secondary structure, and regulatory elements in GABA 
transporters 
A sequence alignment of the four known GABA transporter isoforms with the LeuTAa 
bacterial leucine transporter to highlight regions of sequence similarity (presumably 
leading to structural similarity).  Identical residues are highlighted in orange.  
Transmembrane helices are labeled above the sequences; helices in green (TM 1--5) have 
pseudo-two-fold symmetry with helices in blue (TM 6--10).  TM11 and TM12 which are 
not part of this symmetry are colored purple and magenta, respectively.  Helical regions 
in intracellular loops (IL) and extracellular loops (EL) are identified by boxed slashes 
above the sequences.  The red and blue triangles below the sequences highlight residues 
involved in coordinating ions Na1 and Na2, respectively, and those residues whose side-
chains interact with the Na
+
 ions are shown as green letters.  Residues that coordinate the 
Cl
-
 ion are marked by green triangles below the alignment.  The filled black circles 
specify the residues involved in binding the leucine substrate in LeuTAa, and residues 
whose side chains interact with the leucine are shaded yellow.  The red and black 
diamonds indicate the charged pairs at the extracellular and cytoplasmic entrances, 
respectively.  The residues that form the LeuTAa dimer interface in TM9 and TM12 are 
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shown as underlined brown letters.  N-terminal residues involved in syntaxin 1A binding 
are shown as bold red letters, while IL4 arginines, their interaction partners in the absence 
of syntaxin 1A, are shown as bold blue letters.  The C-terminal sequence implicated in 
constitutive and PKC-regulated endocytosis is boxed.  The R/K-I/L COPII interacting 
residues are highlighted in red.  Distal C-terminal sequences that mediate somatodendritic 
(basolateral) sorting are highlighted in dark blue.  PDZ-interacting motifs are colored 
cyan. 
Figure 2: Topology, folded structure, and substrate binding site in the LeuTAa 
bacterial homologue of the mammalian GABA transporters 
Panel A shows the membrane topology of the SLC6 transporters as exemplified by 
LeuTAa.  Leucine substrate is shown coordinated in the center of the unwound regions of 
TM1 and TM6; the two Na
+
 ions are shown as purple circles.  IL = intracellular loop; EL 
= extracellular loop.  Green arrows highlight region of β-sheet structure; the α-helical TM 
domains are labeled 1--12 and colored according to their pseudo-two-fold symmetrical 
arrangement in the membrane, which is displayed in panel (B). The black ellipse in panel 
B marks the rotation axis for this symmetry.  Panel C depicts the hydrogen bonds and 
ionic interactions that coordinate the substrate (leucine) and the Na
+
 ion in the transporter 
binding site which makes direct contact with the leucine.  Ion spheres are 25% actual size 
in order to display all the interactions.  Image was generated from the 2A65 PDB LeuTAa 
crystal structure using PyMOL v0.99 (DeLano Scientfic, San Francisco, CA). 
Figure 3: Residues that coordinate the binding of the co-transported Na
+
 and Cl
-
 
ions in NSS transporters 
 
A) Na1 in LeuTAa coordinated by residues from TM1a, TM1b, TM6a, and TM7, together 
with the bound leucine, are shown. The location of Na2 is shown in the background.  B) 
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TM1a and TM8 residues from LeuTAa that coordinate Na2 are shown, with the location 
of Na1 and leucine in the background.  C)  Residues from TM2, TM6a and TM7 that 
coordinate Cl
-
 in the GAT-1 transporter.  Residue numbering is for GAT-1 in this panel.   
Underlined residues are almost completely conserved in all NSS transporters.  In all 
panels ion spheres are 25% actual size in order to display all the interactions.  We include 
the interaction between Gln291 and the Cl
-
 ion reported by Zomot et al., which is not 
present in the homology models of Forrest et al. (see Further Reading).  Panels A and B 
were generated using PyMOL v0.99 from the 2A65 PDB LeuTAa crystal structure.  Panel 
C was generated using PyMOL v0.99 from a homology model of GAT-1 based on 
LeuTAa. kindly provided to the authors for the purpose of this review by Dr. L.R. Forrest 
and Dr. B. Honig (Howard Hughes Medical Institute, Center for Computational Biology 
and Bioinformatics, and Department of Biochemistry and Molecular Biophysics, 
Columbia University, NY). 
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Table 1 Cross-species nomenclature of cloned GABA transporters with official gene 
symbols 
 
Species Nomenclature 
Human/Rat GAT-1 BGT-1 GAT-2 GAT-3 
Mouse GAT1 GAT2 GAT3 GAT4 
Gene name SLC6A1 SLC6A12 SLC6A13 SLC6A11 
 
Suggested Cross-References 
 
George Richerson 
 GABA transporters: Regulation of tonic inhibition 
 
Arne Schousboe 
 Glial modulation of excitability via glutamate and GABA transporters 
174 
 
 
 
 
  
175 
 
 
 
 
  
176 
 
 
 
 
 
 
  
177 
 
 
 
Appendix II: Biophysical properties of neuronal nicotinic 
acetylcholine receptors 
 
This appendix describes the trafficking, assembly, and stoichiometry of fluorescently 
labeled α6 and β3 subunits of the neuronal nicotinic acetylcholine receptor.  I performed 
the TIRF studies along with the rhodamine phalloidin fluorescence characterization. 
 
 
Subcellular Trafficking, Pentameric Assembly, and Subunit
Stoichiometry of Neuronal Nicotinic Acetylcholine Receptors
Containing Fluorescently Labeled 6 and 3 Subunits□S
Ryan M. Drenan, Raad Nashmi, Princess Imoukhuede, Herwig Just, Sheri McKinney, and
Henry A. Lester
Division of Biology, California Institute of Technology, Pasadena, California
Received July 2, 2007; accepted October 11, 2007
ABSTRACT
Neuronal nicotinic acetylcholine (ACh) receptors are ligand-
gated, cation-selective ion channels. Nicotinic receptors con-
taining 4, 6, 2, and 3 subunits are expressed in midbrain
dopaminergic neurons, and they are implicated in the response
to smoked nicotine. Here, we have studied the cell biological
and biophysical properties of receptors containing 6 and 3
subunits by using fluorescent proteins fused within the M3-M4
intracellular loop. Receptors containing fluorescently tagged 3
subunits were fully functional compared with receptors with
untagged 3 subunits. We find that 3- and 6-containing
receptors are highly expressed in neurons and that they colo-
calize with coexpressed, fluorescent 4 and 2 subunits in
neuronal soma and dendrites. Fo¨rster resonance energy trans-
fer (FRET) reveals efficient, specific assembly of 3 and 6 into
nicotinic receptor pentamers of various subunit compositions.
Using FRET, we demonstrate directly that only a single 3
subunit is incorporated into nicotinic acetylcholine receptors
(nAChRs) containing this subunit, whereas multiple subunit
stoichiometries exist for 4- and 6-containing receptors. Fi-
nally, we demonstrate that nicotinic ACh receptors are localized
in distinct microdomains at or near the plasma membrane using
total internal reflection fluorescence (TIRF) microscopy. We
suggest that neurons contain large, intracellular pools of as-
sembled, functional nicotinic receptors, which may provide
them with the ability to rapidly up-regulate nicotinic responses
to endogenous ligands such as ACh, or to exogenous agents
such as nicotine. Furthermore, this report is the first to directly
measure nAChR subunit stoichiometry using FRET and plasma
membrane localization of 6- and 3-containing receptors us-
ing TIRF.
6 nicotinic ACh receptor subunits are expressed in sev-
eral catecholaminergic nuclei in the central nervous system,
including retinal ganglion cells (Gotti et al., 2005b), locus
coeruleus (Le´na et al., 1999), and dopaminergic neurons lo-
cated in the substantia nigra and ventral tegmental area
(Whiteaker et al., 2000; Zoli et al., 2002; Champtiaux et al.,
2003). Ligand-binding studies using the 6-specific probe
-conotoxin MII suggest that many 6* (* indicates that
other subunits may be present in the receptor) receptors are
located on presynaptic terminals in the superior colliculus
and striatum (Whiteaker et al., 2000). Indeed, this binding
activity disappears in the brains of 6 knockout mice
(Champtiaux et al., 2002). This strikingly specific expression
pattern could indicate a unique function for 6* receptors,
and 6* receptors are candidate drug targets for diseases or
disorders such as Parkinson’s disease or nicotine addiction
(Quik and McIntosh, 2006).
Functional, voltage-clamped 6-dependent responses are
elusive in heterologous expression systems such as Xenopus
laevis oocytes (Kuryatov et al., 2000; Broadbent et al., 2006),
but native 6* receptors are readily studied using synapto-
some preparations from brain tissue (Whiteaker et al., 2000;
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Grady et al., 2002; Champtiaux et al., 2003; Gotti et al.,
2005a). Indeed, -conotoxin MII-sensitive receptors are phar-
macologically and stoichiometrically distinct from -cono-
toxin MII-resistant receptors in mediating [3H]dopamine re-
lease from striatal synaptosomes (Grady et al., 2002;
Salminen et al., 2007). Recent studies using 4 and 3 knock-
out mice demonstrate the existence of functional 62,
623, 642, and 6423 receptors (Salminen et al.,
2007). It is noteworthy that native 6423 receptors have
the highest affinity (EC50  0.23  0.08 M) for nicotine of
any nicotinic receptor reported to date. Because nicotine is
likely to be present at concentrations 0.5 M in the cere-
brospinal fluid of smokers (Rowell, 2002), only those recep-
tors with the highest affinity for nicotine, including some 4*
and 6* receptors, are likely to be important in nicotine
addiction. Although previous studies offer major conceptual
advances in our understanding of 6* receptors in the brain,
there is a lack of information regarding the subcellular local-
ization and biophysical properties of 6 subunits.
3 subunits are expressed in most of the same locations as
6, including midbrain dopaminergic neurons projecting to
the striatum (Zoli et al., 2002). 3 knockout mice demon-
strate that 3 subunits are important for the biogenesis of
6* receptors in the brain (Cui et al., 2003; Gotti et al.,
2005a). This is corroborated by studies in X. laevis oocytes
and tissue culture cells (Kuryatov et al., 2000). 3 also in-
creases 6-specific binding activity in HEK293 cells (Tumko-
sit et al., 2006). Uncertainty exists, however, because others
have reported that 3 incorporation into nAChRs acts as a
dominant negative (Boorman et al., 2003; Broadbent et al.,
2006), suppressing ACh-evoked responses by an incompletely
understood gating mechanism. This effect occurred appar-
ently without significantly altering the surface expression of
nAChRs. What is clear is that 3 acts more like a muscle 
subunit than a “typical” neuronal  subunit; it does not
participate in forming the :non- interface that comprises
the neuronal ligand binding site, and other  subunits, either
2 or 4, must be present to form functional nicotinic recep-
tors (Broadbent et al., 2006). This presents a problem both for
basic and therapeutic-oriented research on 3* receptors,
because there are no pharmacological ligands that can visu-
ally or functionally isolate 3-specific actions in cell culture
systems or intact brain tissue. Given the precise localization
and unique functional properties of 3* receptors, potential
for therapeutic intervention that would be afforded by 3-
specific probes, and involvement in nicotine addiction (Bierut
et al., 2007), it is important to develop and exploit tools to
study 3.
We have sought to compare characteristics of 6 and 3
with the better understood 4 and 2 subunits. We previ-
ously generated fluorescently labeled 4 and 2 subunits,
and we used these subunits to study assembly, trafficking,
and nicotine-dependent up-regulation of 42 receptors
(Nashmi et al., 2003). We have now fluorescently labeled 6
and 3 subunits by inserting a yellow fluorescent protein
(YFP) or cyan fluorescent protein (CFP) in the M3-M4 intra-
cellular loop. With this approach, one can optically monitor
functional nicotinic ACh receptors containing these subunits
in live cells and in real time. We measured 1) functional re-
sponses using two-electrode voltage-clamp and patch-clamp
electrophysiology, 2) subcellular distribution and colocalization
in neurons using confocal microscopy and spectral imaging, 3)
receptor assembly and subunit stoichiometry using Fo¨rster res-
onance energy transfer (FRET), and 4) plasma membrane lo-
calization and distribution patterns using total internal reflec-
tion fluorescence (TIRF) microscopy.
Materials and Methods
Reagents. Unless otherwise noted, all chemicals were from
Sigma-Aldrich (St. Louis, MO). DNA oligonucleotides for PCR and
site-directed mutagenesis were synthesized by Integrated DNA
Technologies, Inc. (Coralville, IA). Restriction enzymes for molecular
biology were purchased from Roche Diagnostics (Indianapolis, IN) or
New England Biolabs (Ipswich, MA). Glass-bottomed dishes (35 mm)
coated with L-polylysine were purchased from MatTek (Ashland,
MA).
Cell Culture and Transfection. N2a cells (American Type Cul-
ture Collection, Manassas, VA) were maintained in Dulbecco’s mod-
ified Eagle’s medium (high glucose with 4 mM L-glutamine; Invitro-
gen, Carlsbad, CA)/Opti-MEM (Invitrogen) mixed at a ratio of 1:1
and supplemented with 10% fetal bovine serum (Invitrogen), peni-
cillin (Mediatech, Herndon, VA), and streptomycin (Invitrogen). N2a
cells were transfected in DMEMwithout serum or antibiotics. Trans-
fection was carried out using Lipofectamine/PLUS (Invitrogen) ac-
cording to the manufacturer’s instructions and with the following
modifications. For a 35-mm dish, 1 to 2 g of total plasmid DNA was
mixed with 100 l of DMEM and 6 l of PLUS reagent. DMEM/DNA
was combined with a mixture of 100 l of DMEM and 4 l of
Lipofectamine reagent. Rat hippocampal neurons were dissociated
and plated on glass-bottomed imaging dishes as described previously
(Slimko et al., 2002). For primary neuron transfection, Lipo-
fectamine 2000 (Invitrogen) was used in conjunction with Nupherin
(BIOMOL Research Laboratories, Plymouth Meeting, PA) as de-
scribed below. In brief, in total 1 g of DNA was incubated with 20
g of Nupherin in 400 l of Neurobasal medium without phenol red
(Invitrogen), whereas 10 l of Lipofectamine 2000 was mixed in 400
l of Neurobasal medium (Invitrogen). After 15 min, the two solu-
tions were combined and incubated for 45 min. Neuronal cultures in
35-mm glass-bottomed culture dishes were incubated in the result-
ing 800-l mixture for 120 min, followed by removal of transfection
media and refeeding of the original, pretransfection culture media.
Plasmids and Molecular Biology. Mouse 4 and 2 nAChR
cDNAs in pCI-neo, both untagged and modified with YFP or CFP
fluorescent tags, have been described previously (Nashmi et al.,
2003). Mouse 3 and 3 nAChR cDNAs in pCDNA3.1 were a gener-
ous gift of Jerry Stitzel (Institute for Behavioral Genetics, University
of Colorado, Boulder, CO). A full-length mouse 6 I.M.A.G.E. cDNA
(ID no. 4501558) was obtained from Open Biosystems (Huntsville,
AL). A modified 6 cDNA was constructed that 1) lacked the 5 and
3 untranslated regions and 2) contained a Kozak sequence (GCC
ACC) before the ATG start codon to facilitate efficient translation
initiation. Rat 4 cloned into pAMV was provided by Cesar Labarca
(California Institute of Technology, Pasadena, CA). pEYFP-N1 and
pECFP-N1 (Clontech, Mountain View, CA) were used to construct
fluorescent nAChR cDNAs. mGAT1 labeled with CFP was provided
by Fraser Moss (California Institute of Technology). YFP-Syntaxin
was provided by Wolfhard Almers (Vollum Institute, Oregon Health
and Science University, Portland, OR). CFP-tau was provided by
George Bloom (University of Virginia, Charlottesville, VA). A Quik-
Change (Stratagene, La Jolla, CA) kit was used to construct 3 (WT
or XFP-modified) cDNAs containing a V13’S point mutation.
To design fluorescently labeled 6 and 3 subunits, we chose to
insert the XFP moiety in the M3-M4 loop each subunit. We have
previously found that this region is appropriate for insertion in
nAChR 4 and 2 subunits (Nashmi et al., 2003), the nAChR 
subunit (data not shown), and GluCl  and  subunits (Slimko et al.,
2002). Similar to our previous studies, we inserted the XFP moiety in
the M3-M4 loop at positions that avoided the conserved amphipathic
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-helix and putative cell sorting motifs and phosphorylation sites
(Fig. 1, A and B). To construct nAChRs with XFP inserted into the
M3-M4 loop, a two-step PCR protocol was used. First, YFP or CFP
was amplified with PCR using oligonucleotides (sequences available
upon request) designed to engineer 5 and 3 overhangs of 15 base
pairs that were identical to the site where XFP was to be inserted, in
frame, into the nAChR M3-M4 loop. A Gly-Ala-Gly flexible linker
was engineered between the nAChR sequence and the sequence for
YFP/CFP at both the 5 and 3 ends. In the second PCR step, 100 ng
of the first PCR reaction was used as a primer pair in a modified
QuikChange reaction using Pfu Ultra II (Stratagene, Cedar Creek,
TX) polymerase and the appropriate nAChR cDNA as a template. All
DNA constructs were confirmed with sequencing and, in some cases,
restriction mapping.
cRNA for injection and expression in X. laevis oocytes was pre-
pared using a T7 or SP6 in vitro transcription kit (mMessage mMa-
chine; Ambion, Foster City, CA) according to the manufacturer’s
instructions. RNA yield was quantified with absorbance at 260 nm.
RNA quality was assessed by observing absorbance profiles across a
range of wavelengths between 220 and 320 nm. Spectrophotometric
analysis was performed using a ND-1000 spectrophotometer (Nano-
Drop, Wilmington, DE).
Confocal Microscopy. N2a cells were plated on 35-mm glass-
bottomed dishes, transfected with nAChR cDNAs, and they were
imaged live 24–48 h after transfection. X. laevis oocytes were imaged
3 days after RNA injection. Oocytes were placed in an imaging
chamber and allowed to settle for 20 min before imaging. To elimi-
nate autofluorescence, growth medium was replaced with an extra-
cellular solution containing the following components: 150 mMNaCl,
4 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, and 10 mM
D-glucose, pH 7.4. Cells were imaged with a Nikon (Nikon Instru-
ments, Melville, NY) C1 laser-scanning confocal microscope system
equipped with spectral imaging capabilities and a Prior (Rockland,
ME) remote-focus device. For oocytes, a Nikon Plan Apo 20  0.75
numerical aperture (NA) air objective was used, whereas a Nikon
Plan Apo 60  1.40 NA oil objective was used for mammalian tissue
culture cells. Pinhole diameter was 30–60 m, and cells were imaged
at 12-bit intensity resolution over 512  512 pixels at a pixel dwell
time of 4 to 6 s. CFP was excited using a 439.5-nm modulated diode
laser, and YFP was excited with an argon laser at 514.5-nm. In most
cases, imaging was carried out using the Nikon C1si DEES grating
and spectral detector with 32 parallel photomultiplier tubes. This
allowed us to collect spectral images ( stacks). In such images, each
pixel of the X-Y image contains a list of emission intensity values
across a range of wavelengths. We collected light between 450 and
600 nm at a bandwidth of 5 nm. The 515-nm channel was intention-
ally blocked while we used the 514.5-nm laser for YFP bleaching.
Because the emission profile of YFP and CFP significantly overlap,
we used the Nikon EZC1 linear unmixing algorithm to reconstruct
YFP and CFP images. Experimental spectral images with both YFP-
and CFP-labeled nAChR subunits were unmixed using reference
spectra from images with only YFP- or CFP-labeled nAChR sub-
units. For each pixel of a spectral image, intensity of YFP and CFP
was determined from fluorescence intensity values at the peak emis-
sion wavelength derived from the reference spectra.
Spectral FRET Analysis. To examine FRET between various
nAChR subunits, the acceptor photobleaching method (Nashmi et
al., 2003) was used with a modified fluorescence recovery after pho-
tobleaching macro built into the Nikon EZC1 imaging software. In
this method, FRET was detected by recording CFP dequenching
during incremental photodestruction of YFP. A spectral image was
acquired once before YFP bleaching and at six time points every 10 s
during YFP bleaching at 514.5 nm. Laser power during bleaching
varied from cell to cell, but was between 25 and 50%. One bleach scan
per cycle was used. This bleaching protocol was optimized to achieve
70 to 80% photodestruction of YFP while still enabling us to record
incremental increases in CFP emission at each time point. In the
confocal microscope, nAChRs labeled with XFP usually exhibit a
uniform, intracellular distribution, regardless of the subunit being
examined. This is consistent with our previous observations (Nashmi
et al., 2003). To measure FRET, spectral images were unmixed into
their CFP and YFP components as described above. We found little
or no difference in FRET for various cellular structures or organelles
in N2a cells, and we measured CFP and YFP mean intensity
throughout the entire cell by selecting the cell perimeter as the
boundary of a region of interest in Nikon’s EZC1 software. CFP and
Fig. 1. 6 and 3 nicotinic ACh receptor con-
structs used in this study. A, XFP insertion
points in the 6 M3-M4 intracellular loop.
The M3-M4 loop primary sequence of the
mouse 6 nAChR subunit was analyzed for
sequences predicted to be involved in forming
-helices (light gray boxes), phosphorylation
sites (white boxes), or intracellular traffick-
ing motifs (dark gray boxes); these were spe-
cifically avoided. Arrows adjacent to XFP in-
dicate insertion points. The inserted XFP
(YFP or CFP) protein was modified 1) to have
a flexible Gly-Ala-Gly linker flanking the
XFP coding sequence and 2) to lack its STOP
codon. B, XFP insertion points in 3 M3-M4
intracellular loop. Mouse 3-XFP fusion pro-
teins were designed similarly to 6, as indi-
cated in A. C, 6 and 3 nAChR constructs
used in this study. In addition to WT, three
6-XFP and two 3-XFP fusions were con-
structed. A V13’S mutation on the WT and
XFP background was introduced into 3 for
characterization in X. laevis oocytes.
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YFP components were saved in Excel format, and fluorescence in-
tensities were normalized to the prebleach time point (100%). FRET
efficiency (E) was calculated as E  1  (IDA/ID), where IDA repre-
sents the normalized fluorescence intensity of CFP (100%) in the
presence of both donor (CFP) and acceptor (YFP), and ID represents
the normalized fluorescence intensity of CFP in the presence of donor
only (complete photodestruction of YFP). The ID value was extrapo-
lated from a scatter plot of the fractional increase of CFP versus the
fractional decrease of YFP. The E values were averaged from several
cells per condition (see Table 1 for n values). Data are reported as
mean  S.E.M.
TIRFMicroscopy.N2a cells cultured in glass-bottomed, polyeth-
ylenimine-coated imaging dishes were transfected with cDNA mix-
tures as described above. Cells, superfused with the same imaging
solution used for confocal microscopy, were imaged 18 to 24 h after
transfection to minimize overexpression artifacts. TIRF images were
obtained with an inverted microscope (Olympus IX71; Olympus
America, Inc., Center Valley, PA) equipped with a 488-nm air-cooled
argon laser (P/N IMA101040ALS; Melles Griot, Carlsbad, CA). Laser
output was controlled with a UNIBLITZ shutter system and drive
unit (P/N VMM-D1; Vincent Associates, Rochester, NY) equipped
with a Mitutoyo (Mitutoyo America, City of Industry, CA) microme-
ter to control TIRF evanescent field illumination. TIRF imaging was
carried out with an Olympus PlanApo 100  1.45 NA oil objective,
and images were captured with a 16-bit resolution Photometrics
Cascade charge-coupled device camera (Photometrics, Tucson, AZ)
controlled by SlideBook 4.0 imaging software (Intelligent Imaging
Innovations, Santa Monica, CA).
Two-Electrode Voltage-Clamp Electrophysiology. Stage V to
VI X. laevis oocytes were isolated as described previously (Quick and
Lester, 1994). Stock RNAs were diluted into diethyl pyrocarbonate-
treated water and injected 1 day after isolation. RNA was injected in
a final volume of 50 nl per oocyte using a digital microdispenser
(Drummond Scientific, Broomall, PA). After injection, oocytes were
incubated in ND-96 solution (96 mM NaCl, 2 mM KCl, 1 mM CaCl2,
1 mM MgCl2, and 5 mM HEPES/NaOH, pH 7.6) supplemented with
50 g/ml gentamicin and 2.5 mM sodium pyruvate. After 1 to 4 days
for nAChR expression, oocytes were used for recording or confocal
microscopy.
Agonist-activated nicotinic receptor responses were measured by
two-electrode voltage-clamp recording using a GeneClamp 500 (Mo-
lecular Devices, Sunnyvale, CA) voltage clamp. Electrodes were con-
structed from Kwik-Fil borosilicate glass capillary tubes (1B150F-4;
WPI, Sarasota, FL) using a programmable microelectrode puller
(P-87; Sutter Instrument Company, Novato, CA). The electrodes had
tip resistances of 0.8 to 2.0 M after filling with 3 M KCl. During
recording, oocytes were superfused with Ca2-free ND-96 via bath-
application and laminar-flow microperfusion using a computer-con-
trolled application and washout system (SF-77B; Warner Instru-
ments, Hamden, CT) (Drenan et al., 2005). The holding potential was
50 mV, and ACh was diluted in Ca2-free ND-96 and applied to the
oocyte for 2 to 10 s followed by rapid washout. Data were sampled at
200 Hz and low-pass filtered at 10 Hz using the GeneClamp 500
internal low-pass filter. Membrane currents from voltage-clamped
oocytes were digitized (Digidata 1200 acquisition system; Molecular
Devices) and stored on a PC running pCLAMP 9.2 software (Molec-
ular Devices). Concentration-response curves were constructed by
recording nicotinic responses to a range of agonist concentrations
(six to nine doses) and for a minimum of six oocytes. EC50 and Hill
coefficient values were obtained by fitting the concentration-re-
sponse data to the Hill equation. All data are reported as mean 
S.E.M.
Whole-Cell Patch-Clamp Electrophysiology. N2a cells ex-
pressing YFP-labeled nicotinic receptors were visualized with an
inverted microscope (Olympus IMT-2, DPlan 10  0.25 NA and
MPlan 60  0.70 NA) under fluorescence illumination (mercury
lamp). Patch electrodes (3–6 M) were filled with pipette solutions
containing 88 mM KH2PO4, 4.5 mM MgCl2, 0.9 mM EGTA, 9 mM
HEPES, 0.4 mM CaCl2, 14 mM creatine phosphate (Tris salt), 4 mM
Mg-ATP, and 0.3 mM GTP (Tris salt), pH 7.4 with KOH. The extra-
cellular solution was 150 mM NaCl, 4 mM KCl, 2 mM CaCl2, 2 mM
MgCl2, 10 mM HEPES, and 10 mM D-glucose, pH 7.4. Standard
whole-cell recordings were made using an Axopatch 1-D amplifier
(Molecular Devices), low-pass filtered at 2 to 5 kHz, and digitized
online at 20 kHz (pClamp 9.2; Molecular Devices). Series resistance
was compensated 80%, and the membrane potential was held at 70
mV. Recorded potentials were corrected for junction potential.
ACh was delivered using a two-barrel glass -shaped tube (outer
diameter 200 m; pulled from 1.5-mm-diameter -shaped borosili-
cate tubing) connected to a piezoelectric translator (LSS-3100, Bur-
leigh Instruments, Fishers, NY) as described previously (Nashmi et
al., 2003). ACh was applied for 500 ms (triggered by pCLAMP 9.2),
and solution exchange rates measured from open tip junction poten-
tial changes during application with 10% extracellular solution were
typically 300 s (10–90% peak time). Data are reported as mean 
S.E.M. for the peak current response to 1 M ACh, and statistical
significance was determined using a Wilcoxon signed rank test.
Results
Design and Construction of 6 and 3 XFP Fusions.
Based on previous work (Slimko et al., 2002; Nashmi et al.,
2003), we chose to insert XFP fusions in the M3-M4 loop of
mouse 6 and 3 nAChR subunits. Like all members of the
Cys-loop family, 6 and 3 have predicted -helices at the N-
and C-terminal ends of their M3-M4 loop (Fig. 1, A and B)
that may be important in ion permeation (Miyazawa et al.,
1999). In addition to avoiding these regions, we also avoided
potential phosphorylation sites and trafficking motifs (Fig. 1,
A and B). Our XFP fusion cassette also consisted of a Gly-
Ala-Gly flexible linker flanking the XFP open reading frame
on both the N- and C-terminal side. We built three indepen-
dent XFP fusions for 6 and two XFP fusions for 3 (Fig. 1C).
These were designated according to the residue immediately
N-terminal to the beginning of the Gly-Ala-Gly linker (e.g.,
TABLE 1
FRET efficiency calculations for nicotinic ACh receptors with various
subunit compositions
Unless noted otherwise, all experiments with 6 and 3 subunits were performed
with 6A405 and 3P379. Data are reported as mean FRET E  S.E.M. n refers to the
number of independently analyzed cells.
Subunit Composition FRET E n
%
4C/2Y 29  2 10
4/2C/3Y 22  2 9
4C/2/3Y 20  2 8
3Y/GAT1C 3  3 9
4/2C/3YG367 22  1 7
6Y/2C 36  2 12
6Y/GAT1C 1  4 9
6YG387/2C 38  2 7
6YG366/2C 29  2 11
6Y/2C/3 32  2 13
6Y/2/3C 25  3 8
6/2Y/3C 36  2 14
4Y/4C/2 22  2 10
4/2Y/2C 16  2 9
6Y/6C/2 28  2 22
4/2/3Y/3C 3  1 10
4Y/4C/2/3 14  1 10
6Y/6C/2/3 21  1 10
6Y/4C/2 22  1 21
6Y/4C/2/3 21  2 11
3Y/GluCl C 6  4 5
6Y/GluCl C 14  2 5
Y refers to YFP, and C refers to CFP.
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6-YFPG366 denotes that the GAG-YFP-GAG cassette was
inserted between G366 and V367). Unless otherwise noted,
all experiments were conducted with 6-XFP	405 and
3-XFPP379.
Functional Expression of 6 and 3 Subunits.Despite
exhaustive attempts to functionally reconstitute 6* nAChRs
in X. laevis oocytes and mammalian tissue culture cells, we
recorded no robust, reproducible responses from cells ex-
pressing 6, either with untagged subunits or the fluorescent
subunits (Supplemental Data; Table 1). 3-YFP, however,
was well expressed on the plasma membrane of X. laevis
oocytes when coexpressed with 3 and 4 subunits to support
functional expression (Fig. 2A). As a control for oocyte
autofluorescence, we imaged oocytes expressing untagged 3
subunits (Fig. 2A). No fluorescence was detected in this case,
indicating that our 3-YFP signal was specific.
3 subunits do not drastically alter the EC50 for ACh or
nicotine when incorporated into nAChRs (Boorman et al.,
2003), but they do profoundly alter single-channel kinetics
(Boorman et al., 2003). Channel burst duration was signifi-
cantly shortened for nAChRs containing 3 versus those
without it (Boorman et al., 2003), suggesting that 3 reduces
the probability of channel opening, Popen. Consistent with
this, macroscopic voltage-clamped responses from oocytes
and mammalian cells expressing 3* receptors were signifi-
cantly smaller than for non-3* receptors (Broadbent et al.,
2006). To assess the functionality of our 3-YFP construct,
we compared the ability of untagged and YFP-labeled 3
subunits to attenuate nicotinic responses. 3 must be coex-
pressed with other  and  subunits, so we chose to use 34
receptors for this purpose. We did so because 3 has been
well characterized with this receptor combination (Boorman
et al., 2003; Broadbent et al., 2006). When WT, untagged 3
was coexpressed with 34 receptors, we found a significant
attenuation of the peak response to 200 M ACh (Fig. 2B),
consistent with previous findings (Broadbent et al., 2006).
When 3-YFP was tested in this assay, it was also able to
attenuate the maximal response in a manner identical to
untagged 3 (Fig. 2B). It is possible that, although 3-WT
attenuates responses via a gating mechanism on the plasma
membrane, YFP-labeled 3 might do so via a different mech-
anism such as sequestering 3 or 4 subunits inside the cell.
To further test the functionality of YFP-labeled 3, we took
advantage of the fact that a gain-of-function TM2 mutation
in 3 is able to reverse the attenuation of peak responses
seen for 3-WT (Broadbent et al., 2006). We reasoned that if
the YFP label in the M3-M4 loop is not disturbing the func-
tion of 3, we should detect the same gain-of-function re-
sponse for unlabeled and YFP-labeled 3 when they are
engineered to express a mutation of this sort. When a Val13
to Ser mutation (V13S) was introduced into unlabeled 3, we
observed not only a reversal of this attenuation behavior, but
a significant increase in the peak response to 200 M ACh
with 34 receptors (Fig. 2C). When 3-YFPV13S was tested
in this assay, we observed an identical behavior. Taken to-
gether, these data suggest that 3-YFP is fully functional
and incorporates into nAChRs in X. laevis oocytes.
To further characterize our 3-YFP construct, we con-
structed concentration-response curves for 34 receptors
containing either 3WT or 3-YFP. Consistent with previous
reports (Boorman et al., 2000), we measured an EC50 for ACh
of 230 22 M for 343 receptors, which is slightly higher
than for 34 (165  9 M) (Fig. 3A). When 3-YFP was
substituted for WT 3, the EC50 was shifted slightly, but
acceptably, to 109  8 M (Fig. 3A). We also noticed that the
addition of 3 to 34 receptors increased the Hill coefficient
from 1.5  0.1 to 2.0  0.3, and this effect was retained when
3-YFP was coexpressed with 34 receptors. Likewise, we
also constructed concentration-response relationship curves
for oocytes expressing 3V13S and 3-YFPV13S. Compared
with the EC50 for 343 (230  22 M), we measured an
EC50 for 343
V13S of 28  3 M (Fig. 3B). This is consis-
tent with others who have reported an approximate 6-fold
reduction in EC50 for the inclusion of 3 with a similar
hypersensitive mutation, Val9’Ser (Boorman et al., 2000). We
reasoned that if 3-YFP retained the WT function of 3, then
there should be a similar gain-of-function phenotype when it
is coexpressed with 34. We measured an EC50 for 343-
YFPV13S of 34  3 M (Fig. 3B), confirming that this con-
struct behaves identically to 3-WT. Collectively, our work in
X. laevis oocytes with YFP-labeled 3 subunits suggests that
insertion of YFP into the M3-M4 loop does not significantly
alter the assembly, subcellular trafficking, or function of this
subunit.
Subcellular Localization and Trafficking of 6 and
3 Subunits. To probe the subcellular localization and traf-
ficking of 6* and 3* receptors, we chose a mouse neuro-
blastoma cell line, N2a, to transiently express our fluorescent
Fig. 2. Fluorescently labeled 3 subunits are functional and expressed on
the cell surface in X. laevis oocytes. A, X. laevis oocytes were injected with
cRNA encoding WT (control) or YFP-labeled 3 (15 ng) along with 3 (2
ng) and 4 (3 ng). The oocyte surface was imaged with direct fluorescence
confocal microscopy. True YFP signal was acquired by linear unmixing of
the background fluorescence spectra (untagged 3 with 34) and a YFP
reference spectrum. Scale bar, 54 m. B, fluorescently labeled 3 sub-
units are indistinguishable fromWT subunits in their ability to attenuate
nicotinic receptor responses. A representative voltage-clamped response
from X. laevis oocytes expressing 34, 343, or 343-YFP is shown.
Agonist (ACh; 200 M) was applied and removed as indicated by the bar.
C, reversal of 3-mediated suppression of nicotinic responses is identical
in untagged and YFP-labeled hypersensitive 3. Representative voltage-
clamped responses from oocytes expressing 34, 343V13S, or 343-
YFPV13S are shown. Agonist application is identical to B.
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nicotinic receptor subunits. We prefer these cells over, for
example, HEK293 cells, because they 1) are of mouse origin,
the same species as our fluorescent constructs; 2) are of
neuronal origin, suggesting that they will be a permissive
environment for correct expression, subcellular localization,
and assembly of our ectopic nAChR subunits; and 3) express
only moderate quantities of transfected membrane protein.
To study the subcellular localization of 3* receptors, we
coexpressed 3-YFP with the previously described fluores-
cently labeled 4 and 2 subunits (Nashmi et al., 2003). 3 is
able to assemble and function when coexpressed with 42
receptors (Broadbent et al., 2006). When coexpressed with
fluorescent 4 or 2 receptors, 3-YFP was localized primar-
ily in the endoplasmic reticulum of live N2a cells (Fig. 4A, i
and B, i). We used CFP-labeled 4 (Fig. 4B, ii) or 2 (Fig. 4,
A and C, ii) subunits along with a confocal microscope with
spectral imaging capabilities to unambiguously assign YFP
and CFP signals to each pixel for the spectral images of the
cells. In these experiments, YFP was assigned green, CFP
was assigned red, and yellow indicated pixels where 3-YFP
was colocalized with either 2-CFP (Fig. 4A, iii) or 4-CFP
(Fig. 4B, iii). We noted that 3-YFP was completely colocal-
ized with either 4 or 2 in this experiment, suggesting that
these subunits are assembled in the same pentameric recep-
tors. To further define the extent of this colocalization, we
plotted the 3-YFP and 4-CFP or 2-CFP pixel intensity
across a two-dimensional region of interest transecting the
cell (Fig. 4, A and B, iv). We noted that the YFP and CFP
intensity profiles strongly resembled each other, suggesting
that these subunits were indeed colocalized and coassembled
in intracellular compartments of the cell. With respect to
42* receptors, this localization pattern is not an artifact of
overexpression, because this is the same pattern we observed
previously (Nashmi et al., 2003). This is also the expression
pattern of endogenous, YFP-labeled 4* receptors in 4-YFP
knockin mice (Nashmi et al., 2007). This indicates that 1) a
large pool of intracellular receptors exists in neurons, and 2)
YFP tag does not interfere with the delivery of receptors to
the plasma membrane. Thus, the localization pattern we
observe here for 3 subunits is the expected result if it is
assembling with 42 receptors.
We expressed 6-YFP along with 2-CFP in N2a cells, and
we analyzed its localization pattern as described above for
3. We also found that 6 was localized in intracellular
compartments in the cell (Fig. 4C, i), and that it was com-
pletely colocalized with 2 subunits (Fig. 4C, ii–iv). Although
Fig. 3. 3 nAChR subunit function is not affected by XFP insertion in
M3-M4 loop. A, concentration-response relations for WT and fluores-
cently labeled 3-containing receptors are similar. X. laevis oocytes ex-
pressing the indicated receptor subunits were voltage-clamped during
agonist application and washout. Peak responses to the indicated ACh
concentration (molar) were normalized and the data were fitted to the
Hill equation. B, concentration-response relation for 3 subunits with a
hypersensitive mutation is not affected by the presence of YFP in the
M3-M4 loop. X. laevis oocytes were assayed and data were analyzed as
described in A. 34 data from A are shown for comparison. Error bars
are  S.E.M., and n  6 for each condition.
Fig. 4. 3-YFP and 6-YFP expression in neuronal cells. A, 3 and 2
nAChR subunits are localized similarly in N2a cells. N2a cells expressing
42-CFP3-YFP receptors were imaged live with spectral confocal mi-
croscopy. Spectral images were acquired and specific 3-YFP and 2-CFP
signals were extracted with linear unmixing. Green (3-YFP; i) and red
(2-CFP; ii) pseudocolor was assigned, and yellow (Merge; iii) indicates
colocalized proteins. Pixel intensities for the YFP and CFP channel were
plotted (iv) along a line (iii) transecting the imaged cell. B, 3 and 4
nAChR subunits are localized similarly in N2a cells. N2a cells expressing
4-CFP23-YFP receptors were imaged live as described in A. C, 6 and
2 nAChR subunits are localized similarly in N2a cells. N2a cells ex-
pressing 6-YFP2-CFP were imaged live as described in A and B. D,
4-YFP, 3-YFP, and 6-YFP are localized intracellularly and in pro-
cesses in differentiated neurons. N2a cells were differentiated for 2 days
(see Materials and Methods for details) to induce neurite outgrowth,
followed by transfection with the indicated nAChR cDNA combinations
plus soluble CFP to mark cellular morphology. One day after transfec-
tion, cells were imaged live as described in A to C. Scale bar, 10 m.
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this is the first fluorescence imaging reported for 6* recep-
tors, there is other evidence to corroborate our findings. Stud-
ies with [3H]epibatidine demonstrate that a significant por-
tion of 62 and 623 receptors are intracellular (50 and
20%, respectively), although some are delivered to the sur-
face (Kuryatov et al., 2000; Tumkosit et al., 2006).
To further investigate the subcellular localization and traf-
ficking of 6 and 3 subunits, we imaged live, differentiated
N2a cells and primary neurons. N2a cells can be induced to
differentiate and undergo neurite outgrowth if serum is with-
drawn and an activator of protein kinase A, dibutyryl-cAMP,
is added (Fowler et al., 2001). In our previous work, 42
receptors were localized to dendrites, but not axons, when
expressed in primary midbrain neurons (Nashmi et al.,
2003). We were interested in whether our fluorescent nico-
tinic receptor subunits were localized to N2a cell processes in
a manner analogous to dendrites in primary neurons. Fur-
thermore, we wanted to address the question of whether 3 is
localized with other subunits at distal sites such as den-
drites. This is an unsolved question, as there is no high-
affinity probe (pharmacological or immunological) that can
reliably and unambiguously isolate 3* receptors. N2a cells
were plated on glass-bottomed dishes, and they were then
differentiated for 2 days (see Materials and Methods) fol-
lowed by transfection with various combinations of YFP-
labeled and unlabeled nAChR subunits. Cells were also co-
transfected with an expression plasmid for soluble CFP to
mark total cell morphology. We found that 42 receptors
were indeed localized to neuronal processes in differentiated
N2a cells (Fig. 4D, arrow), along with abundant expression in
the cell soma. When 3-YFP was coexpressed with 42, we
observed a very similar pattern. We found that 3 was
present even at the most distant elements of neuronal pro-
cesses (Fig. 4D, arrow). Because this pattern is identical to
that of 42 in differentiated N2a cells, we conclude that 3
is likely assembling with 42 receptors and that the YFP
label in the M3-M4 loop is not disrupting the normal cellular
trafficking of 423 pentamers. To further characterize the
localization of 3* receptors, we coexpressed 3-YFP with
42 receptors in primary rat hippocampal neurons (Nashmi
et al., 2003). To minimize overexpression artifacts, cells were
imaged live only 18 to 24 h after transfection. We found that
3* receptors were localized very similarly to 42 receptors
in our previous studies with primary neurons; we noted uni-
form localization in the soma, suggestive of endoplasmic re-
ticulum, and dendritic localization (Fig. 5A, arrow) and an
absence of localization in axons. A high-magnification micro-
graph demonstrates the dendritic localization of these puta-
tive 423 receptors (Fig. 5A, right). In cells coexpressing
4/2/3Y with soluble CFP [to mark total cell morphology,
similar to Nashmi et al. (2003)], 3 subunits did not traffic to
a subregion of the cell interior likely to be axons (data not
shown). To more directly determine whether 3* receptors
could be localized to axons in these neurons, we coexpressed
423Y receptors with a CFP-labeled axonal marker, tau.
The tau-CFP decorated axons in hippocampal neurons, with
proximal (relative to the cell body) portions of the axon being
labeled more strongly than distal portions (Fig. 5B). In all
cells examined, we noted the presence of YFP-labeled 3
subunits in these proximal axons but not distal axons (Fig.
5B, arrow). These data in differentiated N2a cells and pri-
mary neurons suggest that 3 assembles efficiently with
42 receptors, and it is thus cotrafficked and targeted to
distal sites in neurons.
Because 6-YFP* receptors do not function in our hands,
we wanted to determine whether this is due to a subtle
trafficking defect that could prevent the correct delivery of
6-YFP to the plasma membrane. Although we could readily
detect 6 fluorescence in the cell body of undifferentiated
N2a cells, we wanted to further probe the cellular trafficking
of 6* receptors by expressing them in differentiated N2a
cells that contain processes. To evaluate the subcellular lo-
calization of 6* receptors, we expressed 6-YFP with 2 in
differentiated N2a cells. To our surprise, we found that 62
receptors were trafficked to neuronal processes in a manner
analogous to 42 and 423 receptors (Fig. 4D, arrow). To
further address this question, we expressed 6-YFP2 recep-
tors in rat hippocampal neurons as described for 423-
YFP. We observed a localization pattern for 6-YFP that was
very similar to 423-YFP. These receptors were well ex-
pressed in the cell soma, but they were readily detectable
in dendrites as well (Fig. 5A, arrow). In experiments with
coexpressed soluble CFP and 6-YFP2 receptors, 6 sub-
units were not detected in putative axons (data not shown).
In tau-CFP/6-YFP2 coexpression experiments, 6 sub-
units (similar to 42 but not 423 receptors) were not
detected in tau-labeled axons (Fig. 5B, arrow). These data
indicate that, although 6* receptors produce little or no
agonist-induced conductance in mammalian tissue culture
cells, they are expressed well and trafficked similarly com-
pared with 42 and 3* receptors.
FRET Revealed Assembly of 6 and 3 Subunits into
nAChR Pentamers. The fact that 4/2/3 and 6/2 sub-
units are colocalized in the cell body and cotargeted to pro-
cesses and dendrites in neurons suggests that they are as-
sembled into pentameric receptors. The question of receptor
assembly is often answered by simply measuring agonist-
induced conductance increases in cells expressing a subunit
combination of interest, or by applying a selective agonist or
inhibitor to a pure receptor population of known pharmaco-
logical properties. This approach is not applicable, however,
for 6* and 3* receptors. 6* receptors do not function well
in heterologous expression systems, so it is not straightfor-
ward to determine the extent to which free 6 subunits
Fig. 5. Localization of 3* and 6* receptors in primary neurons. A,
3-YFP and 6-YFP are localized in the cell soma and in dendrites in
primary hippocampal neurons. E18 rat hippocampal neurons were plated
and cultured for 14 days followed by transfection with the indicated
nAChR cDNAs. One day after transfection, cells were imaged live. Right,
higher magnification image of the boxed area in the left panel. B, 3* and
6* receptors are absent from axons. Neurons were transfected with the
indicated nAChR cDNAs along with CFP-tau, followed by live confocal
imaging as described in A. Scale bar, 10 m.
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assemble into pentameric receptors. Similarly for 3, al-
though it is functional in oocytes (Fig. 2), there are no phar-
macological probes that can be applied to 3* receptors to
study their assembly or subunit composition. Others have
indirectly measured receptor assembly of nicotinic subunits
by using biochemical techniques such as immunoprecipita-
tion (Zoli et al., 2002; Champtiaux et al., 2003) and centrif-
ugation (Kuryatov et al., 2000) or by forcing subunits to
assemble by using molecular concatamers (Tapia et al.,
2007). To directly determine whether two nicotinic receptor
subunits interact and, possibly, assemble to form pentameric
receptors, we have used FRET coupled with our CFP- and
YFP-tagged receptors. In the context of our nicotinic receptor
subunits labeled with YFP or CFP in the M3-M4 loop, only
subunits that interact will undergo FRET, because FRET
occurs only when donors and acceptors are within 100 Å.
Furthermore, we previously demonstrated that the efficiency
of FRET directly correlates with the number of functional,
plasma membrane-localized pentameric receptors (Nashmi
et al., 2003). To measure FRET between subunits, we used
the acceptor photobleaching method (Nashmi et al., 2003). In
this method, we measure CFP dequenching during incremen-
tal photodestruction of YFP. CFP was excited at 439 nm,
whereas YFP was bleached at 514 nm (Fig. 6A). Because the
emission spectra for CFP and YFP overlap significantly, we
imaged using a confocal microscope with spectral imaging
capabilities along with a linear unmixing algorithm (de-
scribed under Materials and Methods).
Fluorescent 4 and 2 subunits are functional and undergo
robust FRET in mammalian cells (Nashmi et al., 2003), so we
used these subunits in our acceptor photobleaching assay
with XFP-tagged 3 and 6. We expressed 3-YFP with
untagged 4 and 2-CFP in N2a cells, followed by live cell
FRET imaging. We recorded the whole-cell fluorescence in-
tensity for 3-YFP and 2-CFP before and after photobleach-
ing of YFP with the 514-nm laser, and we expressed with
pseudocolor intensity scaling (Fig. 6B). In this experiment,
2-CFP was clearly dequenched after 3-YFP photodestruc-
tion (Fig. 6B), indicating that the two subunits had been
undergoing FRET. In a similar experiment, we recorded mul-
tiple spectral images at several time points during YFP pho-
todestruction. This revealed a corresponding increase in CFP
intensity (Fig. 6C). A reciprocal experiment was also done,
where 3-YFP was coexpressed with 4-CFP and untagged
2. We recorded a similar dequenching for 4-CFP after YFP
photobleaching (Fig. 6, D and E), indicating FRET between
these subunits as well. Both for 2/3 and 4/3 FRET, we
found no difference between FRET inside the cell versus
FRET at the cell periphery at or near the plasma membrane.
These results directly demonstrate that 3 is able to assem-
ble with 42 receptors in neuronal cells. This assembly
likely occurs in the endoplasmic reticulum, which is consis-
tent with previous findings (Nashmi et al., 2003).
There are many different putative 6* receptor subtypes
in brain, including 62, 623, 642, and 6423
(Salminen et al., 2007). To begin to study 6* receptor as-
sembly, we measured FRET between 6-YFP and 2-CFP. In
response to YFP bleaching, we recorded a robust dequench-
ing of 2-CFP throughout the cell, indicating FRET between
these subunits (Fig. 6, F and G). The pattern of localization
and FRET pattern was identical to 423 receptors.
To further quantify FRET between 4/2 subunits and
Fig. 6. FRET reveals assembly of 3 and 6 nAChR subunits with 4 and
2. A, Nicotinic receptor FRET schematic diagram. Gray cylinders indi-
cate nAChR subunits, whereas cyan or yellow cylinders attached to
nAChR subunits indicate CFP or YFP, respectively. FRET between
nAChR subunits used the acceptor photobleaching method. When sub-
units are assembled, 439-nm excitation of CFP (donor) results in some
emission of CFP at 485 nm, and some nonradiative transfer of energy
(FRET) to YFP (acceptor) and resulting in emission at 535 nm. Acceptor
photobleaching reveals FRET by measuring incremental dequenching of
CFP during photodestruction of YFP with high-power 514-nm excitation.
B, 3 assembles with 2 in the presence of 4. N2a cells expressing
42-CFP3-YFP receptors were imaged live for FRET. The 439-nm
laser line was coupled to a confocal microscope equipped with spectral
imaging capabilities; this instrument generated spectral images before
and after photodestruction of YFP using the 514-nm laser. Specific CFP
and YFP signals were generated with linear unmixing as described under
Materials and Methods. YFP and CFP intensity throughout the cell
before and after YFP photodestruction is shown using intensity scaling.
C, plot of 3-YFP and 2-CFP intensity during incremental photodestruc-
tion of 3-YFP. Normalized data from a representative cell were fitted to
an exponential decay. D, 3 assembles with 4 in the presence of 2. N2a
cells expressing 4-CFP23-YFP were imaged live for FRET as de-
scribed in B. E, plot of 3-YFP and 4-CFP intensity during incremental
photodestruction of 3-YFP, similar to C. F, 6 assembles with 2. N2a
cells expressing 6-YFP2-CFP were imaged live for FRET as described
in B. G, plot of 6-YFP and 2-CFP intensity during incremental pho-
todestruction of 6-YFP, similar to C. Scale bar, 10 m.
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3 or 6, we measured FRET E values for various recep-
tor subtypes. 4-CFP2-YFP, 42-CFP3-YFP, and 4-
CFP23-YFP receptors were expressed in N2a cells fol-
lowed by acceptor photobleaching FRET (Fig. 7A). We
acquired spectral images with 439-nm laser excitation before
and during incremental photobleaching of YFP-labeled sub-
units, followed by extraction of true CFP and YFP image data
using linear unmixing (see Materials and Methods). A scat-
terplot of CFP intensity in response to YFP photobleaching
reveals FRET between the subunits in question (Fig. 7B)
when the slope of the linear regression line is 
0. This slope
was used to calculate FRET efficiency values, which were
expressed as bar graphs (Fig. 7C) or listed (Table 1). As
shown qualitatively in Fig. 6, significant FRET occurred in
all nAChR pentamer conditions. We noted a higher FRET E
for 4C/2Y than for 3Y with either 2C or 4C (Y, YFP; C,
CFP). To assess the specificity of this measurement, we also
measured FRET between 3 and a non-nAChR, CFP-labeled
protein, mGAT1. GAT1 is also a multipass transmembrane
protein with a CFP-tag at its C terminus, which faces the
cytoplasm. This protein is mainly localized to the endoplas-
mic reticulum (data not shown). These two points are impor-
tant, because it was critical for a specificity probe to have 1)
the same membrane topology as our labeled nicotinic recep-
tors, with respect to the attached fluorophore; and 2) the
same subcellular localization such that they are capable of
interacting with each other. In N2a cells expressing 3-YFP
and mGAT1-CFP, we could not detect any FRET between
these proteins (Table 1; Fig. 7C). In an even more rigorous
test, we assessed FRET between 3-YFP and another Cys-
loop receptor labeled in the M3-M4 loop, the CFP-labeled
GluCl  subunit (Slimko et al., 2002; Nashmi et al., 2003).
FRET between 3 and the GluCl  subunit was significantly
smaller (FRET E  6  4%) than for 4 or 2 nAChR
subunits (Table 1; Fig. 7C). Thus, our FRET results between
3 and other labeled nAChR subunits cannot be explained by
random collision or interaction with unassembled subunits.
Finally, we were interested in whether subtle changes in the
location of the fluorophore within the 3 M3-M4 loop could
influence its ability to undergo FRET with another subunit.
FRET E decreases strongly with the distance between fluoro-
phores. We reasoned that changes in the insertion point of
YFP in 3, while holding the position of CFP in 2 constant,
might alter FRET between these two subunits. To address
this, we compared the FRET E between 2-CFP and two
different 3-YFP constructs, 3-YFPP379 and 3-YFPG367,
which have different insertion points for YFP within the
M3-M4 loop. To our surprise, there was no change in the
FRET E for these two subunits (Table 1; Fig. 7D).
We quantitatively measured FRET between 6 and 4/2
subunits as well. We expressed either 6Y2C or 6Y4C2
in N2a cells to measure FRET (Fig. 8A). The latter receptor
was studied because recent work indicates that nAChR re-
ceptors containing both 6 and 4 1) exist and are functional
in mouse brain tissue (Salminen et al., 2007), and 2) are both
necessary to form the nAChR subtype with the highest affin-
ity for nicotine yet reported in a functional assay (Salminen
et al., 2007). Acceptor photobleaching FRET experiments
reveal robust CFP dequenching in response to YFP photo-
bleach for both of these receptor subtypes, indicating FRET
(Fig. 8B). Similar to 3-YFP* receptors, we measured FRET
E values for these two subtypes, and we found a FRET E of
36.0  2.4% for 6Y2C and 21.9  1.1% for 6Y4C2
(Table 1; Fig. 8C). We also assessed the specificity of our
FRET measurements for 6 by measuring FRET between
6-YFP and mGAT1-CFP as described above for Fig. 7. Sim-
ilar to 3 and mGAT1, we could record no significant FRET
between 6 and mGAT1 (Table 1; Fig. 8C). FRET experi-
ments between 6 and the GluCl  subunit, the most rigor-
ous test conducted, yielded a small FRET signal (FRET E 
14  2%) (Table 1; Fig. 8C). Because these subunits presum-
ably do not form functional channels, there may be a small
distortion of our 6 FRET signals that is due to partially
assembled receptors. Because this signal is significantly
smaller than for all other 6 combinations, FRET between
subunits in pentameric receptors remains the most plausible
explanation for the energy transfer we observe for 6. Fi-
nally, we studied FRET between 2-CFP and three 6-YFP
constructs (6-YFPA405, 6-YFPG387, and 6-YFPG366) that
differed only in their insertion point for YFP within the
M3-M4 loop. Again, we were surprised to find no significant
difference in FRET E between these three 6 constructs
(Table 1; Fig. 8D).
Several results described above gave us confidence that our
XFP-labeled 3 and 6 constructs were performing as ex-
pected. After confirming that these subunits assemble and
Fig. 7. 3 specifically assembles with 42 nAChRs. A, fluorescently
labeled nicotinic receptor pentamers assayed for FRET in this experi-
ment. N2a cells expressing the indicated receptor pentamers were as-
sayed live for FRET using the acceptor photobleaching method. B, linear
plots of donor (CFP) dequenching versus acceptor (YFP) photodestruction
for nAChRs with the indicated fluorescent subunits. FRET efficiency was
calculated by extrapolating linear regression plots to 100% YFP photode-
struction as described under Materials and Methods. C, specific FRET
signal detected between 3 and 4 or 2. The FRET efficiency for the
given donor-acceptor pair was calculated from the linear plot shown in B
as described under Materials and Methods. FRET between 3-YFP and
mGAT1-CFP or GluCl -CFP was measured as a specificity control. D,
FRET efficiency for 3-YFP does not depend on the insertion site in the
M3-M4 loop. Two 3-YFP constructs, 3-YFPP379 and 3-YFPG367, were
compared for their ability to assemble with 42-CFP as measured by
FRET. FRET efficiency was calculated as described in C. Error bars are
S.E.M., and n  5 to 15 cells for each condition. , p  0.001; , p 
0.01.
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traffic normally when expressed independently of each other,
we used these constructs together to study 623 nAChRs.
This receptor represents a modest population of the total
striatal nAChR pool, and it contributes to nicotine-stimulated
dopamine release (Salminen et al., 2007). 623 receptors,
where one subunit is untagged and the remaining subunits
are either YFP- or CFP-tagged (6Y2C3, 6Y23C, and
62Y3C), were expressed in N2a cells (Fig. 9A). We mea-
sured robust donor dequenching for all receptor subtypes (Fig.
9B), which was confirmed with FRET E measurements (Table
1; Fig. 9C). Thus, aside from 6 functional measurements, we
conclude that XFP-labeled 6 and 3 subunits exhibit normal
subcellular trafficking and assembly compared with our well
characterized fluorescent 4 and 2 subunits.
6 and 3 Subunit Stoichiometry Probedwith FRET.
Having established that fluorescently labeled 6 and 3 are
functional (3 only), have a reasonable subcellular localiza-
tion pattern, and assemble into nicotinic receptor pentamers
with other subunits, we used these tools to probe an impor-
tant question facing the nicotinic receptor field: subunit stoi-
chiometry. A variety of creative approaches have been taken
to understand subunit stoichiometry, including immunopre-
cipitation (Zoli et al., 2002; Champtiaux et al., 2003), density
gradient centrifugation (Kuryatov et al., 2000), molecular
concatamers/linked subunits (Tapia et al., 2007), reporter
mutations (Boorman et al., 2000), and mouse genetic ap-
proaches (Gotti et al., 2005a; Salminen et al., 2007). We now
use FRET to address the problem of subunit stoichiometry
because FRET occurs only when subunits are directly inter-
acting, and often assembled, with one another.
We have previously shown that FRET efficiency correlates
directly with functional receptor pentamers (Nashmi et al.,
2003). To examine the number of 6 and 3 subunits in a
nicotinic receptor pentamer, we first used FRET to examine
the stoichiometry of a well studied receptor, namely, 42
receptors. It is widely accepted that 4 and 2 subunits
assemble to form both high-sensitivity (HS) and low-sensi-
tivity (LS) receptors. Cells often produce a mixture of these
two receptors (Buisson and Bertrand, 2001; Nashmi et al.,
2003), although they can be induced to express a pure popu-
lation of one or the other (Nelson et al., 2003; Briggs et al.,
2006). The subunit stoichiometry of HS receptors is postu-
lated to be (4)2(2)3, whereas the LS receptors is thought to
be (4)3(2)2 (Nelson et al., 2003). Regardless of the fraction
of HS and LS receptors, we took advantage of the fact that all
42 receptors presumably contain two or more 4 and two
or more 2 subunits. We reasoned that when cells express
4-YFP and 4-CFP along with 2 (Fig. 10A), a fraction of
the receptors will contain both YFP- and CFP-labeled 4
subunits, and they will therefore be detectable by FRET.
Confirming this hypothesis, we did detect modest dequench-
ing of 4-CFP upon incremental 4-YFP photobleaching (Fig.
10B). FRET E for 4Y4C2 receptors was 22.2  2.3%
(Table 1; Fig. 10C). We also conducted a similar experiment
with 2, and we found a modest FRET signal (FRET E 
16.3  1.7%) between 2-YFP and 2-CFP within the same
pentamer (Table 1; Fig. 10, B and C). We next used this assay
to determine whether 6* and 3* receptors have one or
more than one 6 or 3 subunit per pentamer. N2a cells
expressing either 6Y6C2 or 423Y3C receptors were
Fig. 8. 6 specifically assembles with 4 and 2 nAChR subunits. A,
fluorescently labeled nicotinic receptor pentamers assayed for FRET in
this experiment. N2a cells expressing the indicated receptor pentamers
were assayed live for FRET using the acceptor photobleaching method. B,
linear plots of donor (CFP) dequenching versus acceptor (YFP) photode-
struction for nAChRs with the indicated fluorescent subunits. FRET
efficiency was calculated by extrapolating linear regression plots to 100%
YFP photodestruction as described under Materials and Methods. C,
specific FRET signal detected between 6 and 4 or 2. The FRET
efficiency for the given donor-acceptor pair was calculated from the linear
plot shown in B as described under Materials and Methods. FRET be-
tween 6-YFP and mGAT1-CFP or GluCl -CFP was measured as a
specificity control. D, FRET efficiency for 6-YFP does not depend on the
insertion site in the M3-M4 loop. Three 6-YFP constructs, 6-YFPA405,
6-YFPG387, and 6-YFPG366, were compared for their ability to assemble
with 2-CFP as measured by FRET. FRET efficiency was calculated as
described in C. Error bars are  S.E.M., and n  5 to 15 cells for each
condition. , p  0.001; , p  0.01.
Fig. 9. FRET reveals assembly of 623 nAChRs. A, fluorescently
labeled nicotinic receptor pentamers assayed for FRET in this experi-
ment. N2a cells expressing the indicated receptor pentamers were as-
sayed live for FRET using the acceptor photobleaching method. B, linear
plots of donor (CFP) dequenching versus acceptor (YFP) photodestruction
for nAChRs with the indicated fluorescent subunits. FRET efficiency was
calculated by extrapolating linear regression plots to 100% YFP photode-
struction as described under Materials and Methods. C, specific FRET
signal detected between 6-YFP and 2-CFP with 3 present, 6-YFP
and 3-CFP with 2 present, and 2-YFP and 3-CFP with 6 present.
The FRET efficiency for the given donor-acceptor pair was calculated
from the linear plot shown in B as described under Materials and Meth-
ods. Error bars are  S.E.M., and n  10 to 15 cells for each condition.
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analyzed for FRET (Fig. 10A). We measured a strong FRET
signal between 6-YFP and 6-CFP in donor dequenching
(Fig. 10B), corresponding to a robust FRET E of 27.8  1.7%
(Table 1; Fig. 10C). Thus, these data are the first to directly
demonstrate that 6* receptors are capable of containing at
least two 6 subunits, similar to other  subunits such as 3
and 4. In contrast to 6, 3 is thought to be an “ancillary
subunit”, only able to incorporate into nAChRs with other 
and  subunits (Groot-Kormelink et al., 1998). We could
detect little or no FRET between 3-YFP and 3-CFP (FRET
E  2.6  1.3%) (Table 1; Fig. 10, B and C). This was a
specific result, because 3-YFP and 3-CFP were able to
FRET with other subunits (Figs. 7 and 9), thus ruling out the
notion that one of these subunits is not able to undergo
FRET. These data are the first to directly demonstrate that
receptors containing 3 subunits are only able to incorporate
a single copy of this subunit. We interpret this to mean that
3 incorporates into the “accessory” position in a nAChR
pentamer (Tumkosit et al., 2006), and it likely does not
contribute to either of the two :non- interfaces that form
the ligand-binding sites.
After confirming via FRET that 3 incorporates into
nAChRs at a frequency of one subunit per pentamer, we used
3 coexpression to further probe the subunit stoichiometry of
4* and 6* receptors. We coexpresssed 3-WT with 4-YFP,
4-CFP, and 2 such that 3 was in excess. In this experi-
ment, 3 is incorporated into 4-XFP2 receptors and will
displace either an 4 or 2 subunit. There was a significant
decline in FRET for cells expressing 4Y4C23 receptors
versus those expressing 4Y4C2 (Table 1; Fig. 10, D and
G). We interpret this result to mean that 3 incorporation
has fixed the subunit stoichiometry of FRET-competent
receptors to (4Y)1(4C)1(2)2(3)1 versus the following
mixture of FRET-competent receptors without 3: (4Y)2-
(4C)1(2)2, (4Y)1(4C)2(2)2 and (4Y)1(4C)1(2)3. A re-
duction in FRET for two XFP-labeled 4 subunits (YFP and
CFP) versus three is reasonable and expected based on the
work of others (Corry et al., 2005), and on our calculations
that predict the relative FRET efficiencies in pentamers with
XFP-labeled subunits (data not shown). Thus, 3 incorpora-
tion into nAChR pentamers likely displaces one subunit, and
Fig. 10. 3 and 6 subunit stoichiom-
etry studied by FRET. A, fluorescently
labeled nicotinic receptor pentamers
assayed for FRET in this experiment.
N2a cells expressing the indicated re-
ceptor pentamers were assayed live
for FRET using the acceptor photo-
bleaching method. B, linear plots of
donor (CFP) dequenching versus ac-
ceptor (YFP) photodestruction for
nAChRs with the indicated fluores-
cent subunits. FRET efficiency was
calculated by extrapolating linear re-
gression plots to 100% YFP photode-
struction as described under Materi-
als and Methods. C, 6-containing
receptors have multiple 6 subunits
whereas 3-containing receptors have
only one 3 subunit. The FRET effi-
ciency for the given donor-acceptor
pair was calculated from the linear
plot shown in B as described under
Materials and Methods. D to F, linear
plots of donor (CFP) dequenching ver-
sus acceptor (YFP) photodestruction
for nAChRs with the indicated fluores-
cent subunits. FRET efficiency was
calculated by extrapolating linear re-
gression plots to 100% YFP photode-
struction as described under Materi-
als and Methods. G, 3 coexpression
with 42 or 62 receptors reduces
FRET between YFP- and CFP-labeled
 subunits. FRET E value for a given
subunit combination was calculated
from the linear plot in D, E, or F. Error
bars are  S.E.M., and n  10 to 15
cells for each condition. , p 0.001;
, p  0.05.
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results in a decrease in 4 to 4 FRET for pentamers with a
mixed subunit stoichiometry.
To determine whether 6* receptors have a fixed or a
mixed subunit stoichiometry, we coexpressed 3 in excess
with 6-YFP, 6-CFP, and 2. If 6* receptors only incorpo-
rate two 6 subunits, we expect to observe little or no change
in FRET between 6-YFP and 6-CFP because 3 will only
displace one unlabeled 2 subunit. However, if 6* receptors
exist as a mixture of (6)2(2)3 and (6)3(2)2 subtypes sim-
ilar to 4* receptors, we expect to observe a similar decline in
FRET when 3 is present to induce only the (6)2(2)23
stoichiometry. The latter was the case. We noted a significant
decline in the slope of the donor dequenching profile for
6Y6C* receptors when 3 was present (Table 1; Fig. 10E)
and a decline in the FRET E for 6Y6C23 (21.7  1.4%)
versus 6Y6C2 (27.8  1.7%) (Table 1; Fig. 10G). Thus,
fluorescent 6* receptors behave identically to 4* receptors,
and these results suggest that 6* receptors are capable of
forming either of two subunit stoichiometries: (6)2(2)3 and
(6)3(2)2.
Several groups have reported the existence of 46* recep-
tors in brain tissue (Zoli et al., 2002; Salminen et al., 2007),
and 4623* receptors (presumably 41612231) have
high affinity for nicotine (Salminen et al., 2007). To learn
about the subunit stoichiometry of 46* receptors, we ex-
pressed 6-YFP and 4-CFP along with 2 subunits in N2a
cells. We noted a modest FRET signal, indicating that these
subunits are present in some of the same nicotinic receptor
pentamers (Fig. 8, B and C; Fig. 10F). In contrast to our
results with 623 and 423 receptors, there was no
difference between cells transfected with 6Y/4C/2 and
6Y/4C/2/3 subunits (Fig. 10, F and G). This shows that
addition of excess 3 subunits did not reduce FRET between
6Y and 4C. Thus, this experiment is not informative re-
garding 4623 receptors in N2a cells. For instance, the
: subunit stoichiometry as measured by FRET may not
change in the presence of 3.
TIRF Revealed 4*, 6*, and 3* Receptor Plasma
Membrane Localization. Having confirmed that fluores-
cent 6 and 3 subunits assemble to form nicotinic receptor
pentamers, we probed the plasma membrane localization of
nAChRs containing these subunits using TIRF microscopy.
For nicotinic receptor subunits fused to fluorescent proteins,
TIRF illumination selectively excites only receptors at or
very close to the plasma membrane. We imaged live N2a cells
expressing 423-YFP, 6-YFP2, and 4-YFP2. In epi-
fluorescence mode (Fig. 11, epi), these receptors exhibited
an intracellular, endoplasmic reticulum-like localization
identical to our confocal imaging data in Fig. 4. In TIRF
mode, however, we noted robust plasma membrane fluores-
cence for all receptor combinations. We were surprised to find
4Y2 receptors to be localized to distinct, filamentous struc-
tures protruding from the cell body (Fig. 11A, arrow). This
specific filamentous pattern was seen for
90% of the plasma
membrane fluorescence. These structures were reminiscent
of filopodia, which are actin-dependent plasma membrane
protrusions. To test whether these structures contain actin, a
hallmark of filopodia, we imaged cells stained with rhodam-
ine-phalloidin, a marker of polymerized actin. We noted dis-
tinct, actin-containing protrusions (Fig. 11B, arrow). These
structures were actin-dependent, because they were de-
stroyed by treatment with latrunculin B, an actin-disrupting
agent (Fig. 11B, right). These data indicate that, in N2a cells,
4Y2 nicotinic receptors are localized to membrane protru-
sions that strongly resemble filopodia.
Similar to 4Y2, we imaged live N2a cells, in TIRF mode,
expressing either 423Y or 6Y2. To our surprise, we
noted a very different localization pattern compared with
4Y2. 3* and 6* receptors were well expressed on the
plasma membrane, but there was no evidence of membrane
Fig. 11. Distinct plasma membrane localization for 42 versus 3* and
6* receptors. A, plasma membrane localization of 42 receptors. N2a
cells plated on polyethylenimine, expressing 4-YFP2 receptors were
imaged live under TIRF illumination. Arrows indicate 42 receptors in
distal parts of membrane protrusions. Epifluorescence (non-TIRF) im-
ages and bright-field images are shown for reference. Scale bars, 10 m.
B, filopodia in N2a cells. N2a cells were plated as described in A and
stained with rhodamine-phalloidin to mark actin filaments (left, arrows)
in the cytoplasm and in filopodia-like protrusions. Cells were imaged with
confocal microscopy. Cells were treated with latrunculin B to disrupt
actin filaments (right). C and D, lattice-like and punctate localization of
423-YFP and 6-YFP2 receptors on the plasma membrane. N2a
cells expressing the indicated nAChR subunits were imaged in TIRF
mode as described in A. Epifluorescence and bright-field images are
shown for reference. E, syntaxin1A plasma membrane localization is
similar to 3 and 6 nicotinic receptors. N2a cells expressing YFP-
syntaxin1A were imaged as described in A, C, and D. F, 3-YFP subunits
on the plasma membrane are functional. N2a cells expressing either
4-YFP2 or 423-YFPV13S were studied using whole-cell patch-clamp
electrophysiology. Voltage-clamped cells were stimulated with 1 M ACh
for 500 ms. A representative response from the indicated nAChR subtype
is shown. Scale bar, 300 pA and 500 ms. G, quantification of electrophys-
iology data in F. Peak current responses from 4-YFP2 and 423-
YFPV13S (1 M stimulation) were averaged for four cells. , p  0.001.
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protrusion or filopodia localization for these receptors.
Rather, these proteins exhibited a punctate, lattice-like lo-
calization pattern on the plasma membrane (Fig. 11, C and
D). This pattern was consistently seen in other cells types
such as HEK293 (data not shown), and it suggests that 3*
or 6* receptors cluster in microdomains distinct from 42
receptors. Alternatively, some of these puncta could be clus-
ters of assembled receptors adjacent to the plasma mem-
brane within the 100-nm evanescent wave. We also recorded
movies to monitor plasma membrane nAChRs, and we noted
that although they exhibited localized, stochastic movements,
most of these receptor clusters did not travel or translocate to
any significant degree (data not shown). This localization pat-
tern resembles that of the soluble N-ethylmaleimide-sensitive
factor attachment protein receptor protein syntaxin1, which
was localized to distinct granules or microdomains in the
plasma membrane when observed in TIRF (Ohara-Imaizumi et
al., 2004). Because soluble N-ethylmaleimide-sensitive factor
attachment protein receptor proteins are important regula-
tors of ion channel subcellular trafficking and function in
neuronal soma and synaptic terminals (Bezprozvanny et al.,
1995), we compared the plasma membrane localization pat-
tern of YFP-syntaxin1A with 3-YFP* and 6-YFP* recep-
tors in N2a cells. We observed a plasma membrane distribu-
tion pattern for syntaxin1A that was very similar to 3 and
6 subunits; syntaxin1A was also localized to distinct clus-
ters adjacent to the plasma membrane or microdomains on
the plasma membrane (Fig. 11E).
It is possible that the different plasma membrane localiza-
tion pattern observed for 4Y2 versus 423Y reflects the
localization pattern of functional versus nonfunctional nico-
tinic receptors, respectively. To address this, we used whole-
cell patch-clamp electrophysiology to record voltage-clamped
responses from functional, fluorescent nAChRs expressed in
N2a cells. Because WT (Broadbent et al., 2006) or YFP-
tagged 3 subunits (Fig. 2B) significantly attenuated nAChR
responses, we used 3-YFPV13S subunits to reverse this at-
tenuation. We reasoned that, if coexpressed and coassembled
with 42 receptors, 3-YFPV13S subunits should 1) induce
the high-sensitivity (4)2(2)2(3)1 subunit stoichiometry
similar to previous work (Broadbent et al., 2006); and 2)
lower the EC50 for activation of this high-sensitivity form by
approximately 1 order of magnitude (Fig. 3B). When voltage-
clamped N2a cells expressing 4Y2 receptors were stimu-
lated with 1 M ACh, a dose that induces minimal (20–30
pA) responses in our previous work with HEK293 cells
(Nashmi et al., 2003), we observed an identical phenotype
(Fig. 11F). Responses to 300 M ACh were robust (200–400
pA), indicating significant plasma membrane expression of
these receptors (data not shown). However, cells expressing
423YV13S receptors exhibited robust responses to 1 M
ACh (Fig. 11F), which were significantly larger than the
response size for 42 receptors (Fig. 11G). This is the ex-
pected result if 3-YFPV13S subunits are incorporated into
functional nAChRs in N2a cells, and it is consistent with our
X. laevis oocyte experiments (Figs. 2 and 3), and with the
work of others (Broadbent et al., 2006). These data confirm
that both 4Y2 and 423Y receptors are functional in
N2a cells and that the observed plasma membrane localiza-
tion pattern for functional 4Y2 and 423Y receptors is
significantly different.
Discussion
Subcellular Localization of Nicotinic ACh Recep-
tors. 42 receptors were localized intracellularly in our
previous studies in HEK293 cells and primary midbrain neu-
rons (Nashmi et al., 2003), although enough receptors are
expressed on the cell surface to record responses using elec-
trophysiology. Furthermore, knockin mice with YFP-labeled
4 subunits show uniform intracellular and plasma mem-
brane localization of 4* receptors (Nashmi et al., 2007).
Other investigators have found a similar localization pattern
for 42 (Xu et al., 2006), 34 (Grailhe et al., 2004), 7 (Xu
et al., 2006), and 5-hydroxytryptamine3A (Grailhe et al.,
2004) receptors. In light of these studies, it is not surprising
that we found fully assembled 3* and 6* receptors in
intracellular stores in N2a cells. This suggests that neurons
produce more assembled nAChRs than they can use at any
particular time and that they may require the ability to
rapidly change either their total number or specific stoichi-
ometry of receptor subtypes on the plasma membrane in
response to different extracellular signals. The specific phe-
nomenon of up- or down-regulation of nicotinic receptors
occurs during chronic nicotine exposure (Marks et al., 1983;
Nashmi et al., 2007) and in other neurological disorders
including autism and Alzheimer’s disease (for review, see
Graham et al., 2002).
42 receptors were localized to actin-dependent mem-
brane protrusions akin to filopodia, whereas 3* and 6*
receptors were not. Filopodia are critical sensory components
of growth cones, influencing growth cone orientation and
turning toward extracellular cues. Nicotinic receptors are
required for growth cone orientation in some neuronal types
(Zheng et al., 1994). Interestingly, 4 and 2 subunits are
highly expressed during embryogenesis (Azam et al., 2007),
suggesting a role for these subunits in neuronal development
and in adult function. 6 and 3 subunits, in contrast, are not
expressed at appreciable levels until after birth (Azam et al.,
2007). We speculate that the differences we observe for
42 versus 3 or 6 receptors on the plasma membrane
could reflect their involvement (or lack thereof) in neuronal
development.
6 Functional Expression. Although it remains unclear
why it is very difficult to record functional responses from
6* receptors, this study advances our knowledge of this
problem. In 20 different attempts, using several expression/
assay systems, we could record no 6 functional responses
(Supplemental Data; Table 1). This could be a result of many
different problems, such as 6 mRNA stability, 6 protein
production, proper assembly of 6* receptors, intracellular
trafficking, or plasma membrane delivery. We (herein) and
others have demonstrated that cells do not have an apparent
problem synthesizing 6 subunits (Kuryatov et al., 2000;
Tumkosit et al., 2006), and either partial or full assembly of
6* receptors occurs in mammalian tissue culture cells and
X. laevis oocytes (Kuryatov et al., 2000; Tumkosit et al.,
2006). We found robust ectopic expression of 6-YFP sub-
units in tissue culture cells and in primary neurons. Further-
more, based on our FRET measurements, 6 subunits are
fully capable of assembling with 4, 2, and 3 subunits in a
manner indistinguishable from that of 4 and 2. These are
the presumptive subunits necessary for expression of 6*
receptors in vivo (Salminen et al., 2007). Assembled 6*
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receptors are also localized identically to 4* receptors in our
experiments. Finally, and most surprisingly, we ruled out the
possibility that 6* receptors are not delivered to the plasma
membrane. Plasma membrane localization for 6* receptors
was identical to that of assembled, functional 3* receptors.
From these data, we conclude that, although fully assembled
and partially localized on the plasma membrane, 6* recep-
tors do not yield responses in standard functional assays.
This information should facilitate the design of new experi-
mental approaches to develop robust, reproducible reconsti-
tution of 6 function in vitro.
Because we found no difference in FRET between 462
receptors  3, the experiments probing the stoichiometry of
4623 receptors are uninformative. It is possible that
there are no assembled 4623 receptors in N2a cells. We
suggest that catecholaminergic or retinal ganglion cells,
which are those cells in vivo that produce high levels of
functional 6* receptors (Le´na et al., 1999; Whiteaker et al.,
2000; Champtiaux et al., 2002, 2003; Zoli et al., 2002; Gotti et
al., 2005b), express a unique protein or factor that is essen-
tial for proper function of these receptors. It is also possible
that these cells are specially suited to traffic 6* and/or 3*
receptors to distal axons/presynaptic terminals. Our results
probing 6 and 3 axonal targeting (Fig. 5B) may be negative
as a result of differences in the cell trafficking machinery in
hippocampal (6-negative) versus catecholaminergic (6-pos-
itive) neurons, and they highlight the need for a more de-
tailed study of 6/3 axonal targeting in 6-positive neurons.
Perhaps there is an 6-associated protein similar to other
nicotinic receptor-associated proteins, such as lynx1 (Miwa et
al., 1999), which remains to be characterized.
6* and 3* Receptor Assembly and Subunit Stoichi-
ometry. We previously demonstrated that FRET between
XFP-labeled nicotinic receptor subunits not only reveals
proximity between subunits but that increased FRET effi-
ciency correlates with increased assembled, functional recep-
tors (Nashmi et al., 2003). Because we cannot measure
functional responses from 6* receptors, we must draw con-
clusions about their behavior inferentially by comparing it to
42 receptors, which are functionally expressed. Using
these criteria, we conclude that 6 subunits assemble with
4, 2, and 3 subunits. Furthermore, we conducted several
specificity controls (FRET with GAT1C and GluCl ) that
revealed that FRET between 6 or 3 and other nAChR
subunits is robust and likely explained by pentameric assem-
bly. These experiments also reveal that a subpopulation of 6
subunits may be contained in partially assembled receptors.
It may be this feature that precludes routine measurement of
functional responses, further supporting the notion of a spe-
cial factor in vivo that promotes 6* nAChR assembly and
function.
We noted a slightly higher FRET efficiency for 6* versus
4* receptors in all assays reported herein. Because FRET E
depends on distance, we speculate that this is largely due to
the smaller M3-M4 intracellular loop of 6 (136 residues)
versus 4 (270 residues). When the same XFP-labeled 2
construct is expressed with 4 versus 6, the relative dis-
tance between fluorophores, and therefore the efficiency of
FRET, will be different. Although the lack of structural in-
formation about these M3-M4 loops precludes us from mak-
ing any quantitative predictions or correlations with our
observed FRET E values, we assert that, at a qualitative
level, the differences in FRET E for 4 versus 6 are likely
explained by the differences in M3-M4 loop length.
In this study, we use FRET to describe 6 and 3 subunit
stoichiometry in assembled pentamers containing these sub-
units. Based on our data, only one 3 subunit is able to
incorporate into a nicotinic receptor pentamer with other 
and  subunits. It is not clear whether 3 does so because it
lacks residues required for formation of an : ligand-bind-
ing interface, or whether it is due to specific residues in the
transmembrane segments or intracellular loops. What is
clear is that 3 is able to displace one subunit in a pentamer,
which affords the ability to alter the subunit stoichiometry of
receptors containing this subunit. Although this has been
assumed based on indirect experiments (Broadbent et al.,
2006), the present study is the first to directly elucidate the
stoichiometry of 3* receptors.
Based on our data, 6* receptors, like 4*, are stoichiomet-
rically heterogeneous. Previous reports using immunopre-
cipitation or genetic techniques have identified the specific
subunits coassembled with 6, but not their stoichiometry
(Zoli et al., 2002; Salminen et al., 2007). For example, Salmi-
nen et al. (2007) demonstrated the existence of native 62,
623, and 4623 subtypes, among others. But for 62
receptors, how many 6 and 2 subunits are present in a
given pentamer? Our FRET results suggest that a mixture of
stoichiometries exist for 6* receptors. We interpret the 3-
induced decline in FRET between 6Y and 6C in 62 recep-
tors to mean, at least in part, that 3 is displacing a third 6
subunit and stabilizing a stoichiometry of (6)2(2)2(3)1. The
alternative, that 6* receptors adopt a strict (6)2(X)3 stoichi-
ometry, is less likely. Such a scenario would require that 3 is
able to significantly reduce FRET between 6Y and 6C with-
out changing 6 stoichiometry. It is more reasonable to assume
that 6 is behaving similar to 4, whose stoichiometry is varied
and can be altered by 3 coexpression (Broadbent et al., 2006).
6 and 3 subunits are present in 4623 receptors in stri-
atum and nucleus accumbens, which have the highest affinity
for nicotine of any nicotinic subtype yet reported (Salminen et
al., 2007). Their localization on dopaminergic nerve terminals
coupled with this high affinity for nicotine ensures that they are
among the first nicotinic subtypes activated during a smoking-
induced bolus of nicotine. These and other high-affinity recep-
tors are important targets for smoking cessation and Parkin-
son’s disease medications, so understanding their subunit
stoichiometry is important for the rational design of small mol-
ecule modulators of nAChR function.
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